METHODS IN MOLECULAR BIOLOGY ™
309
RNA Silencing Methods and Protocols Edited by
Gordon G. Carmichael
RNA Silencing
M E T H O D S I N M O L E C U L A R B I O L O G Y™
John M. Walker, SERIES EDITOR 321. Microfluidic Techniques: Reviews and Protocols, edited by Shelley D. Minteer, 2006 320. Cytochrome P450 Protocols, Second Edition, edited by Ian R. Phillips and Elizabeth A. Shephard, 2006 319. Cell Imaging Techniques, Methods and Protocols, edited by Douglas J. Taatjes and Brooke T. Mossman, 2006 318. Plant Cell Culture Protocols, Second Edition, edited by Victor M. Loyola-Vargas and Felipe Vázquez-Flota, 2005 317. Differential Display Methods and Protocols, Second Edition, edited by Peng Liang, Jonathan Meade, and Arthur B. Pardee, 2005 316. Bioinformatics and Drug Discovery, edited by Richard S. Larson, 2005 315. Mast Cells: Methods and Protocols, edited by Guha Krishnaswamy and David S. Chi, 2005 314. DNA Repair Protocols: Mammalian Systems, Second Edition, edited by Daryl S. Henderson, 2005 313. Yeast Protocols: Second Edition, edited by Wei Xiao, 2005 312. Calcium Signaling Protocols: Second Edition, edited by David G. Lambert, 2005 311. Pharmacogenomics: Methods and Applications, edited by Federico Innocenti, 2005 310. Chemical Genomics: Reviews and Protocols, edited by Edward D. Zanders, 2005 309. RNA Silencing: Methods and Protocols, edited by Gordon G. Carmichael, 2005 308. Therapeutic Proteins: Methods and Protocols, edited by C. Mark Smales and David C. James, 2005 307. Phosphodiesterase Methods and Protocols, edited by Claire Lugnier, 2005 306. Receptor Binding Techniques: Second Edition, edited by Anthony P. Davenport, 2005 305. Protein–Ligand Interactions: Methods and Applications, edited by G. Ulrich Nienhaus, 2005 304. Human Retrovirus Protocols: Virology and Molecular Biology, edited by Tuofu Zhu, 2005 303. NanoBiotechnology Protocols, edited by Sandra J. Rosenthal and David W. Wright, 2005 302. Handbook of ELISPOT: Methods and Protocols, edited by Alexander E. Kalyuzhny, 2005 301. Ubiquitin–Proteasome Protocols, edited by Cam Patterson and Douglas M. Cyr, 2005 300. Protein Nanotechnology: Protocols, Instrumentation, and Applications, edited by Tuan Vo-Dinh, 2005 299. Amyloid Proteins: Methods and Protocols, edited by Einar M. Sigurdsson, 2005
298. Peptide Synthesis and Application, edited by John Howl, 2005 297. Forensic DNA Typing Protocols, edited by Angel Carracedo, 2005 296. Cell Cycle Control: Mechanisms and Protocols, edited by Tim Humphrey and Gavin Brooks, 2005 295. Immunochemical Protocols, Third Edition, edited by Robert Burns, 2005 294. Cell Migration: Developmental Methods and Protocols, edited by Jun-Lin Guan, 2005 293. Laser Capture Microdissection: Methods and Protocols, edited by Graeme I. Murray and Stephanie Curran, 2005 292. DNA Viruses: Methods and Protocols, edited by Paul M. Lieberman, 2005 291. Molecular Toxicology Protocols, edited by Phouthone Keohavong and Stephen G. Grant, 2005 290. Basic Cell Culture Protocols, Third Edition, edited by Cheryl D. Helgason and Cindy L. Miller, 2005 289. Epidermal Cells, Methods and Applications, edited by Kursad Turksen, 2005 288. Oligonucleotide Synthesis, Methods and Applications, edited by Piet Herdewijn, 2005 287. Epigenetics Protocols, edited by Trygve O. Tollefsbol, 2004 286. Transgenic Plants: Methods and Protocols, edited by Leandro Peña, 2005 285. Cell Cycle Control and Dysregulation Protocols: Cyclins, Cyclin-Dependent Kinases, and Other Factors, edited by Antonio Giordano and Gaetano Romano, 2004 284. Signal Transduction Protocols, Second Edition, edited by Robert C. Dickson and Michael D. Mendenhall, 2004 283. Bioconjugation Protocols, edited by Christof M. Niemeyer, 2004 282. Apoptosis Methods and Protocols, edited by Hugh J. M. Brady, 2004 281. Checkpoint Controls and Cancer, Volume 2: Activation and Regulation Protocols, edited by Axel H. Schönthal, 2004 280. Checkpoint Controls and Cancer, Volume 1: Reviews and Model Systems, edited by Axel H. Schönthal, 2004 279. Nitric Oxide Protocols, Second Edition, edited by Aviv Hassid, 2004 278. Protein NMR Techniques, Second Edition, edited by A. Kristina Downing, 2004 277. Trinucleotide Repeat Protocols, edited by Yoshinori Kohwi, 2004 276. Capillary Electrophoresis of Proteins and Peptides, edited by Mark A. Strege and Avinash L. Lagu, 2004
M E T H O D S I N M O L E C U L A R B I O L O G Y™
RNA Silencing Methods and Protocols
Edited by
Gordon G. Carmichael Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT
© 2005 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. Methods in Molecular BiologyTM is a trademark of The Humana Press Inc. All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. This publication is printed on acid-free paper. ∞ ANSI Z39.48-1984 (American Standards Institute) Permanence of Paper for Printed Library Materials. Cover illustration: Figure 2 from Chapter 12, “siRNA Delivery In Vivo” by M. Sioud. Cover design by Patricia F. Cleary. For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail:
[email protected]; or visit our Website: www.humanapress.com Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US $30.00 per copy is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [1-58829-436-6/05 $30.00 ]. Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 Library of Congress Cataloging in Publication Data RNA silencing : methods and protocols / edited by Gordon G. Carmichael. p. ; cm. — (Methods in molecular biology ; 309) Includes bibliographical references and index. ISBN 1-58829-436-6 (alk. paper) eISBN 1-59259-935-4 1. Small interfering RNA—Laboratory manuals. 2. Gene silencing—Laboratory manuals. [DNLM: 1. RNA Interference. 2. Gene Expression Regulation—genetics. 3. MicroRNAs—physiology. 4. RNA, Small Interfering—physiology. QU 58.7 R6273 2005] I. Carmichael, Gordon G. II. Series: Methods in molecular biology (Clifton, N.J.) ; v. 309. QP623.5.S63R634 2005 572.8’65—dc22 2004023107
Preface The past decade has witnessed a true revolution in our understanding of how RNA molecules can act as regulators of gene expression. Central to this new understanding is a growing appreciation that short duplex RNAs can trigger potent and highly specific inhibitory effects, most in the cytoplasm but some also in the nucleus. The underlying regulatory pathway is the ancient and conserved RNA interference (RNAi) pathway utilizing small duplex RNAs. RNAi is carried out in two steps. In the first, long dsRNAs are processed into short 21–23 nt-long effector dsRNAs (siRNAs, small interfering RNAs; 21–25 nt in plants) by the action of the enzyme Dicer. In the second step, the siRNAs are assembled into protein-RNA complexes (RNA-induced silencing complexes, RISC) that direct the specific cleavage of target mRNAs. In these complexes, the short dsRNA duplex is unwound, generating active RISC complexes containing single siRNA strands. In addition to siRNAs, there is another abundant and important class of small ~22 nucleotide noncoding RNA species in cells, the microRNAs (miRNAs). These RNAs are involved in many processes, including regulation of gene expression during development and defense against viruses. In the past several years there has been great progress in the biochemical and computational identification of novel miRNA species, and there are now hundreds of these small RNAs known. Most current models envision miRNAs acting as negative regulators of translation by acting in a still unknown way on translating ribosomes. Though it is important to understand and appreciate the concepts and mechanisms of RNAi and miRNA action, it is also critical to be able to apply these emerging technologies in a rational and effective manner. RNA Silencing: Methods and Protocols is intended to facilitate the translation of gene silencing concepts into practical applications, and includes a broad but useful set of RNA silencing protocols. The first three chapters deal with biochemical aspects of the silencing machinery. Siomi and Siomi describe a powerful biochemical method for the purification and identification of RNAi components. Pham and Sontheimer then describe electrophoretic methods to separate distinct silencing complexes. Then Lee and Kim describe the purification of the Drosha protein, which is a central player in the generation of miRNAs. Chapters 4–6 describe detailed methods for RNA silencing in nonmammalian organisms. Dudley and Goldstein detail methods for RNAi in the nematode C. elegans. Clayton et al. then describe how to carry out RNAi-mediated gene
v
vi
Preface
silencing in Trypanosoma brucei. Finally, Mette et al. describe methods for the study of transcriptional gene silencing in the nuclei of plant cells. Then, there follow a series of chapters detailing ways to design, prepare, and use RNAs to silence gene expression. These include the use of small RNA duplexes (siRNAs). In Chapter 7, Sioud and Walchli describe methods for the design of siRNA libraries. In Chapter 8 Myers and Ferell offer an incredibly valuable and detailed description of how to design, prepare, and use pools of siRNAs generated by in vitro Dicer cleavage. In Chapter 9 Chae and Hla describe a similar approach. Chapters 10 and 11 (Sui and Shi, and Harper and Davidson) describe methods for the design and use of DNA vectors that express short RNA hairpins that can lead to RNAi silencing in vivo. RNA interference cannot be effective in cells unless the active RNAs are efficiently introduced into them, or expressed in them. Therefore, Chapters 12–14 describe several current methods and strategies for the in vivo delivery of siRNAs and silencing vectors. Sioud (Chapter 12) describes some approaches for the delivery of siRNAs, and Simeoni et al. (Chapter 13) describe a novel peptidebased strategy for this purpose. In Chapter 14, Li and Rossi describe how lentiviral vectors can be used for the very efficient delivery and expression of active siRNAs into cultured and primary hematopoietic cells. Chapter 15 describes how RNAi technology can be used to fine-tune the regulation of some gene expression by targeting specific isoforms of a given gene. Chapters 16–18 describe methods for the study and use of microRNAs. Maniataki et al. describe the isolation of the ribonucleoprotein particles that contain miRNAs, and methods for miRNA cloning. Kiriakidou et al. then describe how to detect miRNAs as well as assays for miRNA function. Sioud and Rosok detail a high-throughput analysis of miRNA expression. Finally, I think that it is important to keep in mind that the RNAi and miRNA pathways are not the only ways that cells can use small RNAs to regulate gene expression using natural and endogenous mechanisms. Small RNAs are important in an number of biological processes, including pre-mRNA splicing. It has been shown recently that one of the key components of the splicing machinery, U1 snRNA, can be redirected to nuclear RNA targets in a way that results in a striking downregulation of gene expression. In contrast to siRNAs and miRNAs, which act primarily in the cytoplasm of mammalian cells, U1 snRNA acts only in the nucleus. Thus, Chapter 19 details a U1-based approach that should be considered as an alternative to RNAi, and which is associated with distinct strengths and weaknesses. Gordon G. Carmichael
Contents Preface .............................................................................................................. v Contributors ..................................................................................................... ix 1 Identification of Components of RNAi Pathways Using the Tandem Affinity Purification Method Mikiko C. Siomi and Haruhiko Siomi ................................................... 1 2 Separation of Drosophila RNA Silencing Complexes by Native Gel Electrophoresis John W. Pham and Erik J. Sontheimer ................................................ 11 3 Preparation and Analysis of Drosha Yoontae Lee and V. Narry Kim ........................................................... 17 4 RNA Interference in Caenorhabditis elegans Nathaniel R. Dudley and Bob Goldstein ............................................ 29 5 Down-Regulating Gene Expression by RNA Interference in Trypanosoma brucei Christine E. Clayton, Antonio M. Estévez, Claudia Hartmann, Vincent P. Alibu, Mark Field, and David Horn .............................. 39 6 Analysis of Double-Stranded RNA and Small RNAs Involved in RNA-Mediated Transcriptional Gene Silencing M. Florian Mette, Werner Aufsatz, Tatsuo Kanno, Lucia Daxinger, Philipp Rovina, Marjori Matzke, and Antonius J. M. Matzke ............................................................. 61 7 Strategies for the Design of Random siRNA Libraries and the Selection of Anti-GFP siRNAs Mouldy Sioud and Sébastien Wälchli ................................................. 83 8 Silencing Gene Expression with Dicer-Generated siRNA Pools Jason W. Myers and James E. Ferrell, Jr. ............................................ 93 9 Inhibition of Gene Expression In Vivo Using Multiplex siRNA Sung-Suk Chae and Timothy Hla ...................................................... 197 10 Gene Silencing by a DNA Vector-Based RNAi Technology Guangchao Sui and Yang Shi ............................................................ 205 11 Plasmid-Based RNA Interference: Construction of Small-Hairpin RNA Expression Vectors Scott Q. Harper and Beverly L. Davidson ........................................ 219
vii
viii
Contents
12 siRNA Delivery In Vivo Mouldy Sioud .................................................................................... 13 Peptide-Based Strategy for siRNA Delivery into Mammalian Cells Federica Simeoni, May C. Morris, Frederic Heitz, and Gilles Divita ........................................................................... 14 Lentiviral Vector Delivery of siRNA and shRNA Encoding Genes into Cultured and Primary Hematopoietic Cells Mingjie Li and John J. Rossi .............................................................. 15 Exon-Specific RNA Interference: A Tool to Determine the Functional Relevance of Proteins Encoded by Alternatively Spliced mRNAs Alicia M. Celotto, Joo-Won Lee, and Brenton R. Graveley .............. 16 Immunoprecipitation of MicroRNPs and Directional Cloning of MicroRNAs Elisavet Maniataki, Maria Dels Angels De Planell Saguer, and Zissimos Mourelatos .............................................................. 17 Detection of MicroRNAs and Assays to Monitor MicroRNA Activities In Vivo and In Vitro Marianthi Kiriakidou, Peter Nelson, Stella Lamprinaki, Anup Sharma, and Zissimos Mourelatos ...................................... 18 High-Throughput Analysis of MicroRNA Gene Expression Using Sensitive Probes Mouldy Sioud and Øystein Røsok ..................................................... 19 Modification of Human U1 snRNA for Inhibition of Gene Expression at the Level of Pre-mRNA Peng Liu, Mary L. Stover, Alexander Lichtler, and David W. Rowe ...................................................................... Index ............................................................................................................
237
251
261
273
283
295
311
321 333
Contributors VINCENT P. ALIBU • ZMBH, Heidelberg, Germany WERNER AUFSATZ • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria GORDON G. CARMICHAEL • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT ALICIA M. CELOTTO • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT SUNG-SUK CHAE • Department of Cell Biology, Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT CHRISTINE E. CLAYTON • ZMBH, Heidelberg, Germany BEVERLY L. DAVIDSON • Departments of Internal Medicine, Neurology, Physiology, and Biophysics, University of Iowa, Iowa City, IA LUCIA DAXINGER • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria GILLES DIVITA • Department of Molecular Biophysics & Therapeutics, Centre de Recherches de Biochimie Macromoléculaire, CNRS, Montpellier, France NATHANIEL R. DUDLEY • Biology Department, University of North Carolina, Chapel Hill, NC ANTONIO M. ESTÉVEZ • Instituto de Parasitologia y Biomedicina “Lopez-Neyra,” CSIC, Armilla, Granada JAMES E. FERRELL, JR. • Departments of Molecular Pharmacology and Biochemistry, Stanford University Medical School, Stanford, CA MARK FIELD • Department of Pathology, University of Cambridge, Cambridge, UK BOB GOLDSTEIN • Biology Department, University of North Carolina, Chapel Hill, NC BRENTON R. GRAVELEY • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT SCOTT Q. HARPER • Department of Internal Medicine, University of Iowa, Iowa City, IA CLAUDIA HARTMANN • ZMBH, Heidelberg, Germany FREDERIC HEITZ • Department of Molecular Biophysics & Therapeutics, Centre de Recherches de Biochimie Macromoléculaire, CNRS, Montpellier, France
ix
x
Contributors
TIMOTHY HLA • Department of Cell Biology, Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT DAVID HORN • London School of Hygiene & Tropical Medicine, London, UK TATSUO KANNO • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria V. NARRY KIM • School of Biological Science, Seoul National University, Seoul, South Korea MARIANTHI KIRIAKIDOU • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA STELLA LAMPRINAKI • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA JOO-WON LEE • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT YOONTAE LEE • School of Biological Science, Seoul National University, Seoul, South Korea MINGJIE LI • Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA ALEXANDER LICHTLER • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT PENG LIU • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT ELISAVET MANIATAKI • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA ANTONIUS J. M. MATZKE • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria MARJORI MATZKE • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria M. FLORIAN METTE • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria MAY C. MORRIS • Department of Molecular Biophysics & Therapeutics, Centre de Recherches de Biochimie Macromoléculaire CNRS, Montpellier, France ZISSIMOS MOURELATOS • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA JASON W. MYERS • Department of Molecular Pharmacology, Stanford University Medical School, Stanford, CA
Contributors
xi
PETER NELSON • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA JOHN W. PHAM • Department of Biochemistry, Molecular Biology, and Cell Biology, Northwestern University, Evanston, IL ØYSTEIN RØSOK • Molecular Medicine Group, Institute for Cancer Research, Oslo, Norway JOHN J. ROSSI • Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA PHILIPP ROVINA • Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences, Vienna, Austria DAVID W. ROWE • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT MARIA DELS ANGELS DE PLANELL SAGUER • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA ANUP SHARMA • Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA YANG SHI • Department of Pathology, Harvard Medical School, Boston, MA FREDERICA SIMEONI • Department of Molecular Biophysics & Therapeutics, Centre de Recherches de Biochimie Macromoléculaire, CNRS, Montpellier, France MIKIKO C. SIOMI • Institute for Genome Research, University of Tokushima, Tokushima, Japan HARUHIKO SIOMI • Institute for Genome Research, University of Tokushima, Tokushima, Japan MOULDY SIOUD • Molecular Medicine Group, Institute for Cancer Research, Oslo, Norway ERIK J. SONTHEIMER • Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, IL MARY LOUISE STOVER • Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT GUANGCHAO SUI • Department of Pathology, Harvard Medical School, Boston, MA SÉBASTIEN WÄLCHLI • Molecular Medicine Group, Institute for Cancer Research, Oslo, Norway
01_Siomi.qxd
4/16/05
11:57 AM
Page 1
1 Identification of Components of RNAi Pathways Using the Tandem Affinity Purification Method Mikiko C. Siomi and Haruhiko Siomi 1. Introduction RNA interference (RNAi) is rapidly becoming a standard laboratory technique for understanding and regulating the function of specific genes in evolutionarily diverse organisms, including plants, Caenorhabditis elegans, Drosophila, and mammalian cells (1–10). RNAi is initiated by the conversion of doublestranded RNA (dsRNA) into 21- to 23-nucleotide (nt) fragments of dsRNA by Dicer enzymes. These short, interfering RNAs, or siRNAs as they are known, are incorporated into an RNAi effector complex, the RNA-induced silencing complex (RISC), which uses them as guides to target and destroy complementary messenger RNA (mRNA). Recent findings point to a tight connection between microRNA (miRNA) and RNAi molecular machineries. Recent study also has led to the unmasking of a widespread biological regulatory mechanism involving miRNAs (11–17), and there is a wide agreement that the core RNAi machinery carries out numerous cellular functions by an endogenous pathway important for normal development in many organisms, including gene regulation, virus resistance, and chromatin remodeling (1–17). Although some components of the RNAi cellular machinery have been identified, the overall picture is far from clear. We describe the tandem affinity purification (TAP) method (18–20) to isolate protein components of RISC in cultured Drosophila Schneider-2 (S2) cells. This purification method has allowed us to identify several RISC components, including Argonaute 2 (AGO2), the Drosophila homolog of fragile X mental retardation protein (dFMR1), and a DEAD-box RNA helicase Dmp68 (21,22). Identification of components of RNAi/miRNA pathways by the TAP method eliminates the need for large-scale sample From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
1
01_Siomi.qxd
4/16/05
2
11:57 AM
Page 2
Siomi and Siomi
preparation and overcomes, for example, the potential hazards associated with the use of a radioisotope, thereby placing the method within the scope of the average laboratory. The expression of TAP-tagged AGO2, which is an essential component for a siRNA-directed RNAi response (22,23), will be used to illustrate the method utilized for isolation of components of RNAi. This method will be useful for studying many aspects of RNAi/miRNA machineries. 2. Materials 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12.
13. 14. 15.
16. 17. 18. 19.
Drosophila Schneider-2 (S2) cells. pRmHa-C-FLAG-His expression vector. pRmHa-TAP expression vector. Schneider’s Drosophila medium. Spinner bottles. CELLFECTIN. pCoBlast. Blastcidin S Hydrochloride. TAP buffer: 10 mM Tris-HCl (pH 8.0); 150 mM NaCl; 0.5% Triton X-100 (can be replaced by 0.05–0.1% NP-40); protease inhibitors. IgG Sepharose. TEV protease. TEV buffer: 10X Stock buffer and ditheithreitol (DTT) solution are supplied with TEV enzyme when purchased from Invitrogen. Prepare 1X TEV buffer from the stock solution according to the manufacturer’s instruction. Calmodulin affinity resin. Calmodulin-binding buffer: 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Triton X-100; 10 mM β-Mercaptoethanol, 1 mM MgOAc, 1 mM Imidazole, 2 mM CaCl2. Calmodulin elution buffer: 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Triton X-100; 10 mM β-Mercaptoethanol; 1 mM MgOAc, 1 mM Imidazole, 2 mM EGTA (the concentration of EGTA can be higher (up to 10 mM) if the elution efficiency is lower than desired). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) equipment. Coomassie brilliant blue staining solution: 0.22% Coomassie blue R; 50% Methanol; 10% Acetic acid. SYPRO Ruby (Molecular Probes, Inc.). SYPRO Ruby staining is done according to the manufacture’s manual (see Subheading 3.4.). Silver staining kit (Wako, Inc.). Silver staining is done according to the manufacturer’s manual (see Subheading 3.4.).
3. Methods The methods described below outline (1) the construction of the TAP-tagged expression plasmid, (2) the transfection of the plasmid DNA and the induction of protein expression, (3) the purification of the TAP-tagged protein and its
01_Siomi.qxd
4/16/05
11:57 AM
Page 3
TAP Purification of RNAi Components
3
associated proteins from S2 cells, and (4) the identification of associated proteins by mass spectrometric peptide sequencing. 3.1. Expression Plasmid The pRmHa-C expression system was a kind gift of Dr. Frank Lafont (24) and is based on the pRmHa-3 (25). pRmHa-3 contains the Drosophila metallothionein promoter, which is activated by Cu2+ and a polyadenylation signal. pRmHa-3 was modified by introducing a multiple cloning site (EcoRI-SacINheI-KpnI-SmaI-BamHI-Flag tag-EcoRV-10 × His-SalI), FLAG-tag, and His × 10 tag downstream of the metallothionein promoter to generate pRmHa-C (25). The pBS1479 plasmid was a kind gift of Dr. Bertrand Seraphin (18,19) and is a yeast expression vector that contains a TAP tag consisting of two IgG-binding domains of Staphylococcus aureus protein A and a calmodulinbinding peptide (CBP) separated by a TEV protease cleavage site. A BamHIHindIII fragment containing the TAP tag of pBS1479 was subcloned into pBluScript SK (Stratagene, Inc.), which had been cut with BamHI and HindIII. A recombinant plasmid was isolated and designated pBlue-TAP. A BamHISalI fragment of pBlue-TAP was subcloned into pRmHa-C that had been digested with BamHI and SalI, and the desired plasmid was designated pRmHa-TAP. A cDNA encoding a protein of interest (in this case, AGO2) was subcloned into a multiple cloning site (EcoRI-SacI-NheI-KpnI-SmaI-BamHI) of the plasmid (see Note 1), which gave rise to a C-terminal TAP tag fusion gene (see Fig. 1). 3.2. Protein Induction The next steps in this process involve the transfection of the Schneider line 2 (S2) of Drosophila with the expression plasmid for TAP-tagged AGO2 followed by induction with CuSO4 to achieve the production of the fusion protein. 3.2.1. S2 Cells The S2 line is a highly versatile expression system, useful for both the analysis of gene function and generating substantial quantities of expressed protein (25,26). It was originally derived from primary cultures of late-stage Drosophila melanogaster male embryos. S2 cells have also been demonstrated to be amenable to RNAi, thereby permitting selective silencing of gene activity. The S2 cells were grown at room temperature (25°C) under normal atmosphere in Schneider’s Drosophila medium (Gibco, Inc.) supplemented with 10% fetal calf serum (FCS) at densities between 5 × 105 and 5 × 106 cells/mL. Mass cultures were grown in 1-L spinner bottles in 400 mL of medium.
01_Siomi.qxd
4/16/05
11:57 AM
4
Page 4
Siomi and Siomi
Fig. 1. Schematic drawing of pRmHa-AGO2-TAP. The TAP is tagged at the Cterminus of AGO2. CBP: calmodulin-binding peptide; TEV: TEV protease cleavage site; ProtA: two IgG binding domains of Staphylococcus aureus protein A.
3.2.2. Transfection Transfection was performed using CELLFECTIN (Life Technologies, Inc.) as follows: 1. Put 250 µL of FCS-free medium in each of two 1.7-mL Eppendorf tubes. Tube 1: Add 2–6 µg of plasmid DNA into the tube and mix well by pipetting. If wishing to make a stable line, add 0.1–0.3 µg of a plasmid containing cDNA of a blasticidin-resistant gene (pCoBlast; Invitrogen, Inc.) additionally. Tube 2: Add 8 µL of CELLFECTIN into the tube and mix well by pipetting. 2. Add the well-mixed DNA solution into the CELLFECTIN solution tube and mix well by pipetting. 3. Incubate at room temperature (RT) for 20 min. 4. During the incubation time, wash S2 cells (about 1 × 107 cells) with FCS-free medium one or two times. 5. Resuspend the cells with 0.8 mL of FCS-free medium in a 15-mL conical tube.
01_Siomi.qxd
4/16/05
11:57 AM
Page 5
TAP Purification of RNAi Components
5
6. Add the DNA/CELLFECTIN solution into the cell suspension and mix by gentle tapping. 7. Incubate the mixture for 3 h at 25°C. 8. After 3 h incubation, spin down the cells at 400–700g for 5 min. Discard the supernatant and resuspend the cells with 8 mL of S2 medium containing 10% FCS and incubate at 25°C. 9. For heterologous protein expression, on d 2, one-half of the transfected cells are incubated with CuSO4 at 1 mM, and cells are harvested after 12 h. 10. To generate stably transfected S2 cell lines, on the same day, add blasticidin (Blastcidin S Hydrochloride; Waken, Inc.) at 25 µg/mL to the other half of the transfected cells. After 2–3 wk of selection, resistant clones have grown. Cells are replated in fresh medium every 4 d over the selection period. These clones are kept together and are used as polyclonal cell lines. Note that it is difficult to obtain monoclonal S2 cell lines mainly because S2 cells grow poorly at low densities. Frozen stocks are kept in 80% FCS, 10% dimethyl sulfoxide at –80°C.
3.3. TAP Purification Protein purification by the TAP method is performed as follows. 1. Harvest S2 cells expressing the TAP-tagged protein of interest. 2. Wash the cells twice with cold PBS. 3. Resuspend the cells in cold TAP buffer. One milliliter of TAP buffer is needed per 107–108 cells. 4. Pass the cell suspension through a 25-gauge needle attached to a syringe five times. During this step, the sample should be kept on ice. If cells are not disrupted enough at this point, pass the sample several times through a 30-gauge needle after the 25-gauge needle passage to ensure cell lysis. 5. Transfer the sample to 1.7-mL microtubes and spin at 16,000g for 1–2 min at 4°C. 6. Take the supernatant and transfer it to new microtubes. This is the cytoplasmic lysate used for further purification steps. If you wish to obtain the whole-cell lysate at this point, the cell suspension at step 4 should be sonicated on ice and steps 5 and 6 then followed. 7. The supernatant is now mixed with IgG SepharoseTM 6 Fast Flow beads (Amersham Biosciences, Inc.) in microtubes and rocked for 1–2 h at 4°C. Prior to this step, an aliquot of the IgG beads (approx 30–40 µL) is placed into a 1.7-mL microtube, washed with TAP buffer several times, and kept on ice. 8. Wash the IgG beads with TAP buffer five times (see Note 2). After the last wash, spin the tubes briefly to collect residual buffers to the bottom, suck them up, and discard. 9. Wash with TEV buffer once. Drain the beads well, as in step 8. Add TEV buffer to the beads. The buffer volume used here is about 500 µL per tube. 10. Add TEV (Invitrogen) to the beads. The enzyme volume added is 1/100 vol of the buffer. Rock at 16°C for 2 h. 11. Spin at 16,000g for 1–2 min at 4°C. Transfer the supernatant into new microtubes.
01_Siomi.qxd
6
4/16/05
11:57 AM
Page 6
Siomi and Siomi
Fig. 2. Purification of proteins that associate with AGO2 by using a C-terminal TAP tag. The protein components in the “IgG bound” obtained from S2 cells expressing the Cterminal TAP-tagged AGO2 (AGO2-TAP) and the parental cells (control) were resolved on SDS-PAGE and visualized by Coomassie blue staining. Several distinct bands (indicated with asterisks) are observed only in the AGO2–TAP lane. The purification was done from 150 mL of S2 cell culture. The left lane represents molecular markers. 12. Add 100 µL of TEV buffer to the beads, and mix well by tapping. Take the supernatant after the spinning at 16,000g for 1–2 min at 4°C and combine it with the sample obtained at step 11. 13. Spin again at 16,000g for 1–2 min at 4°C to make sure all of the beads sediment at the bottom of the tubes. Take the supernatant and transfer it to new tubes. 14. Add 3 mL of calmodulin-binding buffer and 2 µL of 1 M CaCl2 per 1 mL of the sample. 15. Mix with calmodulin affinity resin (Stratagene, Inc.) and rock for 1 h at 4°C. An aliquot of the calmodulin beads (approx 30–40 µL) is placed in each microtube and washed with calmodulin-binding buffer several times prior to use. 16. Wash the beads with calmodulin-binding buffer five times. After the last wash, spin briefly to collect the residual buffer to the bottom and drain well.
01_Siomi.qxd
4/16/05
11:57 AM
Page 7
TAP Purification of RNAi Components
7
17. Add EGTA-containing elution buffer to the beads; rock at RT for 15 min or longer to elute the TAP complexes. If the volume is higher than desired at this point, perform a trichloroacetic acid (TCA) precipitation to concentrate the protein sample. 18. Run the sample on a protein gel and stain to visualize the protein bands.
3.4. Identification of TAP Affinity Purified Proteins The final extracts were visualized on SDS-PAGE gels by Coomassie brilliant blue (ICN Biomedicals, Inc.) staining, SYPRO Ruby staining using a SYPRO Ruby Protein gel stain kit (Molecular Probes, Inc.), or silver staining using SilverQuest Silver Staining kit (Invitrogen) or Silver Stain II kit (Wako, Inc). Stained bands (see Fig. 2) were excised from the gels, digested with trypsin, and processed for mass spectrometric fingerprinting as described (21). Using mass spectrometry and the complete Drosophila genome (the Celera/Berkeley Drosophila protein database), it is relatively easy to identify each of the specific bands on the gels. 4. Notes 1. Usually, standard DNA cloning procedures can be used to introduce the C-terminal TAP tag in frame with the coding region of the protein of interest. The upstream sequence of the initiation ATG is often very important for getting sufficient expression levels of the TAP-tagged protein of interest. If the Kozak sequence of the gene of interest is not close to the consensus Kozak sequence of Drosophila melanogaster, you might need to modify the sequence upstream (and downstream) of the initiation ATG of the gene. 2. If the background is high when you visualize proteins recovered following TAP purification, you might use a higher salt concentration in the washing buffer. However, of course, a high salt level would disrupt the interaction of TAP-tagged proteins with proteins. Therefore, you might have to selectively adjust TAP purification conditions (salt and/or detergent concentrations, incubation time for binding, and so on).
Acknowledgments The authors thank Dr. B. Seraphin for providing the TAP plasmids. We also thank Dr. F. Lafont for the pRmHa plasmid. This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) and the Japan Society for the Promotion of Science (JSPS). References 1. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811. 2. Novina, C. D. and Sharp, P. A. (2004) The RNAi revolution. Nature 430, 161–164.
01_Siomi.qxd
8
4/16/05
11:57 AM
Page 8
Siomi and Siomi
3. Dykxhoorn, D. M., Novina, C. D., and Sharp, P. A. (2003) Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4, 457–467. 4. Pederson, T. (2004) RNA interference and mRNA silencing, 2004: how far will they reach? Mol. Biol. Cell 15, 407–410. 5. Denli, A. M. and Hannon, G. J. (2003) RNAi: an ever-growing puzzle. Trends Biochem. Sci. 28, 196–201. 6. Zamore, P. D. (2004) Plant RNAi: how a viral silencing suppressor inactivates siRNA. Curr. Biol. 14, R198–R200. 7. Hutvagner, G. and Zamore, P. D. (2002) RNAi: nature abhors a double-strand. Curr. Opin. Genet. Dev. 12, 225–232. 8. Matzke, A. M. and Matzke, A. J. M. (2004) Planting the seeds of a new paradigm. PLoS Biol. 2, 582–586. 9. Matzke, M. and Matzke, A. J. M. (2003) RNAi extends its reach. Science 301, 1060–1061. 10. Siomi, H., Ishizuka, A. and Siomi, M. C. (2004) RNA interference: a new mechanism by which FMRP acts in the normal brain? What can Drosophila teach us? Ment. Retard. Dev. Disabil. Res. Rev. 10, 68–74. 11. He, L. and Hannon, G. J. (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522–531. 12. Bartel, D. P. and Chen, C. Z. (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5, 396–400. 13. Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297. 14. Bartel, B. and Bartel, D. P. (2003) MicroRNAs: at the root of plant development? Plant Physiol. 132, 709–717. 15. Lai, E. C. (2003) microRNAs: runts of the genome assert themselves. Curr. Biol. 13, R925–R936. 16. Aravin, A. A., Lagos-Quintana, M., Yalcin, A., et al. (2003) The small RNA profile during Drosophila melanogaster development. Dev. Cell 5, 337–350. 17. Stark, A., Brennecke, J., Russell, R. B., and Cohen, S. M. (2003) Identification of Drosophila MicroRNA Targets. PLoS Biol. 1, E60. 18. Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., and Seraphin, B. (1999) A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17, 1030–1032. 19. Puig, O., Caspary, F., Rigaut, G., et al. (2001) The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24, 218–229. 20. Forler, D., Kocher, T., Rode, M., Gentzel, M., Izaurralde, E., and Wilm, M. (2003) An efficient protein complex purification method for functional proteomics in higher eukaryotes. Nat. Biotechnol. 21, 89–92. 21. Ishizuka, A., Siomi, M. C., and Siomi, H. (2002) A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 16, 2497–2508.
01_Siomi.qxd
4/16/05
11:57 AM
Page 9
TAP Purification of RNAi Components
9
22. Okamura, K., Ishizuka, A., Siomi, H., and Siomi, M. C. (2004) Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 18, 1655–1666. 23. Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R., and Hannon, G. J. (2001) Argonaute2, a link between genetic and biochemical analysis of RNAi. Science 293, 1146–1150. 24. Lafont, F., Lecat, S., Verkade, P., and Simons, K. (1998) Annexin XIIIb associates with lipid microdomains to function in apical delivery. J. Cell. Biol. 142, 1413–1427. 25. Benting, J., Lecat, S., Zacchetti, D., and Simons, K. (2000) Protein expression in Drosophila Schneider cells. Anal. Biochem. 278, 59–68. 26. Towers, P. R. and Sattelle, D. B. (2002) A Drosophila melanogaster cell line (S2) facilitates post-genome functional analysis of receptors and ion channels. Bioessays 24, 1066–1073.
01_Siomi.qxd
4/16/05
11:57 AM
Page 10
02_Sontheimer.qxd
4/16/05
4:43 PM
Page 11
2 Separation of Drosophila RNA Silencing Complexes by Native Gel Electrophoresis John W. Pham and Erik J. Sontheimer 1. Introduction Large, multicomponent complexes mediate many stages of eukaryotic gene expression, from transcription to translation. Despite their size, these complexes and their precursors can often be resolved and analyzed by native gel electrophoresis. Although other techniques exist for large-scale separations, native gels require very little sample, making them superior for analytical applications. We have developed a native gel system for rapidly and reliably separating complexes that form on short interfering RNAs (siRNAs) (1). This approach has facilitated our analysis of RNA silencing complexes and holds promise for additional mechanistic studies, particularly those that are limited by sample size [such as experiments with mutant lysates (2)]. In this chapter, we describe the procedures involved in reproducibly detecting Drosophila siRNA/protein complexes and discuss significant issues as well as techniques for optimization. 2. Materials 1. 2. 3. 4. 5. 6. 7. 8. 9.
Oligonucleotide siRNAs (Dharmacon or IDT). T4 Polynucleotide kinase (New England Biolabs). [γ-32P]ATP (MP Biomedicals). 1X Annealing buffer: 30 mM HEPES, pH 7.5, 100 mM potassium acetate, 2 mM magnesium acetate. 1X Lysis buffer: 1X annealing buffer with 5 mM dithiothreitol (DTT) and 1 mg/mL Pefabloc SC (Boehringer Mannheim). 20% 19 : 1 Acrylamide : bisacrylamide (Bio-Rad). Elution buffer: 0.5 M sodium acetate, 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8.0, 0.1% sodium dodecyl sulfate (SDS). 40% Acrylamide (Bio-Rad). 2% Bisacrylamide (Bio-Rad). From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
11
02_Sontheimer.qxd
4/16/05
4:43 PM
Page 12
12
Pham and Sontheimer
10. 11. 12. 13. 14. 15. 16. 17. 18. 19.
Ammonium persulfate (Fisher). TEMED (Bio-Rad). 2X TBE: 178 mM Tris base, 178 mM boric acid, 4 mM EDTA, (final pH 8.3). Glycerol (Fisher). Creatine phosphate (Sigma). Creatine kinase (Calbiochem). 100 mM ATP (Amersham). Dithiothreitol (Sigma). Drosophila embryo extract. Native gel dye: 2 mM Tris-HCl, pH 7.4, 30 mg/mL Ficoll-400, 0.04% bromophenol blue. Heparin mix: 60 mM potassium phosphate, 3 mM magnesium chloride, 3% PEG8000, 8% glycerol, 4 mg/mL heparin. BioMax XAR film (Kodak). RNA guard ribonuclease inhibitor (Amersham). 5X RNA; mix: 125 mM creative phosphate, 5 mM ATP, 25 mM dithiotheritol.
20. 21. 22. 23.
3. Methods 3.1. siRNA Preparation 3.1.1. siRNA Labeling Synthetic single-stranded siRNAs can be labeled either at their 3′ or 5′ ends, using poly(A) polymerase (Amersham) with [γ-32P]cordycepin 5′-triphosphate (New England Nuclear) or T4 polynucleotide kinase (PNK) with [γ-32P]ATP, respectively, using the manufacturer’s instructions (see Note 1). Isolate the labeled siRNAs in a 15% (19 : 1 acrylamide : bisacrylamide) denaturing gel run in 1X TBE and recover them from the gel by gentle agitation at room temperature in 400 µL of elution buffer. Approximately 75–85% of the siRNA will elute from the gel in 2 h. After transferring the aqueous phase to a fresh tube, precipitate the siRNAs by adding 1.1 mL of absolute ethanol, chilling the mixture for at least 20 min at −20°C, and spinning in a centrifuge at 4°C for 15 min at 16,000g. Wash the pelleted siRNAs with 70% ethanol and quantify by Cerenkov counting. 3.1.2. siRNA Annealing Anneal the siRNAs by combining an equimolar amount of each strand in 1X annealing buffer, heating to 95°C for 2 min and cooling at 37°C for 1 h (see Note 2). A typical annealing mixture contains at least 0.5 µM RNA in a 10-µL volume. The siRNAs should be stored at −20°C at this concentration and diluted in 1X annealing buffer to approx 7500 cpm/µL just prior to use (see Note 3). 3.2. Native Gel Preparation 1. To prepare the 4% (40 : 1 acrylamide : bisacrylamide) native gel, combine 13.8 mL distilled water (dH2O), 20 mL 2X TBE, 4 mL 40% acrylamide, and 2 mL 2% bisacrylamide, and mix well.
02_Sontheimer.qxd
4/16/05
4:43 PM
Page 13
Separation of RNA Silencing Complexes
13
2. Add 180 µL 10% ammonium persulfate and 43.3 µL TEMED, and mix. This recipe produces a solution adequate for a 0.8-mm × 17-cm × 23-cm gel. The combs we use produce wells that are approx 0.6 cm wide and are inserted into the gel to a depth of roughly 1 cm. 3. Pour an excess amount of gel solution on top of the comb after inserting it into the gel to facilitate polymerization of the wells. It might be necessary to raise the top end of the gel (approx 25°) to prevent the solution from leaking out of the top. The gel will polymerize in approx 20 min. 4. After the gel polymerizes, assemble the gel apparatus and fill the chamber with 1X TBE. 5. Remove the comb and, using a razor blade, cut off any excess polymerized material at the top of the gel. The gel should be chilled at 4°C until the temperature of the buffer drops to 6°C (see Note 4). 6. Pre-run the gel for at least 30 min at constant power (10 W, which corresponds to approx 360 V using a gel of the dimensions noted above).
3.3. RNAi Reactions 3.3.1. Lysate Preparation 1. Prepare Drosophila embryo lysates as previously described (3). Briefly, collect 0–2 h embryos in a mesh-lined basket and treat them with 50% bleach for 4 min. 2. After rinsing away the bleach with H2O, blot the embryos on Kimwipes until blotting no longer leaves water on the Kimwipes. 3. Carefully transfer the embryos to a preweighed microcentrifuge tube and weigh. 4. Add 1 µL of 1X lysis buffer per milligram of embryos and homogenize (on ice) using a pestle. 5. Spin the lysate at 16,000g at 4°C for 25 min to pellet the cellular debris. 6. Collect the lysate, avoiding the insoluble material, and spin for 5 min. Repeat as necessary until the lysate is free of insoluble material. 7. Flash-freeze the lysate in liquid N2 and store at −80°C.
3.3.2. Sample Preparation and Analysis 1. A typical RNAi reaction mixture supplemented with glycerol can be used for native gel analysis. However, the conditions can be modified to optimize complex formation (see Note 5). We observe consistent, robust complex formation using the following mixture: 0.75 µL of Drosophila embryo extract, 1.75 µL of 1X lysis buffer, 1 µL of 5X RNAi mix, 0.375 µL of 0.2 µg/mL creatine kinase, 0.125 µL of RNAguard, 0.5 µL of glycerol, and 0.5 µL of siRNA duplex (see Subheading 3.1.2.). This mixture can be prepared in larger volumes and separated into 5 µL aliquots. Incubate the 5 µL reaction mixtures at 25°C for 30–60 min (see Note 5) and transfer the tubes to ice. 2. Add 1 µL of heparin mixture, mix well by pipetting up and down, and spin quickly at 4°C. 3. Immediately load onto a prechilled, prerun native gel (see Section 3.2). 4. Load the native gel dye into an unused well. 5. Run the gel at constant power (10 W) until the bromophenol blue dye migrates 11 cm from the bottom of the well. The total run time should be approx 1.5 h.
02_Sontheimer.qxd
14
4/16/05
4:43 PM
Page 14
Pham and Sontheimer
Fig. 1. Native polyacrylamide gel analysis of complexes formed on a radiolabeled siRNA duplex in Drosophila embryo lysate. The name of each complex (1) is given on the right, (see Note 6). 6. Transfer the gel to Whatman paper, dry in a gel-drying apparatus, and expose to film (with an intensifying screen) at −80°C or to a phosphorimager screen overnight. A typical autoradiograph of a native gel lane is shown in Fig. 1. We initially named the three complexes R1, R2, and R3, in order of decreasing mobility (1). The R2 complex has a somewhat variable mobility, but it always migrates between R1 and R3. R1 and R2 are assembly intermediates, whereas R3 is a large (approx 80S) functional form of RISC (1) (see Note 6).
4. Notes 1. We have used both methods and prefer 5′-end labeling because the reagents are comparatively inexpensive. Furthermore, T4 PNK can be used to label siRNAs that already have a 5′-phosphate—prior treatment with a phosphatase is not required. Although an initial report indicated that siRNA 5′-phosphate groups are rapidly removed in Drosophila embryo lysates (4), later work (5) indicated that this is not a consistent phenomenon. 2. For most applications, only one strand of the siRNA duplex needs to be labeled. One should be mindful, however, of the asymmetry rules that determine which RNA strand is incorporated into RISC (5,6).
02_Sontheimer.qxd
4/16/05
4:43 PM
Page 15
Separation of RNA Silencing Complexes
15
3. It may be necessary in some circumstances to control the exact molar amount of siRNA added to a reaction. In these cases, adjust your dilution protocol accordingly. When this level of control is not required, the dilution protocol described will provide a robust signal in an overnight exposure to film (using an intensifying screen), provided that the label has not decayed much beyond two half-lives. 4. It is critical that the gel be prechilled in order to see all of the complexes (particularly R2, which is less stable than the other complexes). It takes about 2 h to chill 1 L of buffer from room temperature to approx 6°C in a 4°C cold room. This amount of time can be significantly reduced by adding frozen 1X TBE to the buffer. 5. A number of factors contribute to consistent and robust complex formation. These factors include incubation time, total protein concentration in the lysate, gel buffer conditions (temperature), and sample volume. Because the complexes appear to be linked in a pathway (1), longer incubation times will favor formation of higherorder complexes (R3, holo-RISC). Likewise, higher protein concentrations will favor holo-RISC formation (presumably by providing more of a limiting factor, although too much protein disrupts complex formation for unknown reasons). We recommend performing an extract titration and time-course to determine the conditions most suitable for analysis. Once the optimal protein concentrations are determined, it would be wise to normalize all extract preparations to match the one determined to be optimal. As noted above, R2 is more stable at lower temperatures. It is also more consistently observed in 5-µL reaction mixtures compared to 10-µL mixtures. This may be due to a surface tension effect, as the mixture spreads to cover the bottom of the microcentrifuge tube at lower volumes. 6. Zamore and co-workers independently developed an agarose native gel system for similar purposes (7) and observed two complexes, A and R, which may resemble R2 and R3, respectively. They also detected a complex (B) that was not apparent in our polyacrylamide gels; conversely, they did not observe a complex that was clearly analogous to R1 (7).
Acknowledgments We are grateful to Richard Carthew and members of his laboratory for help with Drosophila manipulations and for advice and discussions. This work was supported by an NIH Biophysics Training Grant (J. W. Pham), a Burroughs Wellcome Fund New Investigator Award in the Basic Pharmacological Sciences (E. J. Sontheimer), and NIH grant GM068743-01 (R. W. Carthew and E. J. Sontheimer). References 1. Pham, J. W., Pellino, J. L., Lee, Y. S., Carthew, R. W., and Sontheimer, E. J. (2004) A Dicer-2-dependent 80S complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 117, 83–94. 2. Lee, Y. S., Nakahara, K., Pham, J. W., et al. (2004) Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117, 69–81.
02_Sontheimer.qxd
16
4/16/05
4:43 PM
Page 16
Pham and Sontheimer
3. Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P., and Sharp, P. A. (1999) Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13, 3191–3197. 4. Nykanen, A., Haley, B., and Zamore, P. D. (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309–321. 5. Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P. D. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208. 6. Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209–216. 7. Tomari, Y., Du, T., Haley, B., et al. (2004) RISC assembly defects in the Drosophila RNAi mutant armitage. Cell 116, 831–841.
03_Kim.qxd
4/16/05
12:01 PM
Page 17
3 Preparation and Analysis of Drosha Yoontae Lee and V. Narry Kim 1. Introduction 1.1. Drosha, the Class II RNase III Protein Drosha is a member of the ribonuclease (RNase) III family. Like other RNase III proteins, Drosha is a double-stranded RNA (dsRNA)–specific endonuclease that introduces staggered cuts on each strand of the RNA helix (1,2). RNase III proteins are classified based on domain organization. Drosha and its homologs belong to class II, in which each member contains tandem RNase III catalytic motifs and one C-terminal dsRNA-binding domain (dsRBD) (3,4). Drosha also possesses an extended N-terminal domain whose function is currently unknown. Class I proteins are simpler and possess only one RNase III catalytic motif and a dsRNA-binding domain (dsRBD). The Dicer homologs of class III proteins contain a putative helicase domain, a PAZ domain, and a DUF283 domain apart from tandem nuclease domains and a dsRBD. The human genome encodes only two RNase III proteins: Drosha and Dicer. Whereas Dicer homologs are found in a broad range of eukaryotic organisms, Drosha homologs are present only in animals but not in yeast or plants. Drosha was initially identified in Drosophila as an open reading frame adjacent to the RNase H gene (3). The human homolog was first described as a protein that interacts with the transcription factor Sp1 in a yeast two-hybrid screening, although the significance of this interaction is still unclear (5). The first functional study was carried out by Stanley Crooke and colleagues, where human Drosha was referred to as “human RNase III” and was shown to be a nuclear protein (6). The role of Drosha was implicated in pre-rRNA processing in this study because downregulation of Drosha using antisense oligonucleotides resulted in moderate accumulation of pre-rRNA processing From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
17
03_Kim.qxd
4/16/05
12:01 PM
Page 18
18
Lee and Kim
intermediates. It remains to be determined, however, whether Drosha is directly involved in pre-rRNA processing. 1.2. Drosha and MicroRNA Processing A more recent analysis of Drosha revealed that it functions in the initiation step of microRNA processing (7,8). MicroRNAs (miRNAs) are approx 22-nt RNAs that base-pair with mRNAs, leading to the cleavage of the mRNA or to the inhibition of protein synthesis (9). The target genes of miRNA are known to function in cellular differentiation, development, apoptosis, and organogenesis. In animals, miRNA genes are transcribed to yield long primary transcripts (pri-miRNAs), often as long as several kilobases (10). Pri-miRNAs contain local hairpin structures, and the miRNA sequences are located in the stem of the hairpin. From these long pri-miRNA transcripts, mature miRNAs are generated through two sequential processing events. First, Drosha recognizes the substrate and makes cleavage in the nucleus (8). The resulting hairpin RNA (termed pre-miRNA) is approx 70 nt in length and contains an approx 2-nt 3′ overhang. Pre-miRNAs are then exported out of the nucleus by exportin 5, a member of the Ran-dependent nuclear transport receptor family (11–13). In the cytoplasm, another RNase III protein, Dicer, cleaves the pre-miRNA at approx 22 nt away from the bottom of the stem (14–18). MicroRNA maturation appears to be a well-coordinated procedure. Drosha generates short 3′ overhangs on its products, which are believed to be the defining feature of RNAs involved in a small RNA pathway. In fact, this short 3′overhang is effectively recognized by exportin 5 and Dicer, thereby facilitating miRNA biogenesis (8,12). Apart from enhancing the overall yield of miRNA biogenesis, Drosha contributes to the accuracy of miRNA maturation. Drosha creates one end of miRNA by precisely cutting at the lower part of the hairpin. 1.3. How to Prepare the Drosha Protein Partially because of its large size (160 kDa in humans) and low solubility, purification of the full-length recombinant Drosha in Escherichia coli has been unsuccessful. As an alternative, the Drosha protein can be immunopurified from mammalian cells that overexpress Drosha (see Subheading 3.1.). To accomplish this, FLAG epitope-tagged Drosha expression plasmid is transfected into HEK293T cells for the transient expression of Drosha. Total-cell lysate or nuclear extract is incubated with anti-FLAG antibody conjugated to agarose beads for immunoprecipitation. The immunoprecipitated Drosha protein can be characterized in enzyme assay (see Subheading 3.2.). It should be noted that the immunoprecipitation procedure described here does not aim for the purification of the Drosha protein to homogeneity. In fact,
03_Kim.qxd
4/16/05
12:01 PM
Page 19
Preparation and Analysis of Drosha
19
Drosha forms a large complex together with essential co-factor(s) (Lee and Kim, unpublished results). Therefore, complete purification of Drosha is not desirable in the preparation of a catalytically active protein. 1.4. How to Design the Substrates for Drosha The RNA segments to be cleaved in a cropping reaction can be transcribed in vitro. The DNA segment containing miRNA sequences should be amplified from genomic DNA by polymerase chain reaction (PCR) and placed under a T7 promoter (or SP6 promoter). The PCR product can be inserted into a cloning vector containing a T7 promoter (or SP6 promoter). The resulting plasmid should be linearized at a restriction enzyme site located downstream of the primiRNA sequences before transcription. Alternatively, the PCR product can be used directly for in vitro transcription. In this case, the forward primer should contain the promoter sequences to drive transcription directly from the PCR product. The complicated part is in deciding how much of the region around the miRNA should be included to achieve efficient processing. The full-length pri-miRNAs are usually over several kilobases long, which is too long to handle in this kind of experiment. By the rule of thumb, we amplify a genomic segment containing a given miRNA stem loop plus the surrounding sequences approx 100 bp from each side of the stem loop (see Fig. 1). This should include all of the cis-acting element(s) recognized by the Drosha complex. 1.5. Depletion of Drosha The function of Drosha can be studied in vivo by depleting Drosha. This can be achieved by RNA interference (RNAi), which involves transfection of siRNAS targeting Drosha mRNA. The effect on miRNA biogenesis can be examined by reverse transcription (RT)-PCR, RNase protection assay (RPA), or Northern blot analysis. RT-PCR is the easiest means of determining the pri-miRNA level. The primers are usually designed to bind about 50 nt away from the stem loop. RNase protection assay can be used to detect primiRNA, pre-miRNA, and mature miRNA at the same time. However, it is often difficult to optimize the probe and condition. Northern blot analysis is to detect mature miRNA as well as pre-miRNA. Both mature and premiRNA diminishes after depletion of Drosha. However, it might take more than 6 d to obtain a dramatic effect on mature miRNA because mature miRNA has a long half-life. For prolonged incubation, it is desirable to transfect twice; split the cells on the third day and repeat transfection on the fourth day.
03_Kim.qxd
4/16/05
12:01 PM
Page 20
20
Lee and Kim
Fig. 1. Outline of the general experimental strategy to prepare the substrate for Drosha.
2. Materials 2.1. Preparation of the Drosha Protein 1. Mammalian expression plasmid containing human Drosha cDNA and a FLAG epitope fused in frame. 2. HEK293T cells, culture medium (Dulbecco’s modified Eagle’s medium [DMEM] supplemented with 10% fetal bovine serum [FBS]), culture equipments, transfection reagent (calcium phosphate method is the most economic and efficient choice for this experiment).
03_Kim.qxd
4/16/05
12:01 PM
Page 21
Preparation and Analysis of Drosha
21
3. Phosphate-buffered saline (PBS): Dissolve 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 • 2H2O, 0.2 g KH2PO4 in water, check pH (should be 7.2), set volume to 1 L, and autoclave (see Note 1). 4. Lysis buffer: 20 mM Tris-HCl (pH 7.8), 100 mM KCl, 0.2 mM EDTA, 20% (v/v) glycerol, and 1 mM PMSF (see Note 2). 5. Anti-FLAG antibody conjugated agarose (Anti-FLAG M2 Affinity Gel FreezerSafe; Sigma). 6. Sonicator (Sonics, VC130). 7. Microcentrifuge with cooling.
2.2. Detection o f Pri-miRNA Processing Activity 2.2.1. In Vitro Transcription 1. Template plasmid (1 mg/mL): This plasmid contains the T7 or SP6 promoter followed by pri-miRNA sequences. This plasmid must be linearized at a restriction site located downstream of the pri-miRNA sequences (see Note 3). 2. 100 mM Stock solutions of ATP, CTP, GTP, and UTP. 3. α-32P-UTP (20 µCi/µL, 800 mCi/mmol). 4. T7 or SP6 RNA polymerase. 5. 10X transcription buffer (use buffer provided with the polymerase). 6. RNase inhibiter (RNasin or equivalent, 40U/µL). 7. RNase-free water.
2.2.2. Purification of Radiolabeled Pri-miRNA 1. Hoeffer gel apparatus (SE600, 18 × 16 cm) or equivalent, plates, combs (0.75 mm, 10 wells), spacers (0.75 mm), and a power supply. 2. 5X TBE stock solution: 54 g Tris base, 27.5 g boric acid, and 20 mL of 0.5 M EDTA, pH 8.0, dissolved in distilled water to make 1 L. 3. 6% urea–polyacrylamide stock solution: 57 g acrylamide, 3 g bis-acrylamide, 100 mL of 5X TBE stock solution (final, 0.5X), and 420.42 g urea (final, 7M) in distilled water to make 1 L (see Note 4). 4. 20% Ammonium persulfate (APS) solution. 5. N, N,N′,N ′-Tetramethylethylenediamine (TEMED). 6. Phenol : chloroform : isoamyl alcohol (IAA) (25 : 24 : 1), pH 6.6. 7. 5 M ammonium acetate. 8. 3 M sodium acetate, pH 5.5. 9. Glycogen (5 mg/mL; Ambion). 10. TE buffer: 10 mM Tris-HCl, pH 7.5, and 1 mM EDTA. 11. RNA elution buffer: 0.3 M sodium acetate, pH 5.5, and 2% sodium dodecyl sulfate (SDS). 12. RNA loading buffer: 95% deionized formamide, 0.025% bromophenol blue, 0.025% xylene cyanol, 5 mM EDTA, and 0.025% SDS. 13. G-50 prepacked column (NICKTM column; Amersham). 14. Ethanol: 100% and 75%. 15. Microcentrifuge with cooling. 16. Thermoblock at 37°C/95°C. 17. Kodak X-AR5 autoradiography films.
03_Kim.qxd
4/16/05
12:01 PM
Page 22
22
Lee and Kim
2.2.3. In Vitro Processing Assay 1. 2. 3. 4. 5. 6.
7. 8. 9. 10. 11. 12. 13. 14. 15.
Radiolabeled pri-miRNA transcript. HEK293T whole-cell extract or FLAG–Drosha immunoprecipitate. 10X Reaction buffer (64 mM MgCl2) (see Note 5). RNase inhibitor (RNasin or equivalent, 40 U/µL). Hoeffer gel apparatus (18 × 16 cm) or equivalent, combs (0.75 mm, 15 wells), spacers (0.75 mm), and a power supply. Urea–polyacrylamide stock solution (12.5%): 118.75 g acrylamide, 6.25 g bisacrylamide, 100 mL of 5X TBE (final, 0.5X), and 420.42 g urea (final, 7 M) in water to make 1 L. APS solution: 20% dissolved in water. TEMED. RNA elution buffer: 0.3 M sodium acetate, pH 5.5, and 2% SDS. Phenol : chloroform : IAA (25 : 24 : 1), pH 6.6. 3 M sodium acetate solution, pH 5.5. RNA loading buffer: 95% deionized formamide, 0.025% bromophenol blue, 0.025% xylene cyanol, 5 mM EDTA, and 0.025% SDS. Thermoblock at 37°C/95°C. Kodak X-AR5 autoradiography films. Autoradiography cassettes with intensifying screens.
2.3. RNAi Against Drosha 1. Drosha-targeting siRNA duplex (20 µM stock) (Samchully). Targeted mRNA sequence: 5′ AACGAGUAGGCUUCGUGACUU 3′ Sense siRNA: 5′ CGAGUAGGCUUCGUGACUUdTdT 3′ Antisense siRNA: 5′ AAGUCACGAAGCCUACUCGdTdT 3′ 2. OLIGOFECTAMINE (Invitrogen) (see Note 6). 3. Opti-MEM (Gibco-BRL). 4. HeLa cells.
3. Methods 3.1. Preparation of the Drosha Protein (See Note 6) 3.1.1. Preparation of HEK293T Whole-Cell Extract 1. Grow HEK293T cells on 100-mm dish to 95% confluency. 2. Remove the media and rinse the cells with 5 mL of ice-cold PBS. 3. Add 1 mL of ice-cold PBS, collect the cells by pipetting, and transfer to an Eppendorf tube. 4. Centrifuge at 3300 g at 4°C for 5 min. 5. Decant the PBS and resuspend the cell pellet in 500 µL of lysis buffer. 6. Sonicate 10 times (for 5 s each) with short intervals at 30% amplitude. 7. Centrifuge at 13,400 g at 4°C for 15 min. 8. Transfer the supernatant to a fresh tube. This is the HEK293T whole-cell extract.
03_Kim.qxd
4/16/05
12:01 PM
Page 23
Preparation and Analysis of Drosha
23
3.1.2. Immunoprecipitation of the Drosha Protein 1. Prepare HEK293T whole cell extract as described above using HEK293T cells transfected with the Drosha–FLAG expression plasmid. 2. Wash 15 µL of anti-FLAG antibody conjugated beads twice with 1mL of lysis buffer. 3. Add 500 µL of HEK293T whole-cell extract to the washed beads. 4. Rotate the tube at 4°C for 1 h. 5. Centrifuge at 5900 g at 4°C for 2 min. 6. Remove the supernatant, add 1 mL of lysis buffer, and wash the beads by inverting the tube six to seven times. 7. Centrifuge at 5900 g at 4°C for 2 min. 8. Repeat steps 6 and 7 four times. 9. Drain the beads (15 µL) that hold the immobilized FLAG–Drosha protein. Keep the beads wet and cold on ice until they are used for enzyme assay (see Note 6).
3.2. Detection of Drosha Processing Activity 3.2.1. In Vitro Transcription (See Note 6) 1. Mix the following at room temperature (RT): 1 µL of template DNA (linearized, 1 mg/mL), 2 µL of 10X transcription buffer, 2 µL of NTP mixture (10 mM ATP, 10 mM GTP, 10 mM CTP, 1 mM UTP), 0.5 µL of RNase inhibiter (40 U/µL), 1.5 µL of α-32P-UTP (20 µCi/µL, 800 mCi/mmol), 1 µL of RNA polymerase (T7 or SP6), and 12 µL of RNase-free water. Adjust the total volume to 20 µL. 2. Incubate at 37°C for 3 h.
3.2.2. Purification of Radiolabeled Pri-miRNAs 1. Add 220 µL of TE buffer to the above reaction mixture. 2. Add 240 µL of phenol : chloroform : IAA (25 : 24 : 1) and vortex for 30 s. Centrifuge for 5 min at RT and take the upper layer. 3. Add 160 µL of 5 M ammonium acetate, 1 µL of glycogen, 1 mL of 100% ethanol. Mix and leave the tube at −80°C for at least 20 min (or 5 min in dry ice–methanol mix, or overnight at −20°C). 4. Centrifuge at full speed (at least 13,400 g) at 4°C for 15 min. 5. Remove the supernatant carefully so as not to disturb the RNA pellet. 6. Wash the pellet with 500 µL of 75% ethanol. 7. Air-dry and resuspend the pellet in 20 µL of RNA loading buffer. 8. Assemble a gel cast. 9. Mix 20 mL of 6% urea–polyacrylamide stock solution, 100 µL of 20% APS, and 20 µL of TEMED. Pour this mixture into the gel cast immediately and insert a comb as quickly as possible because the gel solidifies in a few minutes. 10. Prerun at 350 V for at least 90 min. Running buffer is 0.5X TBE. 11. Load the RNA sample (step 7) on 6% urea–polyacrylamide gel and run at 350 V until bromophenol blue reaches the bottom of the gel. 12. Dissemble the gel cast and remove one of the glass plates from the gel. Wrap the gel in Saran film and place an X-ray film on the gel for 30 s to 1 min. Make sure to
03_Kim.qxd
4/16/05
12:01 PM
Page 24
24
13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26.
Lee and Kim mark the position and orientation of the gel on the film so that the gel can be aligned with the film once the film is developed. The radiolabled transcript will appear as a strong band on the developed film. Align the film with the gel and cut out the gel slice containing RNA. Put the gel slice in 350 µL of RNA elution buffer. Incubate overnight at 42°C. Transfer the supernatant (about 300 µL) to a fresh tube. Add 100 µL of RNA elution buffer to the gel slice and vortex. Remove the supernatant and add it to the previous supernatant. Prepare G-50 column by prewashing it with 3 mL of TE buffer. Load the supernatant containing RNA onto the column. Place a fresh tube under the column and elute by adding 400 µL of TE buffer onto the column. This is the first fraction. Repeat step 19 to collect the second fraction. To each 400-µL fraction, add 1 µL of glycogen, 40 µL of sodium acetate (pH 5.5), and 1 mL of 100% ethanol. Mix and place the tube at −80°C for at least 20 min (or 5 min in dry ice–methanol mix, or overnight at −20°C). Spin at full speed at 4°C for 15 min. Wash the pellet with 500 µL of 75% ethanol. Dry the pellet. Be careful not to overdry the pellet. Count cpm and resuspend in RNase-free water.
3.2.3. In Vitro Processing Assay 1. Mix the following: 3 µL of 10X reaction buffer (final, 6.4 mM), 3 µL of radiolabeled pri-microRNA (1 × 104 to 105 cpm), 0.75 µL of RNase inhibitor (final, 1U/µL), 8.25 µL of RNase-free water, and 15 µL of HEK293T whole extract or Drosha immunoprecipitate. 2. Incubate at 37°C for 90 min. 3. Add 170 µL of RNA elution buffer to the reaction mixture. 4. Add 200 µL of phenol : chloroform : IAA (25 : 24 : 1) and vortex for 30 s. 5. Centrifuge for 5 min at RT and take the upper layer. 6. Add 20 µL of 3 M sodium acetate, 1 µL of glycogen, and 800 µL of 100% ethanol. Mix and leave at −80°C for at least 20 min (or 5 min in dry ice–methanol mix, or overnight at −20°C) 7. Centrifuge at maximum speed at 4°C for 15 min. 8. Remove the supernatant carefully so as not to disturb the RNA pellet. Wash the pellet with 500 µL of 75% ethanol. 9. Air-dry the pellet. 10. Resuspend the pellet in 15 µL of RNA loading buffer. 11. Prepare 12.5% urea–polyacrylamide gel as described above. 12. Heat the RNA sample at 95°C for 5 min. Load 7.5 µL of RNA samples on the gel and run at 350 V until bromophenol blue reaches the bottom of the gel. 13. Expose the gel on an X-ray film overnight at −80°C and develop this film (see Note 7).
03_Kim.qxd
4/16/05
12:01 PM
Page 25
Preparation and Analysis of Drosha
25
3.3. RNAi Against Drosha (See Note 8) 1. One day before transfection, split HeLa cells in 100-mm plates using 10 mL of medium so that the cells become 30–50% confluent on the day of transfection. DMEM tissue culture medium is supplemented with 10% FBS; no antibiotics should be used. 2. Mix 60 µL of 20 µM siRNA duplex with 1 mL of Opti-MEM. In another tube, mix 60 µL of OLIGOFECTAMINE reagent with 240 µL of Opti-MEM. 3. Incubate at RT for 7–10 min. 4. Combine the solutions and mix gently by pipetting. Do not vortex. 5. Incubate another 20–25 min at RT. The solution turns turbid. 6. Add 760 µL of fresh Opti-MEM to obtain a final volume of 2120 µL. 7. Add the final solution to HeLa cells. 8. After 3 d, extract total RNA or proteins from HeLa cells and analyze the level of Drosha depletion by Northern blotting or Western blotting.
4. Notes 1. It is critical that all of the reagents used are RNase-free and at least of molecular biology grade. 2. Instead of Tris buffer, HEPES and PIPES buffer can also be used as the lysis buffer, as long as the pH ranges between 7.5 and 8.0. 3. To prepare the templates for in vitro transcription, PCR primers are designed to amplify the region covering about 100 bp upstream and downstream from stemloop pre-miRNA sequences. The PCR products are subcloned into a general cloning vector containing T7 or SP6 promoter (e.g., pGEM-T-easy; Promega). It is also possible to use the PCR product directly as the template in transcription reaction if the T7 promoter sequence is included in the forward PCR primer. For efficient transcription, the promoter sequences should be followed by two consecutive Gs. 4. When preparing urea–polyacrylamide stock solution, dissolve urea in water at 60°C because this reaction is an endothermic reaction. 5. RNase III family proteins require magnesium ion for catalysis. The optimal concentration of magnesium chloride for Drosha is 6.4 mM in vitro. The processing efficiency is not significantly reduced down to 3.2 mM, but below 3.2 mM, the processing efficiency decreases gradually with reduced amount of magnesium in the reaction. The original reaction buffer contained ATP, creatine phosphate, and dithiothreitol (DTT) (10). We recently found that these ingredients are dispensable for pri-miRNA processing. 6. If the Drosha protein is to be used for in vitro processing assay, the pri-miRNA transcript should be prepared (see Subheading 3.2.1.) before the beginning of immunoprecipitation (see Subheading 3.1.2.). This is because the Drosha protein immobilized on beads should be prepared freshly for the assay for maximal activity. 7. The product of processing will appear as a band of 60–75 nt depending on the pre-miRNA substrate used in the assay (see Fig. 2). For instance, pre-miR-30a is
03_Kim.qxd
26
4/16/05
12:01 PM
Page 26
Lee and Kim
Fig. 2. Determination of the enzymatic activity of Drosha. (A) Sequences and structure of a substrate, pri-let-7a-1. The cleavage sites are indicated with arrows. Mature let-7a-1 sequences are underlined. (B) A typical result from in vitro processing assay. Pri-let-7a-1 was incubated with HEK293T whole-cell extract (input) or immunoprecitates (FLAG-IP). HEK293T cells had been transfected with either an empty vector, pCK (Mock), or DroshaFLAG expression plasmid, pCK-Drosha-FLAG (Drosha). Pre-let-7a-1 is produced when pri-miRNA is incubated with Drosha immunoprecipitate or whole-cell extract.
03_Kim.qxd
4/16/05
12:01 PM
Page 27
Preparation and Analysis of Drosha
27
63 nt in length, whereas pre-let-7a- is 72 nt in length. Additional bands may appear, which correspond to the flanking sequences around the stem. Contamination by other nuclease(s) or nonspecific chemical cleavage reaction can also result in unexpected cleavage products. 8. The transfection method described here is essentially identical to that developed by Elbashir et al. (20). The efficiency of siRNA transfection may depend on the cell type but also on the passage number and the confluence of the cells. The time and the manner of formation of siRNA–liposome complexes are also critical. Other transfection reagents are also available. We have successfully used RNAiFect transfection reagent (Qiagen), which involves slightly simpler procedures.
Acknowledgments This work was supported by a grant (R02-2004-000-10173-0) from the Basic Research Program of the Korea Science & Engineering Foundation and by the BK21 Research Fellowship from the Ministry of Education and Human Resources Development. References 1. Carmell, M. A. and Hannon, G. J. (2004) RNase III enzymes and the initiation of gene silencing. Nat. Struct. Mol. Biol. 11, 214–218. 2. Zamore, P. D. (2001) Thirty-three years later, a glimpse at the ribonuclease III active site. Mol. Cell 8, 1158–1160. 3. Filippov, V., Solovyev, V., Filippova, M., and Gill, S. S. (2000) A novel type of RNase III family proteins in eukaryotes. Gene 245, 213–221. 4. Fortin, K. R., Nicholson, R. H., and Nicholson, A. W. (2002) Mouse ribonuclease III. cDNA structure, expression analysis, and chromosomal location. BMC Genomics 3, 26. 5. Gunther, M., Laithier, M., and Brison, O. (2000) A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening. Mol. Cell. Biochem. 210, 131–142. 6. Wu, H., Xu, H., Miraglia, L. J., and Crooke, S. T. (2000) Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J. Biol. Chem. 275, 36,957–36,965. 7. Kim, V. N. (2004) MicroRNA precursors in motion: exportin-5 mediates their nuclear export. Trends Cell. Biol. 14, 156–159. 8. Lee, Y., Ahn, C., Han, J., et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415–419. 9. Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297. 10. Lee, Y., Jeon, K., Lee, J. T., Kim, S., and Kim, V. N. (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21, 4663–4670. 11. Bohnsack, M. T., Czaplinski, K., and Gorlich, D. (2004) Exportin 5 is a RanGTPdependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185–191.
03_Kim.qxd
28
4/16/05
12:01 PM
Page 28
Lee and Kim
12. Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., and Kutay, U. (2004) Nuclear export of microRNA precursors. Science 303, 95–98. 13. Yi, R., Qin, Y., Macara, I. G., and Cullen, B. R. (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011–3016. 14. Bernstein, E., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363–366. 15. Grishok, A., Pasquinelli, A. E., Conte, D., et al. (2001) Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106, 23–34. 16. Hutvagner, G., McLachlan, J., Pasquinelli, A. E., Balint, E., Tuschl, T., and Zamore, P. D. (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293, 834–838. 17. Ketting, R. F., Fischer, S. E., Bernstein, E., Sijen, T., Hannon, G. J., and Plasterk, R. H. (2001) Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654–2659. 18. Knight, S. W. and Bass, B. L. (2001) A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 293, 2269–2271. 19. Chen, C. Z., Li, L., Lodish, H. F., and Bartel, D. P. (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83–86. 20. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.
04_Goldstein.qxd
4/16/05
12:04 PM
Page 29
4 RNA Interference in Caenorhabditis elegans Nathaniel R. Dudley and Bob Goldstein 1. Introduction The introduction of double-stranded RNA (dsRNA) into Caenorhabditis elegans hermaphrodites results in the rapid and sequence-specific degradation of endogenous mRNAs (1,2). This RNA-mediated interference, or RNAi, effectively shuts down expression of the target gene and can phenocopy lossof-function mutations. RNAi is also remarkably potent, requiring only substoichiometric amounts of dsRNA to elicit a response (1). Another notable aspect of RNAi in C. elegans is that it is systemic in that the silencing can spread between tissues throughout the adult as well as its progeny (1,3,4). Many neurons, however, are refractory to the spreading effect in wild-type backgrounds (5). Although discovered in C. elegans, the use of dsRNA to silence gene expression has quickly become a widely used tool to study gene function in a number of organisms, including mammals (6,7). RNAi may have evolved from an ancient phenomenon used to regulate gene expression and combat transposable elements and viruses (8). The ability to use RNAi to target single or multiple transcripts and the ability to apply RNAi to large-scale genomic screens further highlight the power of this technique (9–12). 2. Materials 1. Wild-type C. elegans. 2. NGM agar plates: 2.5 g peptone, 17 g agar, 3 g NaCl, 975 mL distilled water (dH2O). Autoclave (30 min). Let cool to 55°C and add the following sterile solutions: 1 mL of 5 mg/mL cholesterol (stock in EtOH), 1 mL of 1 M CaCl2, 1 mL of 1 M MgSO4, 25 mL of 1 M KH2PO4. From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
29
04_Goldstein.qxd
30
4/16/05
12:04 PM
Page 30
Dudley and Goldstein
3. OP50 Escherichia coli. 4. Agarose, low electroendosmosis (EEO) electrophoresis grade (Fisher Scientific, Suwanee, GA). 5. Large plastic Petri dishes, 100 × 15 mm (Fisher Scientific). 6. Sterile M9 buffer: 3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 mL of 1 M MgSO4; fill to 1 L with dH2O. 7. 15-mL polypropylene tube. 8. 50–100–20 buffer: 50 mM Tris-HCl, 100 mM NaCl, 20 mM EDTA, pH 7.5. 9. 50–100–20 + Sodium dodecyl sulfate (SDS) + proteinase K: 1% SDS, 200 µg/mL proteinase K in 50–100–20 buffer. 10. Phenol : chloroform (1 : 1). 11. 3 M sodium acetate, pH 5.2. 12. 100% ethanol. 13. Worm pick: 36-gauge platinum wire attached to glass Pasteur pipet (Fisher Scientific). 14. TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 7.6. 15. DNase-free RNase A. 16. Oligonucleotide primers specific to target gene. 17. Oligo (dT)12–18 (500 µg/mL). 18. Sterile diethylpyrocarbonate (DEPC) H2O. 19. 5X first strand buffer, supplied with enzyme (Stratagene, La Jolla, CA). 20. 0.1 M dithiothreitol (DTT), supplied with enzyme (Stratagene). 21. 10 mM dNTP stock in DEPC–dH2O (Stratagene). 22. SuperScript II enzyme (200 U/µL) (Stratagene). 23. 0.5 M EDTA. 24. 2 mM dNTPs. 25. Taq polymerase. 26. Polymerase chain reaction (PCR) thermocycler and supplies. 27. PCR purification kit (Qiagen, Valencia, CA). 28. Phenol : chloroform : isoamylalcohol (25 : 24 : 1). 29. Chloroform. 30. 10 M NH4Ac. 31. 70% EtOH. 32. Agarose gel electrophoresis apparatus. 33. Ultraviolet (UV) transilluminator. 34. Ethidium bromide (EtBr) (0.3 µg/mL). 35. Ultraviolet spectrophotometer. 36. Gel extraction kit (Qiagen). 37. T7 transcription kit (Ambion Megascript T7, Austin, TX or Promega, T7 Ribomax, Madison, WI). 38. Speed vacuum apparatus. 39. Borosilicate capillaries model 1B100F (World Precision Instruments, Sarasota, FL). 40. Needle puller (Sutter Instruments, Novato, CA). 41. Halocarbon oil, series 700 (Sigma, St. Louis, MO).
04_Goldstein.qxd
4/16/05
12:04 PM
Page 31
RNA Interference in C. elegans
31
42. Injection pads (24 × 50 mm #1 cover slip with 2% agarose). 43. RNAi soaking buffer: 0.05% gelatin, 5.5 mM KH2PO4, 2.1 mM NaCl, 4.7 mM NH4Cl, 3 mM spermidine. Add spermidine fresh before each use. 44. NGM plates + 1 M Isopropyl-β-D-thiogalactopyranoside (IPTG) + ampicillin poured fresh (1–3 d before use). 45. Ampicillin 100 mg/mL. 46. Luria–Bertani (LB) ampicillin agar plates (50 µg/mL). 47. LB tetracycline agar plates (12.5 µg/mL). 48. Sterile, RNase free dH2O. 49. Siliconized 0.6 mL eppendorf tubes. 50. Siliconized 200 µL pipet tips. 51. C. elegans feeding library (MRC Geneservice). 52. IPTG.
3. Methods The methods below outline (1) the preparation of genomic DNA from C. elegans, (2) dsRNA synthesis, and (3) RNA interference methods. Methods for handling C. elegans are described in ref. 13 and detailed methods for injection are described in ref. 14. 3.1. Preparation of Genomic DNA from C. elegans 1. Grow up one to two large plates of worms on NGM plates, using agarose in place of the agar. 2. Wash worms off of a recently starved plate (to avoid excess bacteria) using sterile M9 buffer, into a 15-mL polypropylene tube. 3. Pellet worms by centrifugation and carefully discard supernatant. 4. Wash worms with 10 mL of 50–100–20 buffer. 5. Pellet worms by centrifugation and carefully discard supernatant. 6. Add 2 mL of 50–100–20 + 1% SDS + 200 µg/mL proteinase K and incubate at 65°C. 7. Periodically agitate until suspension is viscous (use gentle agitation to avoid shearing DNA). This takes about 30 min. 8. Add 2 mL of phenol : chloroform and invert gently for 5 min. 9. Centrifuge to separate phenol : chloroform and aqueous phases. 10. Transfer top (aqueous) phase to a clean 15-mL tube. 11. Add 270 µL of 3 M sodium acetate. This results in a final concentration of 0.4 M sodium acetate. 12. Add 2.5 vol of 100% ethanol. 13. Wind out DNA precipitate onto the tip of a sealed glass Pasteur pipet (DNA visible as thin threads). 14. Dissolve DNA in 400 µL of TE (see Note 1). 15. Add RNase to 20 µg/mL final concentration. 16. Incubate at 37°C for 20 min. 17. DNA is sufficiently clean for use as template in polymerase chain reaction (PCR). Store at 4°C (see Note 2).
04_Goldstein.qxd
4/16/05
12:04 PM
32
Page 32
Dudley and Goldstein
3.2. dsRNA Synthesis 3.2.1. Primer Design Design primers to amplify approx 1 kb of mostly coding sequence (see Note 3), although 200–500 bp of target sequence often works well and may also reduce the chance of targeting other homologous transcripts. Be sure to target mostly exonic sequences and ensure that you are not targeting other homologous transcripts (see Note 4). 3.2.2. First Strand cDNA Synthesis (If Unable to Use Genomic DNA) In those cases where only small exons separated by large introns are available, cDNA must be used to ensure you have sufficient exonic sequence to target. Before starting, make sure that all of the materials and reagents are sterilized and/or nuclease-free. 1. Mix 1 µL of oligo (dT)12–18 (500 µg/mL), 1–5 µg of mRNA, sterile DEPC H2O to 12 µL. 2. Heat the mixture to 70°C for 10 min, and then quickly chill on ice. 3. Centrifuge briefly to collect mixture at bottom of tube. 4. Add the following: 4 µL of 5X first strand buffer, 2 µL of 0.1 M DTT, 1 µL of mixed dNTP stock. 5. Mix the contents and centrifuge briefly to collect. Place tube at 42°C for 2 min to equilibrate temperature. 6. Add 1 µL of SuperScript II enzyme (200 U/µL) for each microgram of mRNA used in step 1 to the mix. 7. Incubate at 42°C for 1 h. 8. Add 4 µL of 0.5 M EDTA or place tube at 70°C for 15 min in order to terminate the reaction. 9. Store cDNA at –20°C until use.
3.2.3. PCR Amplification is performed in two steps. Designing an in vitro transcription template from a two-step PCR makes synthesizing multiple primers less expensive and may increase the yield of PCR products bearing complete T7 sites. The first step uses two 35-base pair primers, and each primer contains 15 bases of T7 sequence plus 20 bases of sequence from the gene of interest (see Note 5). Example: partial T7 gene of interest Forward primer: 5′ CGACTCACTATAGGGCGATGAGGGCCTATTTATTC 3′ Reverse primer: 5′ CGACTCACTATAGGGGAGAAAGTACACGATATAGC 3′
The first PCR product is cleaned using the Qiagen PCR Purification kit (as per manufacturer’s instructions) and eluted in 33 µL final volume. One-tenth of
04_Goldstein.qxd
4/16/05
12:04 PM
Page 33
RNA Interference in C. elegans
33
Fig. 1. (A) mlc-4 (1) and nmy-2 (2) PCR product amplified from genomic DNA with primers having partial T7 sequences. (B) mlc-4 and nmy-2 second-round PCR products that have been gel-purified using complete T7 primers and restriction sites. (C) Amplified and purified mlc-4 and nmy-2 dsRNAs. M is the DNA marker in each panel.
the recovered product is analyzed on an agarose gel (see Fig. 1A) and visualized using EtBr and UV illumination. The second PCR uses the same primer on each end—a primer containing the full T7 polymerase promoter plus restriction sites for use with cloning: EcoRI, XbaI, and HindIII (see Note 6): EXHT7:
5′ ATAGAATTCTCTAGAAGCTTAATACGACTCACTATAGGG 3′
One-tenth of the recovered product is analyzed on an agarose gel (see Fig. 1B) and visualized using EtBr and UV illumination. 3.2.4. In Vitro Transcription The second PCR product is then gel purified (Qiagen Gel Extraction kit, as per manufacturer’s instructions) and 1–2 µg of PCR product are used as the template for transcription. Commercially available in vitro transcription kits such as Ambion’s Megascript-T7 kit or Promega’s T7 Ribomax kit can be used to obtain high yields of dsRNA (see Note 7).
04_Goldstein.qxd
4/16/05
12:04 PM
Page 34
34
Dudley and Goldstein
3.2.5. RNA Recovery Pass the RNA through a Qiagen PCR purification column (treating the RNA as if it were a PCR product) to purify the RNA. RNA-specific columns can be used instead, although these are more expensive. Alternatively, dsRNA can be purified using phenol–chloroform extraction followed by ethanol precipitation (see Subheading 3.2.7.). Assess dsRNA integrity on an agarose gel (see Fig. 1C) and determine concentration using a UV spectrophotometer. 3.2.6. Storage Mix the resulting solution with 2 vol 100% EtOH and store at –80°C. Before use, the EtOH should be evaporated in a speed-vaccum apparatus and the dsRNA pellet can be resuspended in sterile distilled water at your desired concentration. 3.2.7. Phenol–Chloroform Extraction and Ethanol Precipitation Instead of using expensive columns (see Subheading 3.2.5.) you can purify your dsRNA using phenol–chloroform extraction followed by ethanol precipitation. 1. Add an equal volume of phenol : chloroform : isoamylalcohol (25 : 24 : 1) to the in vitro transcription reaction. 2. Mix (vortex) the contents of the tube until an emulsion forms. 3. Centrifuge the mixture at 11,750g for 15 s in a microcentrifuge at room temperature. 4. Transfer the upper (aqueous) phase containing dsRNA to a fresh tube. Discard the interface and the lower (organic) phase. 5. Add an equal volume of chloroform and repeat extraction steps (steps 2–4). 6. Add 1/3 vol of 10 M NH4Ac. 7. Add 2.5 vol of 100% EtOH and put at –20°C for 30 min. The dsRNA can be stored at this step at –20°C if desired. 8. Spin down for 10 min at 11,750g in a microcentrifuge at 4°C to pellet dsRNA. 9. Wash pellet with 70% EtOH. 10. Air-dry pellet. 11. Resuspend in 100 µL of TE, pH 7.6. 12. dsRNA should be stored at –20°C in 1–2 vol of 100% EtOH.
3.3. Microinjection The dsRNA for microinjection can be injected anywhere in the body cavity or gonad of the C. elegans hermaphrodite (1). Additional details can be found in ref. 14. 3.3.1. Preparing and Storing Needles 1. Pull capillaries to a finely tapered tip using a needle puller. 2. Use a Petri dish containing a strip of modeling clay to hold the needles. If kept dust-free, needles can be stored indefinitely.
04_Goldstein.qxd
4/16/05
12:04 PM
Page 35
RNA Interference in C. elegans
35
3.3.2. Injection Pads 1. A drop of 2% agarose (in dH2O) is flattened between two 24 × 50-mm #1 cover slips. 2. After hardening, remove the top cover slip and let the pad dry in open air (Alternatively, pads can be baked at 60°C for 1 h). If letting the pads air-dry, they should be made at least 1 d prior to use. Pads made either way can be stored for several weeks at room temperature. 3. Inject dsRNA solution into hermaphrodite gut or gonad.
3.3.3. Loading and Breaking the Needle 1. Place a 0.5 µL drop of the dsRNA solution on the back (blunt) end of the needle; the needle contains an inner glass filament that will wick the dsRNA solution to the tapered end. 2. Load needle onto an injection microscope. Use the edges of the agarose injection pad to gently break the needle. This step here takes practice to ensure that the needle does not have too large an opening, which would tend to damage the worms during injection (see Note 8).
3.3.4. Mounting and Injecting Worms 1. Place a drop of Halocarbon oil on the pad. 2. Using a worm pick, transfer young adult hermaphrodites to the oil drop on the pad (see Note 9). 3. Pat the animal down on the agarose pad with your pick until it is firmly stuck to the pad. Minimize the time that the worms spend drying out on the pad during injection to increase the viability of the worms.
3.3.5. Recovery Put the pad under the dissecting scope and place a drop of M9 buffer on the oil drop containing your worms. Your worms will rehydrate and begin to swim. Transfer worms to a fresh NGM plate. 3.4. Feeding RNA interference can be performed in C. elegans by feeding RNAse IIIresistant bacteria expressing dsRNA to C. elegans (5). A genomic feeding library has been constructed (15) and is available commercially. The library consists of genomic fragments cloned into an IPTG-inducible T7 polymerase vector (the PCR product made in Subheading 3.2.3. can also be cloned into this feeding vector). The vectors are transformed into the RNAse III-resistant bacterial strain. 1. Streak out –80°C stock feeding strain that contains the desired construct onto LB tetracycline plates (tetracycline will select for feeding competent bacteria). 2. Pick a bacterial colony from streaked plates with a sterile toothpick (using sterile technique) and place it in approx 2 mL of LB/amp (ampicillin will select for the cloned gene of interest).
04_Goldstein.qxd
4/16/05
36
12:04 PM
Page 36
Dudley and Goldstein
3. Shake overnight at 37°C. 4. Inoculate 2 mL fresh LB plus ampicillin with 20 µL of the overnight culture. Grow at 37°C until the optical density is between 0.35 and 0.40 (this usually takes about 3 h). 5. Seed NGM + IPTG + ampicillin plates with actively growing culture and allow to dry at room temperature (this will happen anytime between 3 h to overnight) (see Note 10). 6. Add worms to dsRNA-producing bacteria and allow worms to feed. Transfer worms every 24 h to new feeding plates (see Note 11).
3.5. Soaking RNA interference can be performed in C. elegans by soaking worms in dsRNA (16); this method has been used in large-scale screens (12). 1. Pick four young adults onto a fresh unseeded NGM plate to clean off bacteria (see Note 12). 2. Wash worms with a drop of M9 and allow them to crawl away. 3. Add the four worms to 2 µL of RNAi soaking buffer in 0.6-mL siliconized Eppendorf tubes (final dsRNA concentration should be at 1 mg/mL). 4. Place at 20°C for 24 h. 5. Transfer worms to a fresh, seeded plate using siliconized pipet tips. 6. Wash Eppendorf tube with 100 µL of M9 to ensure transfer of all of the soaked worms. 7. Transfer to new plates daily and score progeny.
4. Notes 1. Swirl the tip of the glass Pasteur pipet containing the DNA in a microfuge tube containing 400 µL of TE. 2. Do not freeze genomic sample, as thaw cycles can shear genomic DNA. Multiple genomic DNA preparations can be used as templates when a product does not amplify from a single preparation. 3. Visit www.wormbase.org for gene structure information. 4. Visit http://www.sanger.ac.uk/cgi-bin/blast/submitblast/c_elegans for BLAST tools needed to search for and avoid dsRNAs that target other homologous transcripts. 5. When designing primers, be sure to avoid creating primers that contain primer dimers. Also, primers should not have a high GC content (>50%) and be sure that your primers are also free from strong secondary structure. 6. These DNA templates can be easily cloned into the feeding construct (L4440) discussed in Subheading 3.4. 7. Purchasing rNTPs, T7 polymerase, DNase, and RNase inhibitors separately and then purifying the dsRNA using phenol : chloroform followed by EtOH precipitation also works well (see Subheading 3.2.7.). 8. You can also dip needles in hydrofluoric acid to open needle tips. 9. Be sure to limit the amount of bacteria transferred, as excess bacteria can make it difficult for the worms to adhere to the pad.
04_Goldstein.qxd
4/16/05
12:04 PM
Page 37
RNA Interference in C. elegans
37
10. Be sure that all media for plates are cooled to 50°C before adding IPTG, ampicillin, or tetracycline. 11. You can also place young larvae on plates or have worms lay eggs onto the feeding plates for a couple of hours, followed by removal of the mothers. 12. This protocol can be scaled up as necessary.
Acknowledgments Our work using RNAi in C. elegans has been supported by NIH R01 GM68966 and NSF MCB-0235654. B.G. is a Pew Scholar in the Biomedical Sciences. We thank members of the Goldstein Lab for careful reading of the manuscript. References 1. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811. 2. Montgomery, M. K. and Fire, A. (1998) Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255–258. 3. Grishok, A., Tabara, H., and Mello, C. C. (2000) Genetic requirements for inheritance of RNAi in C. elegans. Science 287, 2494–2497. 4. Winston, W. M., Molodowitch, C., and Hunter, C. P. (2002) Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science 295, 2456–2459. 5. Timmons, L., Court, D. L., and Fire, A. (2001) Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene 263, 103–112. 6. Tijsterman, M., Ketting, R. F., and Plasterk, R. H. (2002) The genetics of RNA silencing. Annu. Rev. Genet. 36, 489–519. 7. Maine, E. M. (2000) A conserved mechanism for post-transcriptional gene silencing? Genome Biol. 1, REVIEWS1018. 8. Plasterk, R. H. (2002) RNA silencing: the genome’s immune system. Science 296, 1263–1265. 9. Dudley, N. R., Labbe, J. C., and Goldstein, B. (2002) Using RNA interference to identify genes required for RNA interference. Proc. Natl. Acad. Sci. USA 99, 4191–4196. 10. Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., and Ahringer, J. (2000) Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408, 325–330. 11. Gonczy, P., Echeverri, C., Oegema, K., et al. (2000) Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III. Nature 408, 331–336. 12. Maeda, I., Kohara, Y., Yamamoto, M., and Sugimoto, A. (2001) Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi. Curr. Biol. 11, 171–176.
04_Goldstein.qxd
38
4/16/05
12:04 PM
Page 38
Dudley and Goldstein
13. Sulston, J. and Hodgkin, J. (1998) The nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 14. Mello, C. C. and Fire, A. (1995) DNA Transformation, in Caenorhabditis elegans: Modern Biological Analysis of an Organism, Epstein, H. F. and Shakes, D. C. (ed.). Academic Press, San Diego, CA, Vol. 48, pp. 452–480. 15. Kamath, R. S. and Ahringer, J. (2003) Genome-wide RNAi screening in Caenorhabditis elegans. Methods 30, 313–321. 16. Tabara, H., Grishok, A., and Mello, C. C. (1998) RNAi in C. elegans: soaking in the genome sequence. Science 282, 430–431.
05_Clayton.qxd
4/16/05
12:04 PM
Page 39
5 Down-Regulating Gene Expression by RNA Interference in Trypanosoma brucei Christine E. Clayton, Antonio M. Estévez, Claudia Hartmann, Vincent P. Alibu, Mark Field, and David Horn 1. Introduction RNA interference (RNAi) in Trypanosoma brucei was first reported in 1998 (1). As in other eukaryotes, interference involves digestion of the interfering double-stranded RNA into short fragments (2), a polysome-associated complex (3), and Argonaute protein (4,5). T. brucei is an ideal organism for testing gene function by RNAi. A complete genome sequence is available, and liquid suspension culture is unproblematic. Various combinations of RNAi vector and host trypanosomes, with different advantages, are available; if procedures are working optimally, it should be possible to obtain a stable cell line with inducible RNAi within 2 wk. The RNAi process itself is apparently not essential for parasite survival (4), although some adverse effects have been reported (5). To analyze the process itself, it is possible to delete candidate genes completely, as the efficiency of homologous recombination is essentially 100%; in situ epitope tagging can also be effected through homologous recombination (6). For general reviews of the peculiarities of trypanosome gene expression and RNA processing, see refs. 7 and 8, and for pre-RNAi methods, such as inducible gene expression and knockouts by homologous recombination, see ref. 9. A few recent applications of RNAi in trypanosomes are found in refs. 10–16. Importantly, in trypanosomes, RNAi can also be used to deplete nuclear RNAs (8,17). In this chapter, we will describe two different options for the construction of RNAi vectors, followed by methods for trypanosome culture and selection of transfectants. At the end, we will highlight various options for testing of phenotypes, as well as various pitfalls with working with RNAi in trypanosomes. From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
39
05_Clayton.qxd
4/16/05
12:04 PM
Page 40
40
Clayton et al.
1.1. Choosing the Life-Cycle Stage T. brucei infects mammals (but not humans), where it replicates in the blood and tissue fluids (bloodstream form), and tsetse flies (procyclic form), where it multiplies in the midgut. Both replicative stages can be cultured in vitro in liquid or on soft agar plates; here, only the liquid culture will be described. The choice of life-cycle stage depends on the gene to be analyzed. Evidently, genes that are expressed exclusively in one stage should be analyzed in that stage. Therefore, it is important to check expression of your target gene, at least at the messenger RNA (mRNA) level, before initiating the experiments. Procyclic trypanosomes are metabolically more complex than bloodstream forms and, in particular, have a much more active mitochondrial metabolism. They grow slightly slower than bloodstream forms. When a gene is essential in both stages, the limited experience so far suggests that experiments on essential genes with procyclic forms are often more informative than with bloodstream forms. Whereas bloodstream forms simply die rapidly, procyclics may show alterations in metabolism or ultrastructure before dying more slowly (see, for example ref. 14). Possible reasons are the more diverse metabolism of procyclics or, simply, their slower growth; the advantage is that there is often a greater opportunity to observe the mutant phenotype. 1.2. Inducible RNAi Using Opposing T7 Promoters The simplest method to achieve RNAi in T. brucei is to use vectors with opposing bacteriophage T7 promoters, controlled by binding of the tet repressor to tet operators (18–20). The host trypanosomes described below already contain stably integrated plasmids constitutively expressing T7 polymerase and the Tn10 tet repressor. The main advantage of this method is that cloning of polymerase chain reaction (PCR) products into the RNAi vector is very rapid and efficient. The disadvantage is that the control of T7 transcription by the tet repressor can be somewhat leaky: If the “background” transcription of double-stranded RNA (dsRNA) is sufficient to cause growth inhibition, no trypanosomes containing the plasmid will be obtained or the phenotype of the RNAi-expressing trypanosomes may be very unstable (see Notes 1 and 2). Despite this, a considerable number of essential genes have been studied using this approach and it is definitely the method of first choice. A particularly impressive use of this method was the construction of a genomic library for RNAi expression. The library is transfected into trypanosomes, the recombinants are grown, and then RNAi is induced. Subsequently, one can select for any loss-of-function mutation that is compatible with survival (10). The major limitation, however, is the low frequency of
05_Clayton.qxd
4/16/05
12:04 PM
Page 41
Downregulating Gene Expression by RNAi
41
transfection of trypanosomes: hence, at present, such an approach is only applicable when an extremely good selection method is available. 1.3. Inducible RNAi Using Stem-Loop Contructs In this strategy, transcription of an RNA stem loop is driven by an RNA polymerase I promoter under tetracycline control (21,22). Construction of the stemloop-expressing vector involves three cloning steps. Two opposing copies of the target sequence are inserted on either side of a “stuffer” DNA, which is required for stability of the plasmid in Escherichia coli, and then the stem loop is cloned into a vector containing an inducible RNA polymerase I promoter (23,24). Disadvantages of this method are the more complicated plasmid construction and the fact that sometimes the chosen sequences resist cloning in opposite orientations. The advantages are that the background RNAi expression is generally lower than with opposing T7 promoters and that the lines are more stable upon cultivation or storage. Examples of the use of this methodology include those described in refs. 13 and 14. For more tips on the choice of strategy, see Notes 3–7. 2. Materials 2.1. Material Specific for T7-Polymerase-Driven RNAi 1. Plasmid DNA (see Fig. 1A). 2. Bloodstream trypanosomes expressing T7 polymerase and the tet repressor, which are not resistant to hygromycin, such as the “single-marker” line containing pHD 328 and pLew114hyg5′ (25). (Note that this line can also be used for RNAi vectors bearing a phleomycin resistance marker.)
An alternative is procyclic trypanosomes expressing T7 polymerase and the tet repressor, which are not resistant to hygromycin, such as the pHD 1313–1333 line, in which T7 polymerase synthesis is tetetracycline inducible, or the pHD1313–514 line, which constitutively expressed the polymerase (26). Results so far suggest that the pHD 1313–1333 line may give the highest transformation efficiencies when the RNAi is very toxic. 2.2. Material Specific to Stem-Loop RNAi 1. “Stuffer” plasmid DNA (see Fig. 1B). 2. A vector containing a tetracycline-inducible trypanosome RNA polymerase I promoter (see Fig. 1C) or an inducible vector containing the stuffer (see Fig. 1D). 3. Bloodstream or procyclic trypanosomes expressing the tet repressor, which are not resistant to hygromycin, such as those containing integrated pHD 1313 (26) or pHD 449 (23).
05_Clayton.qxd
42
4/16/05
12:04 PM
Page 42
Clayton et al.
05_Clayton.qxd
4/16/05
12:04 PM
Page 43
Downregulating Gene Expression by RNAi
43
2.3. Bloodstream-Form Culture and Transfection 1. Medium HMI-9: Component IMDM Sodium bicarbonate Hypoxanthine Thymidine Bathocuproine sulfonic acid
100X Stock
Amount
Final concentration
13.6 mg/mL 3.9 mg/mL 2.82 mg/mL
176.6 g 30.24 g 1.36 g 390 mg 282 mg
1 mM 0.16 mM 0.05 mM
Dissolve to a final volume of 10 L, filter-sterilize, and aliquot 450 mL into bottles. Store at –20°C. Component
100X Stock
Final concentration
Cysteine
18.2 mg/mL
1.5 mM
β-Mercaptoethanol
14 µL /10 mL
Filter-sterilize, store no more than 1 mo, –20°C Filter-sterilize, make fresh
Before use, add the following to 450 mL medium: 5 mL each cysteine and βmercaptoethanol solutions and 50 mL fetal calf serum (FCS) (heat to 56°C for 30 min; if consumption is not very rapid, make 50-mL aliquots in sterile tubes and freeze.)
Fig. 1. (Opposite page) Cloning vectors. Only useful sites are shown. Sequences and DNA are available from the authors. (A) Vectors with opposing T7 promoters. Each of these vectors is designed to be linearized with NotI within a “targeting sequence.” After transfection, the plasmid integrates by homologous recombination via the sequences either side of the NotI site. All integrate into a transcriptionally silent spacer between rRNA genes except p2T7:177, which integrates into silent minichromosomal repeats: In some cases, the minichromosomal site might give a lower background transcription of the RNAi fragment (25). References for the other vectors are as follows: pJZM: ref. 18; p2T7 derivatives: ref. 26. (B) Plasmid for cloning of stem loops. Any other similar plasmid could be used. (C) Plasmids designed for tetracycline-inducible gene expression in T. brucei. Several other similar vectors are available. These vectors can be used for expression of any open reading frame or of stem-loop transcripts. The pHD vectors are derivatives of those described in ref. 23 and their use is described in ref. 13. PLEW79 is described in ref. 24. (D) Inducible plasmid for direct cloning of stem loops (Estévez, unpublished).
05_Clayton.qxd
4/16/05
12:04 PM
Page 44
44
Clayton et al.
Note that powdered HMI-9 is available from laboratories working on trypanosomes in the United Kingdom: contact the authors for details. References for trypanosome cultivation, including plating on soft agar, are refs. 27–29. There is a detailed discussion of this topic at http://tryps.rockefeller. edu/DocumentsGlobal/tryp_culture_commentary.html. 2. Selective drug concentrations: Drug
Stock
Amount for 10 mL Final concentration
Blasticidin 5 mg/mL G418 50 mg/mL Hygromycin 50 mg/mL Phleomycin/ 5 mg/mL bleomycin Puromycin 1 mg/mL Tetracycline 5 mg/mL in EtOH
10 µL 1 µL 1–3 µL 0.4 µL 2 µL 0.2 µL
5 µg/mL 5 µg/mL 5–15 µg/mLa 0.2 µg/mL 0.2 µg/mL 100 ng/mL
aIdeal amount seems to depend on vector and cell line. Try with the lower amount first.
Stocks are stored in small aliquots at –20°C. Tetracyline should be kept frozen in the dark for no more than 1 mo. The half-life of tetracycline in tissue culture medium is about 24 h, so induction should be maintained by adding to 75 ng/mL every 2 d if no additional tetracycline-containing medium is added. An alternative is to initially add 1 µg/mL tetracycline; then the cells can be left for 4 d before readding the drug. 3. Transfection medium (modified Cytomix): Component EGTA KCl CaCl2 Phosphate buffer, pH 7.6a HEPES MgCl2.6H2O Glucose BSA (defatted) Hypoxanthineb aMix
Stock 0.5 M
0.1 M
13.6 mg/mL
How much
Final concentration
0.4 mL 0.9 g 0.0017g 10 mL 0.596 g 0.102 g 0.5 g 10 mg 1 mL
2 mM 120 mM 0.15 mM 10 mM 25 mM 5 mM 0.5% 100 µg/mL 1 mM
8.66 mL of 1M K2HPO4 with 1.34 mL KH2PO4 in 90 mL H2O. dissolve in 0.1 M NaOH.
bHypoxanthine:
Dissolve in 90 mL, adjust to pH 7.6 with 1 M KOH, make up to 100 mL, and filter-sterilize. Store at 4°C.
05_Clayton.qxd
4/16/05
12:04 PM
Page 45
Downregulating Gene Expression by RNAi
45
2.4. Procyclic-Form Culture and Transfection 1. Medium MEM-Pros: Component
g/10 L
Salts CaCl2 • 2H2O KCl MgSO4 • 7H2O NaCl NaH2PO4 • H2O HEPES Other L-Arg • HCl L-Cys • Cys L-Gln L-His • HCl • H2O L-Ile L-Leu L-Lys L-Met L-Phe L-Thr L-Try L-Tyr L-Val L-Pro Adenosine Ornithine • HCl
2.65 4.00 2.00 68.00 1.40 71.40 1.26 0.24 2.92 0.42 0.52 0.52 0.73 0.15 1.00 0.48 0.10 1.00 0.46 6.00 0.12 0.10
Many labs order this or a similar medium as a ready-made powder: contact any of the authors for details. MEM nonessential amino acids MEM vitamins Phenol red (1000X)
100 mL 100 mL 10 mL (or 0.1 g in 10 L)
Make salt solution including HEPES in a volume of about 4 L and adjust pH to 7.4 using NaOH. Add all of the other solids and wait until dissolved; dilute up to about 9 L as necessary. Add the MEM solutions, make up to final volume and sterile-filter. Leave out overnight to check for contamination. Store in aliquots of 450 mL at 4°C. Hemin solution: Dissolve 250 mg of Hemin in 100 mL of 0.1 M NaOH. Autoclave. Aliquot into 10-mL aliquots in sterile tubes and store at 4°C.
05_Clayton.qxd
4/16/05
12:04 PM
Page 46
46
Clayton et al.
Fetal calf serum (FCS): Heat to 56°C for 30 min. Aliquot in 50-mL aliquots in sterile tubes. Final medium: Add 50 mL heat-inactivated FCS and 1.5 mL hemin per 450 mL medium. A detailed discussion of trypanosome culture, including copies of older publications, can be found at http://tryps.rockefeller.edu/DocumentsGlobal/tryp_culture_commentary.html (see Note 8). Some references for MEMPros are ref. 30 (the glycine should be glycerol) and ref. 31. An alternative medium called SDM79 (32) is equally good for continuous cultivation of procyclic trypanosomes. If starting trypanosome culture for the first time, it is usually best to use the medium in which the parasites were previously grown, using the protocols of the laboratory from which the parasites were obtained. 2. Antibiotic concentrations: Drug
Stock
Amount for 10 mL Final concentration
Blasticidin 5 mg/mL G418 50 mg/mL Hygromycin 50 mg/mL Phleomycin/ Bleomycin 5 mg/mL Puromycin 1 mg/mL Tetracycline 5 mg/mL in EtOH
20 µL 3 µL 10 µL 1 µL 10 µL 0.2 µL
10 µg/mL 15 µg/mL 50 µg/mL 0.5 µg/mL 1 µg/mL 100 ng/mL
For details, see Subheading 2.3., item 2. 3. Transfection medium ZPFM:
NaCl KCl Na2HPO4 (anhyd) KH2PO4 (anhyd) MgOAc • 4H2O {CaOAc2 or CaCl2
Amount
Final concentration
7.714 g 0.596 g 1.136 g 0.204 g 0.107 g 0.016 g
132 mM 8 mM 8 mM 1.5 mM 1.5 mM 90 µM
0.014 g
Dissolve in 800 mL, adjust pH to 7.00 ± 0.05 with NaOH or HAc and make up to 1 L. It is also possible to make a 5X stock for storage at 4°C.
2.5. Other Materials 1. 2. 3. 4.
Two PCR primers designed to amplify the target gene. Trypanosome genomic DNA. Taq polymerase, enzyme buffers, and nucleoside triphosphates. Tissue culture flasks (25 mL, 250 mL) and 24-well plates.
05_Clayton.qxd
4/16/05
12:04 PM
Page 47
Downregulating Gene Expression by RNAi
47
5. Electroporation machine: must be capable of delivering a pulse at 1.5 kV at physiological salt without annulling the guarantee. We use BTX machines. 6. Electroporation cuvets. 7. Standard materials for molecular biology including restriction enzymes and competent E. coli.
3. Methods 3.1. Construction of the RNAi Plasmid 3.1.1. Primer Design RNA interference in T. brucei works well with dsRNAs of about 500 bp, and dsRNA will target any sequence with 85% identity or more. In order to target one sequence specifically, you should therefore choose a fragment of about 500 bp that is within the predicted mRNA and has less than 85% identity with other genes (33). It is best to be near the initiator ATG but not to include it (risk of making a truncated protein). The trypanosome genome can be searched from http://www. genedb.org/genedb/seqSearch.jsp?organism=tryp. Primers of 18–20 nt, with compatible melting points, are designed to amplify the fragment from genomic DNA. For unique genes, specific RNAi fragments and appropriate primers with compatible melting points are best designed using the RNAit program, which is a webbased resource (34) (http://www.trypanofan.org/software/RNAit.html). If the target gene is present in multiple copies, it will be necessary to design primers manually; if the coding regions are identical, then try using the 3′-untranslated regions (3′-UTRs). If you intend to build a stem-loop construct, it is necessary to include boundary restriction sites at the 5′ end of the oligonucleotides to allow directional cloning (see below); these sites should be absent from the amplified fragment. Add at least three additional nucleotides 5′ of the restriction sites in order to ensure efficient restriction digestion of the amplified fragments. The choice of enzymes must be made carefully, as some will not cleave close to a double-stranded break. 3.1.2. Expression Vector 3.1.2.1. PCR 1. Mix the following in a PCR tube: 1 µL forward primer (stock = 100 mM); 1 µL reverse primer (stock = 100 mM); 1 µL T. brucei genomic DNA template (about 0.1 µg); 1 µL dNTP’s (stock = 10 mM); 5 µL 10X buffer [MBI Fermentas buffer + (NH4)2SO4]; 3 µL Mg • Cl2 (stock = 25 mM); 0.5 µL Taq DNA polymerase (5 U/mL); 37.5 µL H2O. You can also use your favorite Taq polymerase with appropriate buffer, but be sure to use a classical (non-proof-reading) polymerase, which leaves “A” overhangs. Very high fidelity is not an issue here, as low-frequency PCR errors will not affect the specificity of the RNAi.
05_Clayton.qxd
4/16/05
12:04 PM
Page 48
48
Clayton et al.
2. Set the thermal cycler to the following sequence: 30 s at 94°C; 30 s at 55°C; 40 s at 72°C; 30 Cycles: followed by 10 min final elongation at 72°C. This sequence is for oligonucleotides designed by RNAit, with 60°C melting temperature. 3. Run 5 µL of the PCR product on an agarose gel to check quantity and specificity. 4. Clean the remainder using your favorite method, or you can attempt cloning without purification. One suitable kit is the MinElute PCR purification kit (Qiagen cat. no. 28106); elute in 30 µL of elution buffer. The PCR products can be stored at –20°C until use, but efficiency may be better if the ligation is started immediately.
3.1.2.2. VECTOR PREPARATION AND FRAGMENT CLONING
The parent vector, p2T7 TAblue, is shown in Fig. 1A. Eam1105I sites that flank the LacZ “stuffer” are engineered to leave T-overhanging ends. 1. For approx 20 ligations, prepare the following in a 1.5-mL Eppendorf (scale up if necessary): 4 µL vector (stock = 1 mg/mL); 5 µL 10X reaction buffer (Fermentas); 39 µL dH2O; 2 µL Eam1105I (Fermentas). 2. Incubate at 37°C for 1–2 h. (Note: Longer incubations may lead to damaged DNA ends and higher background.) 3. Check a small sample on a 1% agarose gel with an uncut vector control. If the digest appears complete, it is not necessary to purify the cut vector. 4. Add the following to 10 µL of PCR product: 1 µL Eam1105I digested p2T7; 1.3 µL 10X ligase buffer (NEB); 0.5 µL T4 ligase (NEB: #M0202S). 5. Incubate overnight at 4°C or 16°C. 6. Transfect 5 µL of each ligation into your favorite competent E. coli. 7. Plate onto Lurie–Bertani medium (LB) containing ampicillin (100 ug/mL), X-gal (1 mg/plate), and IPTG (2 mg/plate) and grow overnight. 8. Select and label two to four white colonies from each plate for screening. 9. Make minipreps using your favorite method. 10. Digest 2–5 µL of the miniprep with XhoI and BamHI. This digest should liberate the RNAi target insert, 400–600 bp. XbaI digestion can be used to liberate insert+ approx 1 kbp. HpaI can be used instead of BamHI/XhoI. 11. Run digests on a 1% agarose gel and select apparent positive clones. 12. Use the remaining DNA for sequencing. You can use one of your original PCR primers or use a standard primer (5′ CCGCTCTAGAACTAGTGGA 3′). 13. Select correct clones for midi-prep. Check the DNA concentration and bring to 1 mg/mL. Digest a sample of each with XhoI/BamHI to confirm that no rearrangement has occurred. HpaI can be used instead of BamHI/XhoI.
3.1.3. Stem-Loop Expression Vector In this procedure, the fragment is cloned twice, in opposite orientations, on either side of a “stuffer fragment,” which facilitates maintenance of the inverted repeat in E. coli. When transcribed, the “stuffer” forms the loop of the stem loop.
05_Clayton.qxd
4/16/05
12:04 PM
Page 49
Downregulating Gene Expression by RNAi
49
There are two options: i. Clone the RNAi fragments around the stuffer, then transfer the stem loop to an inducible vector. ii. Clone the RNAi fragments around the stuffer, which has already been cloned into the inducible vector. This is clearly simpler if the fragments are readily cloned in inverted orientation in E. coli and the HYG marker is to be used.
In either case, the genomic fragment is first amplified using oligonucleotides bearing nested restriction sites. For both cloning procedures, the structures of initial DNAs involved are as follows: Amplified fragment: site 1–site 2–fragment–site 3–site 4 Initial recipient plasmid vector (Fig. 1B,D): Vector–site 2–site 3–“stuffer”–site 4–site 1–vector The first cloning intermediate (plasmid A): Vector– site 2–PCR fragment–site 3–“stuffer”–site 4–site 1–vector Final construct for insertion into the expression vector (three-step procedure) or final construct in the two-step procedure: Vector–site 2–PCR fragment–site 3–“stuffer”– site 4–site 3–PCR fragment in inverse orientation–site 2–site 1–vector
3.1.3.1. THREE-STEP PROCEDURE
The following protocol is for cloning either side of a portion of the spliced leader repeat as described in ref. 22. Alternative stuffers of similar size can also be used; the nature of the sequence might influence either cloning efficiency or the effectiveness of RNAi, but there has been no systematic analysis of this. 1. The fragment should not contain BglII, SphI, EcoRI, SalI, HindIII, or NotI sites; however, if it does and you cannot avoid it, the following strategy can be modified by picking other suitable restriction sites. 2. Design two oligos to PCR-amplify that region. The sense oligo should contain a BglII-SphI linker (5′-GAGAAGATCTGCATGC ...) and the antisense oligo, a EcoRI-SalI one (5′-CGGAATTCGTCGAC ...). Please note that the SphI site contains an ATG codon that can act as a initiator codon (shown in italics), so design the oligo so that ATG is placed out of frame. If you cannot avoid including these restrictions sites within the amplified fragment, use alternatives in the polylinkers. 3. Carry out a PCR reaction using standard conditions. Run a gel and purify the PCR product. Digest half with SphI and SalI and the other half with EcoRI and BglII. Store the latter for step 7.
05_Clayton.qxd
4/16/05
12:04 PM
Page 50
50
Clayton et al.
4. Digest the stuffer vector with SphI and SalI. Gel-purify the linearized vector. 5. Ligate the linearized stuffer vector with the PCR product that was digested with SphI and SalI. The resulting plasmid is hereafter referred to as plasmid A. Check minipreps by digesting with XhoI + BglII (pHD1144 yields 2.4 + 0.8 kb; plasmid A yields 2.4 + another band of 0.8 + size of the PCR product). 6. Digest plasmid A with EcoRI and BglII; gel-purify the linearized vector. 7. Ligate the linearized vector with the PCR product digested with EcoRI and BglII (stored in step 3). The resulting plasmid is plasmid B. Check minipreps by digestion with HindIII and BglII (it should yield two bands: one of 2.4 kb corresponding to the vector backbone and another one of approx 2 kb, depending of the size of the original PCR product). Plasmid A can be included as a control; it yields 2.4 kb + another band whose size is very similar to the one obtained in step 5 (around 1.4 kb). At this point, you may discover that it is impossible to clone your desired fragment in the inverted orientation because of recombination in E. coli. If this is so, you can try changing either the fragment you are cloning (if the target gene is long enough to offer alternatives) or the stuffer. 8. Purify the HindIII- BglII 2-kb insert band from plasmid B (bearing the RNAi fragment–stuffer–tnemgarf iANR) to be used in step 10. 9. Digest pHD1146, pHD 1336, or pLEW79 with HindIII and BamHI. These plasmids differ mainly in the selectable marker. Gel-purify the linearized plasmid. 10. Ligate both fragments to obtain the final plasmid, plasmid C (BglII and BamHI leave ends that are compatible). Check by restriction digestion.
3.1.3.2. TWO-STEP PROCEDURE
This is similar to steps 1–7 of Subheading 3.1.3.1., but with the following modifications: 1. The fragment should not contain BglII, HpaI, ApaLI, HindIII, or NotI sites, but if it does and you cannot avoid it, the following strategy can be modified by using a single blunt end on the insert fragment. (If you use two blunt ends, it might be very difficult to obtain the inserts in opposite orientations.) 2. Design two oligos to PCR-amplify that region. The sense oligo should contain a BglII-HindIII linker (5′-GAGAAGATCTAAGCTT ...), and the antisense oligo, a HpaI-ApaI one (5′-CGGTTAACGGGCCC ...). (HpaI gives a blunt end so any other blunt-cutting enzyme will also do; BamHI can be used instead of BglII.) 3. Carry out a PCR reaction using standard conditions. Run a gel and purify the PCR product. Digest half with HindIII and ApaI and the other half with HpaI and BglII. Store the latter for step 7. 4. Digest the stuffer vector pGR19 with HindIII and ApaI. Gel-purify the linearized vector. 5. Ligate the linearized vector with the PCR product that was digested with HindIII and ApaI. Check minipreps. 6. Digest plasmid from step 5 with HpaI and BamHI; gel-purify the linearized vector. 7. Ligate the linearized vector with the PCR product digested with HpaI and BglII (stored in step 3).
05_Clayton.qxd
4/16/05
12:04 PM
Page 51
Downregulating Gene Expression by RNAi
51
3.2. Bloodstream Trypanosome RNAi Lines 3.2.1. Bloodstream Trypanosome Culture The bloodstream trypanosomes used for RNAi studies can be cloned as single cells and grow to a maximum cell density of about 7 × 106/mL. It is very important not to exceed this, as the cells will go into an irreversible stationary phase and die. Ideally, do not exceed 2 × 106/mL; then the cells will remain in log phase. The cell density usually increases 10-to 20-fold in 24 h. The cells are aerobic and are grown in a 5% CO2 incubator at 37°C in flasks with loosened or vented caps. Large volumes can be grown in sealed glass or plastic roller bottles in a warm room, but, in that case, it is important that at least 80% of the volume should be air. This is easiest achieved by equilibrating the bottles for 1 h in the incubator before tightening the caps. An alternative is to use multilayered flasks. To freeze the cells, take a growing culture ([0.5–2] × 106 cells/mL) and add an equal volume of sterile medium containing 20% glycerol. Aliquot 0.5–1 mL of cells per tube and cap tight. Make at least three tubes. Wrap the cells in paper tissue or wadding, with a thickness of about 5 cm. Place in the –70°C freezer. After 1–7 d, place in liquid nitrogen. After a further day, remove a tube and thaw rapidly. Place into medium and incubate overnight to check viability and the ability to grow. Although parasite motility is one indicator of viability, it does not always guarantee that the parasite can grow. Viability of RNAi lines after freezing is very variable (see Notes 1 and 2); do not throw away a growing culture until you are certain that the frozen stock is satisfactory. To recover cells, it can help to try different densities and to omit selective drugs immediately after thawing. (Glycerol can inhibit growth.) 3.2.2. Electroporation and Selection 3.2.2.1. PREPARATION 1. Cut vector (10 µg/cuvet) with NotI. Check 0.2 µg of the digest on a gel. Heat to denature the NotI; then ethanol-precipitate. 2. Wash the precipitate with 70% ethanol and then with 100% ethanol. Fill the tube with the ethanol to sterilize it. Remove the 100% ethanol, spin again, and remove the visible liquid. Then, leave the tube(s) open in the laminar flow hood to dry. 3. In the hood, resuspend the DNA in 25 µL (per 10 µg) of sterile water or TrisEDTA buffer. Make sure that the DNA is well dissolved, heating if necessary. Store at –20°C. 4. The day before transfection, inoculate fresh medium with trypanosomes at a final density of 105/mL. You will need (1–2) × 107 trypanosomes per transfection, and it is best to do two transfections for each DNA. Thus, for each transfection, you need 10–20 mL of culture at 106/mL. Be sure also to allow for no DNA and empty (Not-linearized) plasmid controls!
05_Clayton.qxd
4/16/05
12:04 PM
Page 52
52
Clayton et al.
3.2.2.2. TRANSFECTION 1. On the day of transfection, check cell numbers and wait, if necessary, until minimum numbers are attained. 2. Centrifuge the trypanosomes at about 1000g in a standard cell culture centrifuge and resuspend in ice-cold cytomix (1 mL per transfection; keep in the refrigerator). Set out the electroporation cuvets on ice, thaw the DNA, and label recipient flasks. If the electroporation cuvets come with a small Pasteur pipet, you should leave it, sterile, in the wrapper. Array the lids open side down on the sterile work surface in the laminar flow hood. 3. Recentrifuge the cells, and resuspend in 0.5 mL cytomix per cuvet. Keep on ice. During the centrifugation, aliquot 5 mL of growth medium per flask. We also use 36 mL of medium (in a 25-cm flask—kept upright). 4. Aliquot the trypanosomes into the cuvets, on ice. 5. For each transfection, take two cuvets from the ice and place them on the work surface in the hood. Dry them carefully with tissue. Add 10 µg of cut DNA. Mix up and down with a Pasteur pipet or using a Gilson pipetman. It is critical that the DNA be well mixed. Put on the cap. 6. Electroporate both cuvets using settings of 1.5 kV and resistance R2. The time constant should be about 0.3 and there will be a little foaming. If there is a flash and bang, use the cells anyway; the transfection may still have worked. 7. Transfer the contents of each cuvet to a separate flask with medium. 8. Proceed, two cuvets at a time, until all transfections are complete. 9. Take two flasks at random and count the cell density. It should be no more than 5 × 105/mL and there should clearly be dead cells and debris. Dilute if necessary. 10. Place in the incubator overnight.
3.2.2.3. SELECTION AND CLONING 1. Count the cells in each flask. 2. Dilute to 2 × 105/mL and add selective drug. In fact, in most cases there is no risk of overgrowth and the cells do not need counting before adding the drug and putting in multiwell plates, but counting is safer. 3. Plate the cells out into two 24-well plates with 1 mL per well. Any remaining culture can be kept in a larger flask. The no-DNA control can also be left in a flask. 4. Incubate for 5 d. At this time, any well containing live trypanosomes should be recognizable under the inverted microscope. Upon seeing the parasites, count to determine the cell density. It is also easy to see when the parasites start to grow because the medium turns yellower. The controls are usually dead after 4 d, often earlier. 5. When the density reaches 106/mL, transfer to a larger volume. 6. If there is no visible growth after 8 d, throw the cultures away and start again. 7. If this happens three times and a positive control experiment with empty vector gives clones, the RNAi is probably leaky and lethal. Under these circumstances, you may want to use an alternative region of the gene or switch to the stem-loop procedure if not already doing so.
05_Clayton.qxd
4/16/05
12:04 PM
Page 53
Downregulating Gene Expression by RNAi
53
3.3. Procyclic Trypanosome RNAi Lines 3.3.1. Procyclic Trypanosome Culture Procyclic trypanosomes usually die if they are diluted below about 1 × 105 cells/mL, although the presence of other cells can be mimicked by using conditioned medium. The component of conditioned medium that promotes parasite growth is not known. The parasites grow to a maximum cell density of (1–2) × 107/mL and they can be left for about a day at this density without dying, although such cultures may take a day or two to start growing after dilution. The cell density usually increases fourfold in 24 h, although behavior varies between lines and laboratories. The cells are aerobic and are classically grown at 27°C, but growth at 30°C is also possible. If the ambient temperature rises above about 22°C, it will be necessary to buy a refrigerated incubator, as most incubators can only operate at temperatures 5°C above the ambient temperature. Note that the ability to grow at 30°C allows the parasites to share an incubator or warm room with Saccharomyces cerevisiae; if you do this, contamination can be avoided simply by wrapping the caps of flasks with parafilm. Small volumes are easiest to grow in plastic, and large volumes can be grown in slowly shaking glass conical flasks. The parasites are aerobic, but the flasks cannot be left open in refrigerated incubators or warm rooms because the cultures will dry out. The solution to this is to make sure that at least 80% of the volume is air and—for flat flasks—to lay the flask down to ensure a maximum air–liquid interface. Caps should then be screwed down tightly to avoid evaporation. When using 24- or 96-well plates, seal them with parafilm. Freezing and thawing protocols are exactly as for bloodstream forms but using the appropriate medium. 3.3.2. Electroporation and Selection 3.3.2.1. PREPARATION
Follow subheading 3.2.2.1., steps 1–3. 4. The day before transfection, inoculate fresh medium with trypanosomes at a final density of 5 × 105/mL. You can transfect at densities up to, but not exceeding, 5 × 106/mL.
3.3.2.2. TRANSFECTION
Follow Subheading 3.2.2.2., item 1. 2a. After centrifuging the trypanosomes, transfer the supernatant (used medium) to a new sterile tube or bottle. Store it in the refrigerator. If you are worried about sterility, you can refilter the supernatant. 2b. The electroporation medium is ZPFM.
05_Clayton.qxd
4/16/05
12:04 PM
Page 54
54
Clayton et al.
3.3.2.3. SELECTION AND CLONING 1. Count the cells in each flask. 2. Dilute the cells to 2 × 105/mL using the conditioned medium that you saved from the previous day. Add the selective drug. 3. Plate on a 24-well plate. You can either put 1 mL of the culture per well or make four serial twofold dilutions. Usually the transfection efficiency is sufficiently low that plating the original culture is sufficient to give clonal populations. 4. Incubate for 7 d. At this time, any well containing live trypanosomes should be recognizable under the inverted microscope. Upon seeing the parasites, count to determine the cell density. It is imperative to count the cells, as the appearance of the deep cultures in wells is deceptive and excessive dilution at this stage will kill the parasites. If there are no cells growing well after 10 d, throw away the plates and start again. 5. When the density reaches 2 × 106/mL, transfer to a larger volume, but do not under any circumstances dilute to less than 5 × 105/ml. 6. If the majority of wells is positive, you may not have clones. This can, if necessary, be corrected later by recloning using conditioned medium or using normal (nondrug-resistant) cells as “feeders.”
3.4. Checking for RNAi The effectiveness of RNAi varies between clones, probably due at least partially to variation between integration sites: There are multiple copies of the rRNA spacer region on several different chromosomes. Therefore, it is nearly always necessary to analyze several independent clones in order to find the clone with the most effective reduction in gene expression. 3.4.1. Cell Growth The easiest initial test of the clones is to plate each clone into two neighboring wells on a 24-well plate; use 2 × 105/mL for procyclics and 5 × 104/mL for bloodstream forms. Add tetracycline (final concentration, 100 ng/mL) and follow growth over the next 2–3 d. This is only useful if growth effects are seen in some clones, which can then be picked for further analysis. 3.4.2. Northern and Western Blots Pick up to six clones for each transfection and grow for 2–10 d with and without tetracycline. A Northern blot using any probe for the target gene (including your RNAi fragment) can be done with total RNA from 3 × 107 trypanosomes, Note, however, that effective RNAi in trypanosomes sometimes merely alters the mobility of an RNA rather than eliminating the transcript (35). Messenger RNA levels are strongly affected by parasite density (36), so be sure to make the RNA from cells at similar densities: We usually use (0.5–1.0) × 106/mL for bloodstream forms and (1–2) × 106/mL for procyclics.
05_Clayton.qxd
4/16/05
12:04 PM
Page 55
Downregulating Gene Expression by RNAi
55
The ideal initial screen is to do a Western blot, if antibodies are available. For each lane on a polyacrylamide minigel, spin down (1–2) × 106 trypanosomes in the microfuge, resuspend in 10 µL of sample buffer, boil, and load. 3.5. More Detailed Analysis 3.5.1. Growth Kinetics Growth kinetics after RNAi are highly variable and depend on the stability of the target RNA/protein and its role in the cell. Sometimes, growth inhibition is seen the day following tetracycline addition, but in some cases, only after 10 d. It can also take several days to see a reduction in a protein even if the RNA appears to be depleted. Experience so far indicates that many trypanosome proteins are present in 5- to10-fold excess over that required for maintenance of the wild-type phenotype, so at least 80% depletion is required before any change in phenotype can be seen (see, e.g., refs. 37 and 38). Phenotypes may also be more severe if the cells are grown at low density on the day before RNAi induction; for example, diluting bloodstream forms to 1 × 104/mL or procyclics to 1 × 105/mL and repeating this the next day just before tetracycline addition. The reasons for this are unknown. Cell death might be preceded by the appearance of cells with abnormal morphology, including elongated or multinucleate cells, especially in procyclics. In bloodstream forms, it is more usual to simply see a reduction or stabilization of cell numbers, or a decrease in the apparent growth rate. In our experience, lysis rapidly follows death so that dead cells are not normally seen at high frequency within the cultures. The RNAi experiments in trypanosomes are further complicated by the ability of trypanosomes to “escape” from deleterious manipulations (see Note 1). Usually, if a defect in growth is seen, the parasites will start to escape within a few days. This is easily seen as a regrowth of normal cells. If the RNAi is very deleterious to the cells, the only phenotype that can be observed will be a reduction in numbers, possibly followed by regrowth of normal cells that no longer show the RNAi effect. 4. Notes 1. It is very common to find that the RNAi phenotype of a trypanosome line is lost upon prolonged cultivation in the absence of tetracycline. This is presumed to be caused by “leakage” of dsRNA transcription in the absence of inducer, and consequent negative selection acting on parasites able to express the dsRNA. The escape mechanism could be, for example, elimination of part of the RNAi plasmid or the T7 polymerase (41), some epigenetic mechanism, or an alternative adaptation (such as alterations in metabolism) enabling the parasite to bypass the defect. It is, therefore, important to freeze several aliquots of useful lines as soon as possible to minimize passage. 2. Although RNAi lines are always frozen without tetracycline, “leakage” might prevent their recovery after thawing. Alternatively, lines might be recovered but have
05_Clayton.qxd
4/16/05
12:04 PM
Page 56
56
3. 4.
5.
6.
7.
8.
Clayton et al. lost the RNAi phenotype. This seems to be more frequent with cells made using the p2T7 strategy than with stem loops. For this reason, it is very important to do as many experiments as possible, as rapidly as possible after obtaining the line, and not to rely on the presence of a stabilate. The easiest strategy for RNAi is the p2T7TA Blue approach, so this might be tried first. If RNAi does not give any phenotypic effects—or no clones are obtained—in one life-cycle stage, it is worth trying the other life-cycle stage, assuming that the protein is expressed in that stage. If no clones are obtained that show a reduction in the target RNA, or no clones are obtained at all even thought the empty vector control yields transformants, try using the stem-loop approach. If this too does not work, it will be necessary to use more laborious strategies— either a straight knockout or a knockout that is compensated by the presence of an inducible copy of the wild-type gene (37–40). If it is anticipated that the line will be stored and used for further experiments, and especially if it is planned to retransfect the line with additional plasmids, use a stem-loop strategy. Useful Internet links are as follows: Cultivation of trypanosomes: Molecular Parasitology website: Trypanofan Chromosome I RNA interference project, including protocols and p2T7TABlu sequence:
Trypanosome genome at the Sanger Centre: Trypanosome genome at TIGR:
http://tryps.rockefeller.edu/ http://164.67.60.203/par/molpar/index.html
http://www.trypanofan.org http://homepages.lshtm.ac.uk/~ipmbdhor/ Protocols.htm http://www.genedb.org/genedb/tryp/ index.jsp http://www.tigr.org/tdb/e2k1/tba1/
References 1. Ngo, H., Tschudi, C., Gull, K., and Ullu, E. (2002) Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc. Natl. Acad. Sci. USA 95, 14,687–14,692. 2. Djikeng, A., Shi, H., Tschudi, C., and Ullu, E. (2001) RNA interference in Trypanosoma brucei: cloning of small interfering RNAs provides evidence for retroposon-derived 24–26-nucleotide RNAs. RNA 7, 1522–1530. 3. Djikeng, A., Shi, H., Tschudi, C., Shen, S., and Ullu, E. (2003) An siRNA ribonucleoprotein is found associated with polyribosomes in Trypanosoma brucei. RNA 9, 802–808. 4. Shi, H., Djikeng, A., Tschudi, C., and Ullu, E. (2004) Argonaute protein in the early divergent eukaryote Trypanosoma brucei: control of small interfering RNA accumulation and retroposon transcript abundance. Mol. Cell Biol. 24, 420–427.
05_Clayton.qxd
4/16/05
12:04 PM
Page 57
Downregulating Gene Expression by RNAi
57
5. Durand-Dubief, M. and Bastin, P. (2003) TbAGO1, an Argonaute protein required for RNA interference, is involved in mitosis and chromosome segregation in Trypanosoma brucei. BMC Biol. 1, 2. 6. Shen, S., Arhin, G. K., Ullu, E., and Tschudi, C. (2001) In vivo epitope tagging of Trypanosoma brucei genes using a one step PCR-based strategy. Mol. Biochem. Parasitol. 113, 171–173. 7. Clayton, C. E. (2002) Developmental regulation without transcriptional control? From fly to man and back again. EMBO J. 21, 1881–1888. 8. Liang, X., Haritan, A., Uliel, S., and Michaeli, S. (2003) Trans and cis splicing in trypanosomatids: mechanism, factors, and regulation. Euk. Cell 2, 830–840. 9. Clayton, C. E. (1999) Genetic manipulation of Kinetoplastida. Parasitol. Today 15, 372–378. 10. Morris, J. C., Wang, Z., Drew, M. E., and Englund, P. T. (2002) Glycolysis modulates trypanosome glycoprotein expression as revealed by an RNAi library. EMBO J. 21, 4429–4438. 11. McKean, P. G., Baines, A., Vaugha, S., and Gull, K. (2003) Gamma-tubulin functions in the nucleation of a discrete subset of microtubules in the eukaryotic flagellum. Curr. Biol. 13, 598–602. 12. Drew, M. E., Morris, J. C., Wang, Z., et al. (2003) The adenosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library. J. Biol. Chem. 278, 46,596–46,600. 13. Estévez, A. M., Lehner, B., Sanderson, C. M., Ruppert, T., and Clayton, C. (2003) The roles of inter-subunit interactions in exosome stability. J. Biol. Chem. 278, 34,943–34,951. 14. Guerra-Giraldez, C., Quijada, L., and Clayton, C. E. (2002) Compartmentation of enzymes in a microbody, the glycosome, is essential in Trypanosoma brucei. J. Cell Sci. 115, 2651. 15. Allen, C. L., Goulding, D., and Field, M. C. (2003) Clathrin-mediated endocytosis is essential in Trypanosoma brucei. EMBO J. 22, 4991–5002. 16. Hammarton, T. C., Engstler, M., and Mottram, J. C. (2004) The Trypanosoma brucei cyclin, CYC2, is required for cell cycle progression through G1 phase and for maintenance of procyclic form cell morphology. J. Biol. Chem. 279, 24,757–24,764. 17. Mandelboim, M., Barth, S., Biton, M., Liang, X., and Michaeli, S. (2003) Silencing of Sm proteins in Trypanosoma brucei by RNA interference captured a novel cytoplasmic intermediate in spliced leader RNA biogenesis. J. Biol. Chem. 278, 51,469–51,478. 18. Wang, Z., Morris, J. C., Drew, M. E., and Englund, P. T. (2000) Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J. Biol. Chem. 275, 40,174–40,179. 19. LaCount, D. J., Bruse, S., Hill, K. L., and Donelson, J. E. (2000) Double-stranded RNA interference in Trypanosoma brucei using head-to-head promoters. Mol. Biochem. Parasitol. 111, 67–76. 20. Morris, J. C., Wang, Z., Drew, M. E., Paul, K. S., and Englund, P. T. (2001) Inhibition of bloodstream form Trypanosoma brucei gene expression by RNA interference using the pZJM dual T7 vector. Mol. Biochem. Parasitol. 117, 111–113.
05_Clayton.qxd
58
4/16/05
12:04 PM
Page 58
Clayton et al.
21. Bastin, P., Ellis, K., Kohl, L., and Gull, K. (2000) Flagellum ontogeny in trypanosomes studies via an inherited and regulated RNA interference system. J. Cell. Sci. 113, 3321–3328. 22. Shi, H., Djikeng, A., Mark, T., Wirtz, E., Tschudi, C., and Ullu, E. (2000) Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA 6, 1069–1076. 23. Biebinger, S., Wirtz, L. E., and Clayton C. E. (1997) Vectors for inducible overexpression of potentially toxic gene products in bloodstream and procyclic Trypanosoma brucei. Mol. Biochem. Parasitol. 85, 99–112. 24. Wirtz, E., Leal, S., Ochatt, C., and Cross, G. A. M. (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol. Biochem. Parasitol. 99, 89–102. 25. Wickstead, B., Ersfeld, K., and Gull, K. (2002) Targeting of a tetracyclineinducible expression system to the transcriptionally silent minichromosomes of Trypanosoma brucei. Mol. Biochem. Parasitol. 125, 211–216. 26. Alibu, P., Storm, L., Haile, S., Horn, D., and Clayton, C. (2005) A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma brucei. Mol. Biochem. Parasitol. 139, 75–82. 27. Duszenko, M., Ferguson, M. A. J., Lamont, G., Rifkin, M. R., and Cross, G. A. M. (1986) Cysteine eliminates the feeder cell requirement for cultivation of Trypanosoma brucei bloodstream forms in vitro. J. Exp. Med. 162, 1256–1263. 28. Hirumi, H. and Hirumi, K. (1989) Continuous cultivation of Trypanosoma brucei bloodstream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75, 985–989. 29. Carruthers, V. B. and Cross, G. A. M. (1992) High efficiency clonal growth of bloodstream- and insect-form Trypanosoma brucei on agarose plates. Proc. Natl. Acad. Sci. USA 89, 8818–8821. 30. Ziegelbauer, K., Quinten, M., Schwarz, H., Pearson, T. W., and Overath, P. (1990) Synchronous differentiation of Trypanosoma brucei bloodstream to procyclic forms in vitro. Eur. J. Biochem. 192, 373–378. 31. Vassella, E. and Boshart, M. (1996) High molecular mass agarose matrix supports growth of bloodstream forms of pleomorphic Trypanosoma brucei strains in axenic culture. Mol. Biochem. Parasitol. 82, 91–105. 32. Brun, R. and Schönenberger, M. (1979) Cultivation and in vitro cloning of procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop. 36, 289–292. 33. Durand-Dubief, M., Kohl, L., and Bastin, P. (2003) Efficiency and specificity of RNA interference generated by intra- and intermolecular double-stranded RNA in Trypanosoma brucei. Mol. Biochem. Parasitol. 129, 11–21. 34. Redmond, S., Vadivelu, J., and Field, M. C. (2003) RNAit: an automated webbased tool for the selection of RNAi targets in Trypanosoma brucei. Mol. Biochem. Parasitol. 128, 115–118. 35. Hendriks, E. F., Abdul-Razak, A., and Matthews, K. R. (2003) TbCPSF30 depletion by RNA interference disrupts polycistronic RNA processing in Trypanosoma brucei. J. Biol. Chem. 278, 26,870–26,878.
05_Clayton.qxd
4/16/05
12:04 PM
Page 59
Downregulating Gene Expression by RNAi
59
36. Häusler, T. and Clayton, C. E. (1996) Post-transcriptional control of hsp 70 mRNA in Trypanosoma brucei. Mol. Biochem. Parasitol. 76, 57–72. 37. Krieger, S., Schwarz, W., Ariyanagam, M. R., Fairlamb, A., Krauth-Siegel, L., and Clayton, C. E. (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35, 542–552. 38. Helfert, S., Estévez, A., Bakker, B., Michels, P., and Clayton, C. E. (2001) The roles of triosephosphate isomerase and aerobic metabolism in Trypanosoma brucei. Biochem J. 357, 55–61. 39. Maier, A., Lorenz, P., Voncken, F., and Clayton, C. E. (2001) An essential dimeric membrane protein of trypanosome glycosomes. Mol. Microbiol. 39, 1443–1451. 40. Lorenz, P., Meier, A., Erdmann, R., Baumgart, E., and Clayton, C. (1998) Elongation and clustering of glycosomes in Trypanosoma brucei overexpressing the glycosomal Pex11p. EMBO J. 17, 3542–3555. 41. Chen, Y., Hung, C.-H., Burderer, T., and Lee, G.-S. M. (2003) Development of RNA interference revertants in Trypanosoma brucei cell lines generated with a double stranded RNA expression construct driven by two opposing promoters. Mol. Biochem. Parasitol. 126, 275–279.
05_Clayton.qxd
4/16/05
12:04 PM
Page 60
06_Matzke.qxd
4/16/05
12:05 PM
Page 61
6 Analysis of Double-Stranded RNA and Small RNAs Involved in RNA-Mediated Transcriptional Gene Silencing M. Florian Mette, Werner Aufsatz, Tatsuo Kanno, Lucia Daxinger, Philipp Rovina, Marjori Matzke, and Antonius J. M. Matzke 1. Introduction RNA-mediated gene silencing is triggered by double-stranded RNAs (dsRNAs) that are processed to short RNAs approx 21–25 nucleotides in length. The short RNAs act as guides for enzyme complexes that degrade, modify, or inhibit the function of homologous target nucleic acids. There are three general types of RNA-mediated silencing: (1) RNA interference (RNAi) and the related processes of posttranscriptional gene silencing in plants and quelling in Neurospora crassa, which involve sequence-specific mRNA degradation; (2) microRNA-guided repression of translation; and (3) RNA-directed epigenetic modifications of the genome, such as DNA cytosine (C) methylation and histone methylation (1). This chapter focuses on a specific aspect of the third type of silencing: RNA-directed promoter methylation and transcriptional gene silencing (TGS). The RNAi-dependent heterochromatin assembly involving histone H3 lysine9 methylation has been observed in diverse organisms (2–5). By contrast, RNA-directed DNA methylation (RdDM) has been documented so far only in plants (1,6). RdDM is an unusual process that modifies all Cs, regardless of their sequence context, within the region of RNA–DNA sequence homology (6,7). Unlike RNAi-based heterochromatin, which spreads kilobases from the RNAtargeted nucleation site, RdDM does not infiltrate substantially into adjacent sequences (6,7). This suggests that direct RNA–DNA base-pairing creates a substrate that is recognized by DNA methyltransferases. Double-stranded From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. Carmichael © Humana Press Inc., Totowa, NJ
61
06_Matzke.qxd
4/16/05
12:05 PM
Page 62
62
Mette et al.
Fig. 1. Transgene strategy for inducing RNA-mediated TGS in plants. The silencer locus contains an inverted repeat of target promoter sequences. Transcription of the inverted repeat from an unrelated promoter (shaded box) produces a hairpin RNA, which is processed by a Dicer-Like (DCL) activity into short dsRNAs (21–25 bp) that have two-nucleotide 3′ overhangs. Single-stranded short RNAs are thought to target homologous DNA regions for de novo methylation by DNA methyltransferases (DMTase) and associated chromatin factors. RNA-directed DNA methylation is characterized by methylation (m) of cytosines in all sequence contexts (CNG, CG, CNN, where N is A, T, or C).
RNAs that contain promoter sequences can target homologous promoter elements for methylation and induce TGS (7–13). To study the mechanism of RNA-mediated TGS and promoter methylation, we have established several two-component transgene systems in the model plant Arabidopsis thaliana (7,13). The systems consist of two unlinked transgene loci: a silencer locus and a target locus. The silencer locus contains an inverted DNA repeat of target promoter sequences that is transcribed to produce a double-stranded (hairpin) RNA. The hairpin RNA is processed by Dicer-like activity into short RNAs (14), leading ultimately to de novo methylation and TGS of a homologous promoter at the target locus (see Fig. 1). After briefly outlining the features of transgene constructs that can initiate RNA-mediated TGS, we describe techniques used in our lab for the isolation and detection of dsRNAs and short RNAs active in this silencing pathway (7–9,13,14). 2. Materials 2.1. Chemicals and Solutions 1. 2. 3. 4. 5.
1 M Tris-HCl, pH 8.0 (Sigma 7-9) (Sigma, cat. no. T1378). 1 M Tris-HCl, pH 8.5. 1 M PIPES/NaOH buffer, pH 6.4 (Sigma, cat. no. P9291). 0.5 M Phosphate buffer, pH 7.2. Na2CO3/NaHCO3, 120 mM/80 mM : Dissolve 636 mg sodium carbonate (Sigma, cat. no. S7795) and 336 mg sodium bicarbonate (Sigma, cat. no. S6297) in double distilled water to a final volume of 50 mL. Keep in a tightly closed 50-mL plastic tube at room temperature. Always make fresh. 6. 0.5 M Na2EDTA/NaOH, pH 8.0 (EDTA = Titriplex, Merck, cat. no. K31678818).
06_Matzke.qxd
4/16/05
12:05 PM
Page 63
dsRNA in RNA-Mediated Gene Silencing 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17.
18. 19. 20. 21.
22. 23. 24. 25. 26. 27. 28. 29. 30. 31.
32. 33. 34. 35.
63
20% SDS (sodium dodecyl sulfate). 10 mM Tris-HCl, pH 8, 0.1% SDS. 40% Polyethylene glycol MW 8000 (dissolved in water) (Sigma, cat. no. P2139). 3 M Sodium acetate (NaOAc), pH 5. 5 M NaCl. 0.2 M Dithiothreitol (DTT) (Bio-Rad, electrophoresis grade, cat. no. 161-0611). 40% Ammonium peroxodisulfate (Merck, cat. no. K19701601). Diethylpyrocarbonate (DEPC) (Sigma, cat. no. D5758). Concentrated bleach (sodium hypochlorite solution) (Roth, cat. no. 9062.3). Chloroform. Distilled phenol (phenol p.a. from Merck, cat. no. 1.00206.0250; distill in standard organic chemistry apparatus, with air cooling only, in chemical fume hood; boiling temperature of phenol-182°C. Avoid skin contact.) 20X SSC: 3 M NaCl, 0.3 M sodium citrate. High-salt mix: 0.8 M sodium citrate, 1.2 M NaCl. 10X TBE: 121.1 g Tris-HCl (Sigma 7-9), 51.3 g boric acid, 3.72 g Na2EDTA (Titriplex); dissolve in distilled water; final volume-1 L. Tris-buffer-saturated phenol–chloroform: 100 g distilled phenol, 96 mL chloroform, 4 mL isoamyl alcohol, 100 mg 8-hydroxyquinoline (Sigma, cat. no. H-6378); equilibrated four times with an equal volume of 100 mM Tris-HCl, pH 8. Gel loading buffer: 96% formamide, 20 mM EDTA, 1 mg/mL bromphenol blue. 70% Ethanol. Absolute ethanol. Isoamyl alcohol. Trizol reagent (Invitrogen Life Technologies, cat. no. 15596-018). Urea (Invitrogen, cat. no. 15505-027). Acrylamide:bis-acrylamide 37.5 : 1 (AppliChem, cat. no. A1577.0500). TEMED (N,N,N′,N′-tetramethylethylenediamine) (Bio-Rad, cat. no. 161-0801). Bromophenol blue (Merck, cat. no. 8122). Deionized formamide: Pour 1 L formamide (Merck, cat. no. K31880384) into a baked 1-L glass beaker containing a sterile magnetic stirring bar, add 10 g resin [AG501-X8 (D), Bio-Rad, cat. no. 142-6425], cover with aluminum foil to minimize air contact, and stir until the resistance reaches a stable level of 1 kΩ (measure with a conductivity meter). Add another 5 g of resin and continue stirring until the resistance reaches a stable level of 5 kΩ. Filter through Whatman No. 1 filter paper, aliquot into 50-mL plastic tubes with screw caps, and store at −80°C. 10 mg/mL Ethidium bromide stock (dissolved in double-distilled water) (Merck, cat. no. K26175015). Double-Distilled water. Liquid nitrogen. Chromic acid (Merck, cat. no. 1.02499.1000).
06_Matzke.qxd
4/16/05
12:05 PM
Page 64
64
Mette et al.
36. Hybridization solution: 125 mM sodium phosphate buffer, pH 7.2 (10 mL of a 0.5 M stock), 250 mM sodium chloride (2 mL of 5 M NaCl), 7% SDS (2.8 g of SDS in 40 mL final volume), and 50% deionized formamide (20 mL). 37. Hamilton’s homogenization solution (50 mL): 2.5 mL of 1 M Tris-HCl, pH 8.5, 1 mL of 0.5 M Na2EDTA/NaOH, pH 8, 1 mL of 5 M NaCl, 5 mL of 20% SDS, and 40.5 mL of DEPC-treated double-distilled H2O. 38. RNAseA buffer (200 mL): 20 mM Tris-HCl, pH 7.5 (4 mL of 1 M stock), 60 mM NaCl (2.4 mL of 5 M stock), 5 mM EDTA (2 mL of 0.5 M stock), 10 µg/mL of RNase A (200 µL of 10 mg/mL stock), and distilled water to 200 mL.
2.2. Supplies 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Vinyl gloves (Kimberly Clark, cat. no. 9982). Grinding spheres (Plant DNA isolation kit [Roche, cat. no. 1667319]). Miracloth (Calbiochem, cat. no. 475855). 3MM paper (Whatman, cat. no. 3030917). Zeta-Probe GT nylon membrane (Bio-Rad, cat. no. 162-0197). Sephadex G50 (Pharmacia, cat. no. 17-0573-02). Kodak X-ray film (Sigma, cat. no. F5513-50EA). Hybridization bags (Roche, cat. no. 1666649). Parafilm. Saran Wrap.
2.3. Centrifuges and Tubes 1. 1.5-mL Eppendorf tubes. 2. Eppendorf centrifuge 5415 D. 3. Cooled tabletop centrifuge for 1.5-mL tubes capable of approx 10,000g centrifugation force (e.g., Sigma1-15K at 13,000 rpm). 4. 50-mL plastic conical tubes, sterile (Greiner Bio-one, cat. no. 227261). 5. 15-mL Corex tubes plus rubber adaptors. 6. 30-mL Corex tubes plus rubber adaptors. 7. High-speed refrigerated centrifuge (e.g., Beckman J2-21). 8. High-speed swing-out rotor suitable for 15-mL and 30-mL Corex tubes plus rubber adaptors (e.g., Beckman JS13.1).
2.4. Incubators, Ovens 1. 2. 3. 4. 5.
42°C incubator. 64°C incubator. Heating block (e.g., Eppendorf Thermostat 5320). 80°C vacuum oven. Baking oven (180°C).
2.5. Equipment 1. GeneQuant ultraviolet (UV) spectrophotometer (Pharmacia, cat. no. 80-2190-98). 2. Polyacrylamide gel electrophoresis apparatus (vertical gel electrophoresis system; Biometra, cat. no. V15-17).
06_Matzke.qxd
4/16/05
12:05 PM
Page 65
dsRNA in RNA-Mediated Gene Silencing 3. 4. 5. 6. 7.
65
UV transilluminator. Trans-blot SD semidry transfer cell (Bio-Rad, cat. no. 170-3848). Gilson Pipetman (20 µL, 200 µL, 1 mL, 10 mL), with appropriate autoclaved tips. Plastic dessicator attached to vacuum pump for drying nucleic acid pellets. Hybridization bag sealer (e.g., Audion Elektro, Sealboy 235).
2.6. Enzymes, Radioactive dNTPs/NTPs, Kits, Nucleic Acids 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
RNase One (Promega, cat. no. M 426 C). Megaprimed DNA probe synthesis (Amersham kit RPN 1605). NTP set, 100 mM solutions (Amersham, cat. no. 27-2025-01). [α-32P]dATP (New England Nuclear, cat. no. NEG012H or equivalent). [α-32P]UTP (New England Nuclear, cat. no. NEG507H or equivalent). 0.155 to 0.177-kb RNA size standards (Invitrogen Life Technologies, cat. no. 15623-010). RNasin (Roche, cat. no. 3 335399). RNA polymerase (T7, T3, SP6 as appropriate) (Roche: cat. nos. T7, 881767; T3, 1031163: SP6, 810 274). DNaseI, RNase-free (Amersham, cat. no. 27-0514-01). RNase A (10 mg/mL stock solution in water) (Sigma, cat. no. R-5500). tRNA (1 µg/mL stock solution in double-distilled water) (Roche, cat. no. 109517). pGEM-T easy vector (Promega, cat. no. A1360). DNA oligonucleotides for transcribing short RNA standards (Biolegio or a comparable supplier).
3. Methods The methods described below outline (1) a transgene approach for inducing RNA-mediated TGS via promoter dsRNAs, (2) isolation of dsRNA and small RNAs, (3) polyacrylamide gel electrophoresis (PAGE) of dsRNA and small RNAs, (4) transfer of RNAs from gel to hybridization membrane by electroblotting, and (5) hybridization conditions to detect dsRNA and small RNAs. 3.1. Transgene Strategy for Inducing RNA-Mediated Transcriptional Gene Silencing The basic requirement for RNA-mediated TGS is a dsRNA that contains promoter sequences. This is synthesized most efficiently by transcribing an inverted DNA repeat of target promoter sequences. Factors to consider when assembling a silencing construct for inducing RNA-mediated TGS are (1) the susceptibility of the target promoter to this type of silencing, (2) the length of the inverted repeat and spacer, (3) the region of target promoter to be covered by the RNA trigger, (4) the characteristics of the promoter transcribing the inverted repeat, and (5) the need for transcription termination sequences.
06_Matzke.qxd
4/16/05
12:05 PM
Page 66
66
Mette et al.
3.1.1. Susceptibility of the Target Promoter Although a large number of plant promoters have not yet been examined for susceptibility to RNA-mediated TGS, those tested so far appear to be silenced effectively by this approach. This includes transgene promoters (constitutive and tissue-specific) as well as endogenous gene promoters. Various target promoters have been silenced successfully in different plant species, including Arabidopsis thaliana, Nicotiana tabacum (tobacco), and Petunia hybrida (7–13). Efficient downregulation (up to 50-fold) of even strong, tissue-specific promoters has been achieved using this technique (13). It is conceivable that sequence composition (i.e., number and density of CpG, CpNpG, and CpNpN nucleotide groups) could affect sensitivity to RNA-mediated TGS. For example, a promoter that is rich in CpG dinucleotides, which maintain methylation much more reliably than non-CpGs in the absence of the RNA trigger (7,10), might be more persistently silenced by RNA-mediated TGS than a promoter that is deficient in CpGs. More studies are required to assess this possibility and to determine specific features of target promoters that enhance or reduce susceptibility. 3.1.2. Length of Inverted Repeat and Spacer The silencer locus contains a transcribed inverted repeat of target promoter sequences. From studies carried out so far, the optimal length of each copy of the inverted repeat appears to be 200–400 bp (basepairs), with an intervening spacer region comprising several hundred basepairs of unrelated sequence (7,13). Although a systematic analysis has not yet been conducted, it is likely that longer sequences in the inverted repeat will not always be transferred intact into host chromosomes. A generous spacer is necessary to ensure stability of the inverted repeat construct during cloning steps in bacteria. In our silencing systems, short RNAs originate from the entire dsRNA, indicating efficient processing and subsequently full coverage of the complete DNA sequence that is targeted (14). 3.1.3. Region of Target Promoter to Be Covered by the RNA Trigger Constructs used successfully in our lab have targeted the region around the transcription start site and sequences upstream. Addition of the 5′-untranslated region into the silencing construct does not appear to interfere with RNA-mediated TGS but is not necessary to achieve efficient silencing. Any regions containing cytosine residues that are known to be critical for silencing when methylated should be included in the inverted repeat sequence. 3.1.4. Characteristics of Promoter Transcribing the Inverted Repeat Using a strong constitutive promoter to transcribe the inverted repeat of promoter sequences results in abundant dsRNA and short RNA processing
06_Matzke.qxd
4/16/05
12:05 PM
Page 67
dsRNA in RNA-Mediated Gene Silencing
67
products (7,10,13). For this purpose, we normally use the nominally constitutive 35S promoter of cauliflower mosaic virus, which produces around 1–10 pg of dsRNA per 100 µg total RNA. A tissue-specific promoter can also be employed to transcribe the inverted repeat in selected cell types, but this might not always achieve the desired result. For example, we have used a strong embryo-specific promoter to drive transcription of an inverted repeat containing sequences of a distinct but related embryo-specific promoter. Instead of uniform, complete silencing of the target promoter in embryos, which had been expected based on the individual expression patterns of the two promoters, a random, mottled pattern of silencing was frequently observed (see Fig. 2, left). A more predictable pattern of silencing of the embryo-specific target promoter was achieved using the nominally constitutive 35S promoter (see Fig. 2, right). Although the basis of the uneven silencing observed with the embryo-specific transcribing promoter is not yet known, it is possible that competition for common embryo transcription factors stochastically disturbs the activity of the transcribing promoter. To ensure the most consistent silencing, regardless of the tissue specificity of the target promoter, we recommend using a strong constitutive promoter to transcribe the inverted repeat. 3.1.5. Need for Transcription Termination Sequences Whether to include transcription termination sequences or polyadenylation signals might depend on the system under investigation. Plants have at least one nuclear-localized Dicer-like activity (14), which is thought to process dsRNAs to short RNAs in the nucleus. Accordingly, we routinely avoid placing a transcriptional terminator downstream of the transcribed promoter inverted repeat. This presumably retains the dsRNAs in the nucleus, where they ultimately exert their effect. Further analysis is required to assess the use of RNA-mediated TGS for mammals, where the single Dicer protein is cytoplasmic (15), because promoter dsRNAs might provoke an interferon response in these organisms. For animals that lack an interferon response, information about the subcellular localization of Dicer activities should help to decide whether or not to include transcription termination sequences downstream of the transcribed inverted repeat. 3.2. Detection of dsRNA This protocol was optimized to detect hairpin RNAs that have a perfect stem of about 200–300 nucleotides and are present at a concentration of about 1–10 pg per 100 µg of total RNA. Such RNAs have been used successfully to induce RNA-mediated TGS and de novo methylation of target promoters (see Subheading 3.1.). We have not systematically analyzed whether the procedure will also work for dsRNAs that are larger or are present at lower concentrations.
06_Matzke.qxd
68
4/16/05
12:05 PM
Page 68
Mette et al.
Fig. 2. Pattern of silencing depends on transcribing promoter. The target embryospecific promoter (A) and a related embryo-specific promoter (B) both drive strong and uniform expression of a GUS reporter gene (dark color) in plant embryos. Surprisingly, when the related embryo-specific promoter is used to transcribe an inverted repeat of the target promoter, instead of uniform and complete silencing [which would result in a completely white embryo (D)], incomplete and stochastic silencing of the target promoter is observed (C). By contrast, when a nominally constitute viral promoter, which drives GUS expression primarily in cotyledons (embryonic leaves), (E) is used to transcribe the inverted repeat of the target promoter, silencing occurs in a predictable pattern, which is a mirror image of the pattern of activity of the viral promoter (high in cotyledons, weak in root tip) (F).
To selectively enrich for dsRNAs, total RNA (see Subheading 3.2.1.) is treated with a single-strand-specific ribonuclease (RNase) (see Subheading 3.2.3.) and then separated by gel electrophoresis (see Subheading 3.2.4.). After transfer to a membrane (see Subheading 3.2.5.), the dsRNA of interest is detected by hybridization (see Subheading 3.2.6.).
06_Matzke.qxd
4/16/05
12:05 PM
Page 69
dsRNA in RNA-Mediated Gene Silencing
69
3.2.1. Isolation of Total RNA from Plant Tissues In our laboratory, total RNA is extracted from young tobacco and Arabidopsis leaves using the Trizol reagent according to the manufacturer’s instructions. However, total RNA prepared with any other method should work as well provided that it does not contain RNase One inhibitors (e.g., SDS). All solutions and plasticware (Eppendorf tubes, pipet tips, etc.) should be RNasefree and sterilized by autoclaving. Glass Corex tubes should be cleaned overnight with chromic acid, rinsed thoroughly with tap water and, finally, with distilled water, capped with aluminum foil, and baked overnight in a 180°C oven. To make double-distilled water that is RNase-free for use in enzyme reactions, add DEPC (250 µL/L water) before autoclaving. Vinyl gloves should be worn when carrying out RNA isolation procedures, enzyme reactions, and blot hybridization steps. Total RNA is treated with RNase One to enrich for dsRNA (see Subheading 3.2.3.). Before describing that procedure, we outline a method for making synthetic dsRNA, which can be used to assess the efficiency of the RNase One reaction and to generate size markers. 3.2.2. Synthetic dsRNA Size Markers When investigating a dsRNA encoded by a transgene inverted repeat of known length, a synthetic size standard can be made by annealing sense and antisense RNAs that have been transcribed in vitro. The sequence of interest must be cloned into a plasmid (e.g., pGEM-T easy), which allows in vitro transcription of both insert DNA strands from a promoter of a DNA-dependent RNA polymerase (T3, T7, or SP6). 3.2.2.1. IN VITRO TRANSCRIPTION
OF
SENSE AND ANTISENSE RNAS
1. Cut plasmid containing DNA sequences homologous to dsRNA with appropriate enzymes to allow runoff transcripts from T3, T7, or SP6 RNA polymerase. 2. Set up separate 50-µL reactions for sense and antisense RNA synthesis in two 1.5-mL Eppendorf tubes by adding the following: 2 µL plasmid digest (approx 1 µg plasmid DNA), 34 µL DEPC-treated double-distilled water, 5 µL 10X in vitro transcription buffer (supplied with RNA polymerase); 2.5 µL of 0.2 M DTT; 2 µL RNasin (40 U/µL), 4 µL of 25 mM ATP, CTP, GTP, UTP mix (made by mixing equal volumes of the four 100 mM stock solutions in the NTP set), 1 µL appropriate RNA polymerase (20 U/µL). 3. Incubate at 37°C for 2 h. 4. Add 2.5 µL DNase I (20 U/µL), RNase-free, and incubate at 37°C for 5 min; then add 1 mL Trizol reagent, vortex, add 200 µL chloroform, vortex, and incubate at room temperature for 2–3 min. 5. Centrifuge for 15 min at 4°C, 13,000 rpm (Sigma 1-15K centrifuge); then transfer the upper phase to a new Eppendorf tube.
06_Matzke.qxd
4/16/05
12:05 PM
Page 70
70
Mette et al.
6. Add 0.5 vol of isopropanol and 0.5 vol of 0.8 M sodium citrate, 1.2 M of NaCl (high-salt mix), vortex, and incubate 15 min at room temperature. 7. Centrifuge as in step 5. Discard supernatant and wash pellet with 1 mL of 70% ethanol; centrifuge as in step 5. 8. Discard supernatant and vacuum-dry for 10 min. 9. Dissolve each pellet in 10 µL DEPC-treated double-distilled water; quantify with GeneQuant (see Subheading 3.3.2.). The expected yield for each reaction is several microgram sense or antisense RNA. 10. Aliquots can be used immediately for annealing (see Subheading 3.2.2.2.). 11. As controls for sufficient digestion of single-stranded RNA in the RNase One reaction (see Subheading 3.2.3.), make separate 1 pg/µL stock solutions for sense and antisense RNA in double-distilled water containing 1 µg/µL tRNA as the carrier and store at −80°C. 12. Store remaining sense and antisense RNA at −80°C (solutions most stable if left undiluted).
3.2.2.2. ANNEALING
OF
SENSE AND ANTISENSE TRANSCRIPTS
1. Put the following in a 1.5-mL Eppendorf tube: 0.1 µg sense RNA, 0.1 µg antisense RNA, 20 µL of 5X RNase protection buffer (0.2 M PIPES, pH 6.4, 2 M NaOAc, 5 mM EDTA), and 80 µL deionized formamide. 2. Incubate 5 min at 80°C, switch off heating block, allow to slowly cool to room temperature in the heating block for 5 h, and store at −80°C until use. 3. Make 1 pg/µL stock in double-distilled water containing 1 µg/µL tRNA as a carrier and store at −80°C.
3.2.3. RNase One Treatment For each RNase One reaction (equals one gel lane), 50 or 100 µg of total plant RNA are digested using 1–2 U RNase One per 10 µg RNA (see Note 1). Controls employing synthetic RNAs (see Subheading 3.2.2.1.) can be processed in parallel: 0.3 pg and 1 pg of separate sense or antisense RNA are digested with RNase One in a background of 50 or 100 µg tRNA. The absence of a signal after hybridization indicates sufficient digestion of single-stranded RNA. Then, 0.3 pg and 1 pg of synthetic dsRNA are digested with RNase One in a background of 50 or 100 µg of tRNA. A single well-defined band of the expected size indicates the successful enrichment for dsRNA and provides a measure to estimate the amount of dsRNA in the accompanying plant RNA samples (see Fig. 3, right). 1. To treat total plant RNA with RNase One, put into a sterile 1.5-mL Eppendorf tube RNA dissolved in DEPC-treated double-distilled water and adjusted to 90 µL. 2. Add 10 µL of 10X RNase One reaction buffer (provided with the enzyme by the supplier). Mix well by flicking at the tube, briefly (10 s), then spin in an Eppendorf centrifuge at room temperature to collect the solution at the bottom of the tube. 3. Add RNase One (supplied as 7–10 U/µL), mix well, briefly spin as in step 2, and incubate 10 min at 37°C.
06_Matzke.qxd
4/16/05
12:05 PM
Page 71
dsRNA in RNA-Mediated Gene Silencing
71
Fig. 3. Detection of dsRNA by RNase One digestion. Left: Incomplete RNase One digestion, leading to weak and/or multiple bands in addition to the one of the expected size (255 bp) on the Northern blot (top). Right: Optimal digestion produces a single band of the expected size and the quantitative controls (0.3 pg and 1 pg) display the desired ratio of signal strength. Note that this blot is derived from an ethidium bromidestained gel in which no RNA was visible (bottom, right) as compared to the stained gel for the incomplete RNase One treatment, on which stained bands were still apparent (bottom, left). For further information, see Note 1. 4. Add 5 µL of 20% SDS (stops the reaction). 5. Extract with Tris-buffer-saturated phenol–chloroform (add 150 µL Tris-buffersaturated phenol–chloroform, vortex for 30 s, centrifuge 5 min in an Eppendorf centrifuge at room temperature to separate phases, and transfer the upper aqueous phase to a sterile 1.5-mL Eppendorf tube). 6. Extract with chloroform (add 150 µL chloroform and treat as in step 5; transfer the upper aqueous phase to a sterile 1.5-mL Eppendorf tube).
06_Matzke.qxd
4/16/05
12:05 PM
72
Page 72
Mette et al.
7. Precipitate RNA from aqueous phase: Add 12 µL of 3 M NaOAc, pH 5, then add 300 µL absolute ethanol, mix well by vortexing, and incubate >30 min at −20°C. 8. Centrifuge 15 min at 4°C, 13,000 rpm (Sigma 1–15K centrifuge), discard the supernatant, and wash the sediment with 1 mL of 70% ethanol. 9. Centrifuge 15 min at 4°C, 13,000 rpm (Sigma 1–15K centrifuge), discard the supernatant, and vacuum-dry the sediment for 10 min. 10. Dissolve RNA in 10 µL of 0.2% SDS and store at −20°C or use directly for PAGE (see Subheading 3.2.4.).
3.2.4. PAGE of dsRNA To separate RNase One digestion products (see Subheading 3.2.3.), we typically use a 5% polyacrylamide gel containing 7 M urea (useful range about 100–1000 nucleotides). A suitable size standard for this experiment is the 0.155- to 1.77-kb RNA standard (5 µg per lane) from Invitrogen. If the expected size and sequence of the RNase One digestion product are known (e.g., from a hairpin RNA encoded by a transgene inverted repeat of known length), a synthetic dsRNA can be made and used as a hybridization control and size standard (see Subheading 3.2.2.). Electrophoresis on 5% polyacrylamide–7 M urea gel (0.225X TBE): 1. Size: 18 cm × 13 cm × 1.5 mm, comb for 12 wells, about 10-mm well width; glass plates are cleaned with dishwashing detergent and 70% ethanol. 2. Gel: Add to a 250-mL Erlenmeyer flask the following: 28.8 g urea (final concentration, 7 M), 28.5 mL double-distilled water, 7.5 mL of 40% acrylamide : bisacrylamide 37.5:1 (final percent = 5%) and 1.35 mL of 10X TBE (final, 0.225X). 3. Heat (64°C incubator) until the urea is completely dissolved (swirl flask to mix contents, then filter through Miracloth into a 100-mL Erlenmeyer flask, and let stand at room temperature for 30–45 min to cool. 4. Add 62.5 µL of 40% ammonium peroxodisulfate and 40 µL TEMED; mix well and pour gel. 5. Allow to polymerize overnight (cover with Saran Wrap to avoid dessication), then, set up in gel box with 0.225X TBE running buffer. 6. Prepare the RNA samples: To the RNase One–treated RNA sample dissolved in 10 µL of 0.2% SDS (see Subheading 3.2.3.), add 40 µL gel loading buffer, denature 5 min at 95°C on heating block, place on ice for 5 min, then load samples to gel wells (see Note 2). 7. Carry out the electrophoresis: Set limits of the power supply to 800 V, 25 mA, 10 W and run until the bromophenol blue reaches the lower edge of of the gel (time: 60 min [bromophenol blue has about same mobility as tRNA of 70 nucleotides] or longer [e.g., 90 min, optimal result for RNA of 300 nucleotides]). 8. Stain the gel for 10 min in 0.5X TBE containing 1 µg/mL ethidium bromide and then wash 20 min in 0.5X TBE. At this point, the gel can be optionally photographed under UV transillumination (see Fig. 3, bottom) and can now be used to transfer the RNA to hybridization membrane (see Subheading 3.2.5.).
06_Matzke.qxd
4/16/05
12:05 PM
Page 73
dsRNA in RNA-Mediated Gene Silencing
73
3.2.5. Transfer of RNA to Hybridization Membrane by Electroblotting Whereas the transfer of RNA from agarose gels to hybridization membrane can be carried out by standard capillary blotting, the transfer from polyacrylamide gels requires electroblotting. 1. Setup: Bio-Rad Trans-Blot SD semidry transfer cell in cold room; all steps at 4°C. Place onto transfer cell from bottom (anode) to top (cathode) the following: three sheets of Whatman 3MM, 20 cm × 15 cm, soaked with 0.5X TBE (see Note 3), a piece of Bio-Rad Zeta-Probe GT nylon membrane, 20 cm × 15 cm, soaked with 0.5X TBE, the gel, equilibrated with 0.5X TBE, and, finally, three sheets of Whatman 3MM paper, 20 cm × 15 cm, soaked with 0.5X TBE. 2. Transfer step: Transfer RNA to the membrane at 10 V for 1 h, and then rinse the membrane briefly in 0.5X TBE. Rub gently but firmly with a gloved finger to remove particles that can contribute to background hybridization. Briefly air-dry the membrane. The positions of the bands can be optionally visualized under UV transillumination, and the positions of the bands of the 0.155- to 1.77-kb RNA size standards can be marked with a pencil. 3. Place the membrane between two sheets of Whatman 3MM paper and vacuum-dry at 80°C for 2 h to crosslink the RNA to the membrane.
3.2.6. Hybridization with
32P-Labeled
DNA Probes
To detect dsRNAs of interest, 32P-labeled “megaprimed” DNA probes are used. Details of probe synthesis and hybridization conditions suitable for the membranes used for electroblotting are given in Subheading 3.2.6.1. and Subheading 3.2.6.2., respectively. 3.2.6.1. “MEGAPRIMED” DNA PROBE SYNTHESIS
For this, the Amersham kit RPN 1605 is used. Detailed information is available on the Amersham-Pharmacia website. For each 15-cm × 20-cm membrane, two 50-µL reactions are performed: 1. To a sterile 1.5 mL Eppendorf tube, add the following: 1 µL template DNA (25 ng/µL) (see Note 4), 5 µL primer solution (supplied in kit), 20 µL DEPCtreated double distilled water. 2. Denature 5 min at 95°C on a heating block; incubate 10 min on ice. 3. Add 12 µL dNTPs (minus dATP) (supplied in kit), 5 µL (50 µCi) [α-32P]dATP, 5 µL of 10X reaction buffer (supplied in kit), 2 µL of 1 U/µL Klenow DNA polymerase (supplied in kit) and incubate for 2 h at 37°C. 4. Pool reactions (final volume to 100 µL) and remove unincorporated 32P by gel filtration on a 1-mL column of Sephadex G50 resin equilibrated in 10 mM Tris-HCl, pH 8, 0.1% SDS. 5. Denature the probe for 5 min at 95°C in a heating block, followed by incubating for 10 min on ice.
06_Matzke.qxd
4/16/05
12:05 PM
Page 74
74
Mette et al.
3.2.6.2. HYBRIDIZATION REACTION (DSRNA) 1. Prewet the membrane in double-distilled water, place it in a hybridization bag, and prehybridize membrane in 40 mL hybridization solution at 42°C for 4–5 h (see Note 5 for details of the preparation of the hybridization solution). 2. Replace the hybridization solution and add freshly denatured probe (see Note 6). 3. Hybridize at 42°C overnight. 4. Remove the filter from the bag and place in appropriate tray and wash: a. One time, 15 min in 2X SSC, 0.1% SDS at room temperature. b. One time, 15 min in 0.5X SSC, 0.1% SDS at room temperature. c. Two times, 15 min in 0.1X SSC, 0.1% SDS at 64°C. 5. Expose to X-ray film (see Fig. 3, top).
3.3. Detection of Small RNAs Preparations enriched for low-molecular-weight RNA (about 10–100 nucleotides) are obtained according to the following protocol (see Subheading 3.3.1.), which is a modified version of one provided by Andrew Hamilton (16; A. Hamilton, personal communication). Also described are procedures for quantifying small RNAs (see Subheading 3.3.2.), synthesis of synthetic small RNA markers (see Subheading 3.3.3.), PAGE of small RNAs (see Subheading 3.3.4.), and hybridization conditions and probe synthesis (see Subheading 3.3.5.). 3.3.1. Small RNA Isolation 1. Collect 1 g fresh leaf tissue in a sterile 50-mL conical plastic tube containing five grinding spheres (cleaned in concentrated bleach and then rinsed thoroughly with DEPC-treated double-distilled water). Add liquid nitrogen to freeze tissue. Wait until liquid nitrogen evaporates and grind frozen tissue to powder by vortexing for 1 min. 2. Suspend frozen powder in 5 mL Hamilton’s homogenization solution, vortex, and put on ice. 3. Add 5 mL Tris-buffer-saturated phenol–chloroform; cover tube with parafilm, and vortex. (Caution: Avoid skin contact with phenol. Wash in stream of running tap water if exposed.) 4. Incubate 5 min on ice. 5. Transfer to a clean 15-mL Corex centrifugation tube (baked overnight at 180°C); centrifuge in Beckman JS13.1 rotor, 9000 rpm (about 12,500g) for 15 min at 4°C. 6. Using a 10-mL Gilson pipetman and sterile 10-mL tips, transfer the upper aqueous phase (approx 5 mL) to a clean 15-mL Corex tube, add 5 mL Tris-buffersaturated phenol–chloroform, cover with parafilm, and vortex to mix. 7. Incubate 5 min on ice. 8. Centrifuge in JS 13.1 rotor, 9000 rpm (about 12,500g) at 4°C for 15 min. 9. Collect aqueous supernatant (approx 5 mL) in a clean 30-mL Corex tube.
06_Matzke.qxd
4/16/05
12:05 PM
Page 75
dsRNA in RNA-Mediated Gene Silencing
75
10. Add 0.5 mL of 3 M NaOAc, pH 5, and 15 mL absolute ethanol. Cover with parafilm and mix well. Incubate at least 2 h at −20°C. 11. Centrifuge in JS 13.1 rotor as in step 8. 12. Discard supernatant and wash sediment with 10 mL of 70% ethanol. 13. Centrifuge as in step 8. 14. Vacuum-dry sediment for 10 min. 15. Dissolve in 3.87 mL DEPC-treated double-distilled H2O (cap tube with aluminum foil and incubate for 15 min at 64°C in incubator; vortex briefly after 7 min) (see Note 7). 16. Add 0.5 mL of 5 M NaCl and 0.63 mL of 40% polyethylene glycol, molecular weight = 8000; incubate on ice for 30 min; centrifuge as in step 8. 17. Arabidopsis only: Transfer supernatant to a clean 15-mL Corex tube, add 5 mL Tris-buffer-saturated phenol–chloroform, vortex, and centrifuge as in step 8 (see Note 8). 18. Save supernatant and transfer to a clean 30-mL Corex tube. Add 0.5 mL of 3 M NaOAc and 15 mL absolute ethanol. Cover with parafilm and mix well. Incubate for 2 h at −20°C. Centrifuge as in step 8. Discard supernatant and wash with 10 mL of 70% ethanol. Centrifuge as in step 8. Discard supernatant and vacuum-dry for 10 min. 19. Dissolve in 50–100 µL DEPC-treated double-distilled H2O (cap tube with aluminum foil and place at 64°C for 10 min); mix by pipeting up and down with a 200-µL Gilson pipetman; briefly centrifuge to sediment any remaining particulate material; transfer supernatant to autoclaved 1.5-mL Eppendorf tube. 20. Store at −80°C.
3.3.2. Quantification of Small RNAs 1. Mix 1 µL RNA solution (step 19 of Subheading 3.3.1.) + 3 µL DEPC-treated double-distilled H2O; measure absorbance at 260 nm using the Pharmacia GeneQuant UV spectrophotometer (see Note 9). 2. The yield is typically about 70–140 µg for Arabidopsis and 250–300 µg for tobacco. After quantification, samples are ready for PAGE (see Subheading 3.3.4.1.; per lane, use 20 µL of RNA dissolved in DEPC-treated double-distilled water [approx 30–40 µg for Arabidopsis and 50–80 µg for tobacco]).
3.3.3. Synthetic Small RNA Markers For size markers of known sequence to run on the small RNA gel, sense and antisense short RNAs of the desired size (e.g., 17, 21, and 24 bases) can be synthesized from the appropriate DNA oligonucleotides using T7 RNA polymerase directed in vitro transcription (17). 3.3.3.1. ANNEALING
OF
OLIGONUCLEOTIDES
Run a separate reaction for each length and polarity. 1. Obtain lyophilized DNA oligonucleotides from standard custom synthesis and dissolve to a final concentration of 1 nmol/µL in DEPC-treated double-distilled water.
06_Matzke.qxd
4/16/05
12:05 PM
Page 76
76
Mette et al.
2. Add 1 nmol (1 µL of stock) of each, the T7 promoter oligonucleotide and the oligonucleotide for the short RNA to be synthesized (see Note 10), to 50 µL of 10 mM Tris-HCl, 1 mM Na2EDTA, pH 8.0, in a 1.5-mL Eppendorf tube. 3. Place sample in 95°C heating block for 2 min. 4. Switch off heating block and allow samples to cool down slowly to room temperature overnight.
3.3.3.2. IN VITRO TRANSCRIPTION
OF
SMALL RNAS (100 µL REACTION)
Run a separate reaction for each length and polarity. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
12. 13. 14. 15. 16.
17. 18.
54 µL of DEPC-treated double-distilled water. 10 µL of 10X in vitro transcription buffer (supplied with T7 RNA polymerase). 5 µL of 0.2 M DTT. 20 µL of DNA oligonucleotide templates. 4 µL of 25 mM NTP mix (made from NTP set, 100 mM solutions). 2.5 µL of RNasin (40 U/µL). 5 µL of T7 RNA polymerase (20 U/µL). Incubate at 37°C for 2 h. Add 1 µL of Dnase I (10 U/µL), RNase-free. Incubate for 15 min at 37°C. Extract with Tris-buffer-saturated phenol–chloroform (add 150 µL of Tris-buffersaturated phenol–chloroform, vortex for 30 s, centrifuge for 5 min in an Eppendorf centrifuge at room temperature to separate the phases, and transfer the upper aqueous phase to a sterile 1.5-µL Eppendorf tube). Extract with chloroform (add 150 µL of chloroform, treat as in step 11, and transfer the upper aqueous phase to a sterile 1.5-mL Eppendorf tube). Add 12 µL of 3 M NaOAc, pH 5.0, and 300 µL of ethanol, mix well, and incubate for 2 h at −20°C. Centrifuge for 15 min at 4°C, 13,000 rpm (Sigma 1-15K centrifuge). Vacuum-dry the pellet for 10 min; dissolve in 50 µL of DEPC-treated doubledistilled water. Quantify each short RNA separately with Pharmacia GeneQuant UV spectrophotometer (see Subheading 3.3.2.); dilute to obtain separate “sense” and “antisense” stock solutions containing 1 pmol/µL each of the 17, 21, and 24 nucleotide short RNAs in DEPC-treated double distilled water (see Note 11). Store at −80°C until use. Add 20 µL of 17 + 21 + 24 sense or antisense stock solution (sense or antisense according to the polarity of probe to be used) to 80 µL of 96% deionized formamide, 20 mM EDTA, 1 mg/mL bromophenol blue and load on gel (see Fig. 4).
3.3.4. PAGE of Small RNAs Small RNA preparations are separated on a 15% polyacrylamide gel containing 7 M urea (useful range about 10–100 nucleotides) using essentially the same gel system as described for dsRNA (see Subheading 3.2.4.). Small
06_Matzke.qxd
4/16/05
12:05 PM
Page 77
dsRNA in RNA-Mediated Gene Silencing
77
Fig. 4. Detection of small RNAs. On the stained gel (right), several bands are visible in sample lanes containing preparations from plant sources. They presumably represent 4S tRNA (approx 80 nucleotides) and 5S rRNA (approx 120 nucleotides). These RNA species can serve as loading controls. After electroblotting and hybridization to detect NOSpro short RNAs (left) (see Subheading 3.3.), the stained bands show background hybridization but also visible are the NOSpro short RNAs (21, 22, and 24 nucleotides) in the three sample lanes. The control lane contains a mixture of 17-, 21-, and 24-nt NOSpro RNAs synthesized in vitro (see Note 11). Only the two larger sizes are visible on this exposure.
RNA size standards of the sequence of interest are synthesized in vitro (see Subheading 3.3.3.). Electrophoresis on 15% polyacrylamide–7 M urea gel (0.225X TBE): 1. Size: 18 cm × 13 cm × 1.5 mm, comb for 12 wells, about 10-mm well width; glass plates cleaned with dishwashing detergent and 70% ethanol. 2. Place the following in a 250-mL Erlenmeyer flask: 28.8 g of urea (final concentration, 7 M), 13.5 mL double-distilled water, 22.5 mL of 40% acrylamide : bisacrylamide 37.5 : 1 (final, 15%), and 1.35 mL of 10X TBE (final, 0.225X). 3. Heat (64°C incubator) until the urea is completely dissolved (swirl flask to mix contents). 4. Filter through Miracloth into a 100-mL Erlenmeyer flask and let stand at room temperature for 30–45 min to cool. 5. Combine 62.5 µL of 40% ammonium peroxodisulfate and 40 µL of TEMED. Mix well, pour gel and allow to polymerize overnight. Cover with Saran Wrap to avoid dessication. 6. Set up in gel box with 0.225X TBE running buffer.
06_Matzke.qxd
4/16/05
12:05 PM
Page 78
78
Mette et al.
7. Dissolve 50–100 µg RNA in 20 µL of 0.2% SDS, add 80 µL of gel loading buffer, denature 5 min at 95°C in heating block, and place on ice for 5 min. 8. Load samples to gel wells (see Note 2). 9. For electrophoresis, set limits to 800 V, 25 mA, 10 W and run until bromophenol blue reaches the lower edge of the gel (75 min, bromophenol blue has about same mobility as RNA of 10 nucleotides). 10. Stain the gel for 10 min in 0.5X TBE containing 1 µg/mL ethidium bromide. It is also required to equilibrate the gel to 0.5X TBE for electroblotting. 11. Wash 20 min in 0.5X TBE. At this point, an optional photo can be taken under UV transillumination (see Fig. 4, right). 12. Transfer RNA to hybridization membrane (see Subheading 3.2.5.).
3.3.5. Hybridization with Fragmented
32P-Labeled
RNA Probes
For the detection of small RNAs, fragmented 32P-labeled in vitro transcripts are used. Depending on which polarity of short RNA is to be detected on the blot, either a sense or antisense probe is made. Some purposes might require two blots probed with either a sense or antisense probe, respectively. Details of probe synthesis and hybridization conditions are given in Subheading 3.3.5.1. and Subheading 3.3.5.2., respectively. 3.3.5.1. FRAGMENTED RNA PROBE SYNTHESIS 1. For each 15-cm X 20-cm membrane, one 20-µL reaction is performed, containing 1 µL of a 1 µg/µL linearized template DNA for in vitro transcription (see Note 12), 2 µL of 10X in vitro transcription buffer (supplied with RNA polymerase), 1.5 µL of ATP, CTP, GTP mix, 6.7 mM for each nucleotide (made from NTP set, 100 mM solutions), 1 µL of 0.2 M DTT, 12.5 µL (125 µCi) of [α-32P]UTP, 1 µL of RNasin 40 U/µL and, 1 µL of RNA polymerase 20 U/µL (T7, T3, SP6 as appropriate). 2. Incubate for 2 h at 37°C. 3. Add 1 µL of DNase I, RNase-free 10 U/µL and incubate 15 min at 37°C. 4. Add 300 µL of Na2CO3/NaHCO3 120 mM/80 mM and incubate at 60°C for 2.5–3 h (time depends on probe length; for formula, see Note 13). 5. Add 20 µL of 3 M NaOAc, pH 5.0. 6. Add probe to hybridization buffer without denaturation.
3.3.5.2. HYBRIDIZATION REACTION (SMALL RNAS) 1. Prewet the membrane in double-distilled water, transfer into a hybridization bag, and prehybridize in 40 mL of hybridization solution at 42°C for 4–5 h. 2. Replace hybridization solution, add probe without denaturation (see Note 6), and hybridize at 42°C overnight. 3. Wash two times for 30 min with 2X SSC and 0.2% SDS at room temperature. 4. Expose to X-ray film overnight. 5. After the first overnight exposure, incubate the membrane for 1 h at 37°C in 200 mL of RNAseA buffer to reduce unspecific hybridization signals.
06_Matzke.qxd
4/16/05
12:05 PM
Page 79
dsRNA in RNA-Mediated Gene Silencing
79
6. Briefly (2 min) rinse the membrane in 200 mL of 50 mM sodium phosphate buffer, pH 7.2. 7. Expose to X-ray film (see Fig. 4).
4. Notes 1. Some pilot experiments using synthetic dsRNA as well as the corresponding sense and antisense single-stranded RNA controls should be performed for each individual dsRNA to determine the optimal RNase One concentration and/or in order to avoid underdigestion or overdigestion and loss of signal strength after hybridization. Figure 3 shows two experiments: one with incomplete digestion, in which bands are still visible on the stained gel (bottom, left), and one with complete (but not excessive) digestion, in which the stained gel appears empty (bottom, right). Both resulted in successful detection of the expected 255-bp dsRNA (sample lanes and positive control lane), but the “complete digestion” blot is much cleaner (top, right), lacking the additional larger bands seen on the “incomplete digestion” blot (top, left). In the experiment shown here to detect nopaline synthase promoter (NOSpro) dsRNA, the sense and antisense transcripts used to make the synthetic dsRNA were not perfectly matching but had some unique sequences at the 5′ ends that are derived from the multiple cloning site of the pGEM or pBC vectors during in vitro transcription. For typical control lanes, 1-pg or 0.3-pg synthetic annealed sense and antisense transcripts were digested with RNase One in a background of 50 or 100 µg of tRNA. This simulates the situation when detecting a small amount of natural dsNOSpro RNA derived from the silencer locus in the background of 50 or 100 µg of total RNA extracted from plants. In a suboptimal digestion reaction (Fig. 3; top, left), undigested sense and antisense transcripts somewhat “larger” than the one for the dsRNA are still visible on the blot (three bands total; 1 pg dsRNA and 0.3 pg dsRNA); only with optimal digestion (Fig. 3; top, right), a single band representing the perfectly double-stranded part annealed sense and antisense transcript remained (0.3 pg dsRNA and 1 pg dsRNA). This could serve as a size marker and quantitative measure for NOSpro dsRNA in various plant RNA preparations (Fig. 3; right, sample lanes 1–5). 2. Before loading gel, rinse slots using a buffer-filled syringe. To avoid band “smiling effects”, load empty lanes adjacent to actual RNA lanes with an equivalent amount of gel loading buffer (96% deionized formamide, 20 mM EDTA, 1 mg/mL bromophenol blue). 3. The easiest way to attract the gel to the hybridization membrane is to let the gel float in 0.5X TBE and to bring the membrane under the gel. The membrane plus attached gel is then carefully lifted from the buffer tray and placed on the three presoaked sheets of Whatman 3 MM paper. On top of the gel, three additional presoaked pieces of Whatman 3MM paper are placed. A glass pipet is rolled carefully over the stack in order to remove trapped air bubbles that could interfere with RNA transfer. 4. An appropriate template is a plasmid fragment excised and extracted from an agarose gel (using QIAquick Gel Extraction kit [Qiagen, 28706] according to the
06_Matzke.qxd
80
5.
6.
7. 8.
9. 10.
4/16/05
12:05 PM
Page 80
Mette et al. manufacturer’s instructions) and then dissolved in double-distilled water to a concentration of 25 ng/mL. To make the 40 mL hybridization solution, place 2.8 g SDS in an autoclaved 100-mL capped Erlenmeyer flask containing a magnetic stir bar, add 6 mL doubledistilled water, and stir on a magnetic stirrer at room temperature until the SDS is dissolved. Then add, in the following order, 20 mL deionized formamide, 10 mL of 0.5 M sodium phosphate buffer, pH 7.2, and 2 mL of 5 M NaCl. Continue stirring for approx 5 min; then prewarm the hybridization solution by placing the flask in a 42°C incubator before adding it to the prewetted filter in the hybridization bag. Make sure to remove all larger air bubbles from the hybridization bag by gently moving and pressing the bag to the open side before sealing. This can also be done by rolling a glass pipet over the filled hybridization bag to push air bubbles out at an open corner of the bag. Insoluble material can remain after this step, but usually the small RNAs are completely dissolved. This additional extraction step has been found useful for Arabidopsis small RNA preparations to remove poorly soluble material. Omitting this step can lead to band distortions during polyacrylamide gel electrophoresis. Centrifuge briefly to sediment insoluble material before quantifying RNA. For the synthesis of T7-generated short RNAs from the sequence of interest, an 18-mer oligonucleotide comprising the T7 promoter (T7pro, below) is annealed to the 3′ part of a 34- to 41-mer oligonucleotide (depending on desired final size of short RNA) with the complementary sequence of the T7 promoter downstream of the target sequence (reading the sequence 5′ to 3′). This forms a double-stranded DNA region comprising the T7 promoter sequence that is recognized by T7 RNA polymerase. In vitro transcription is initiated with the last G of the T7pro 18mer as the first nucleotide of the transcript. Transcription proceeds along the single stranded unique part of the 34- to 41-mer oligonucleotide (making an RNA complementary to the single-stranded DNA) until the end is reached and the T7 RNA polymerase “runs off” its template (17). As examples, we list here the sense (S) and antisense (AS) oligonucleotides used for the nopaline synthase promoter (Np) short RNA size markers (17, 21, and 24 bases). These contain a sequence from the Np (18) (not underlined) and the complementary T7pro 18mer at the 3′ ends (underlined). The Np sequences in the oligonucleotides shown here are one nucleotide shorter than the resulting small RNA since the first G of the T7 transcript is complementary to the adjacent base (not included in the oligonucleotide) in the Np sequence. This provides a short RNA of the desired length with full homology to the target Np. In addition to choosing a region where there is a C adjacent to the last nucleotide, a second rule of thumb when selecting sequences for oligonucleotides is to have an intermediate GC content (40–60%) for efficient hybridization with the probe. Note that the 17-base RNA marker does not produce strong signals under the hybridization conditions used (see Fig. 4), probably indicating that a sequence of this length is at the lower limit of hybrid stability.
06_Matzke.qxd
4/16/05
12:05 PM
Page 81
dsRNA in RNA-Mediated Gene Silencing
81
T7pro: 5′ TAA TAC GAC TCA CTA TAG 3′ NpS17+T7: 5′ CAA TAA TGG TTT CTG ACT ATA GTG AGT CGT ATT A 3′ NpS21+T7: 5′ CGC GCA ATA ATG GTT TCT GAC TAT AGT GAG TCG TAT TA 3′ NpS24+T7: 5′ GAA CGC GCA ATA ATG GTT TCT GAC TAT AGT GAG TCG TAT TA 3′ NpAS17+T7: 5′ TCA GAA ACC ATT ATT GCT ATA GTG AGT CGT ATT A 3′ NpAS21+T7: 5′ TAC GTC AGA AAC CAT TAT TGC TAT AGT GAG TCG TAT TA 3′ NpAS24+T7: 5′ ACA TAC GTC AGA AAC CAT TAT TGC TAT AGT GAG TCG TAT TA 3′ 11. Calculate: approx 300 g/mol per nucleotide: “17,” 5100 g/mol; “21,” 6300 g/mol; “24,” 7200 g/mol. Therefore, 1 pmol: “17,” 5.1 ng; “21,” 6.3 ng; “24,” 7.2 ng. Dilute 10 ng/µL ≅ 1 pmol/µL. Load on gel 20 µL (≅ 20 pmol) plus 80 µL 96% formamide, 20 mM EDTA, 1 mg/mL bromophenol blue. 12. An appropriate template is cloned in pGEM or other appropriate vector providing promoter sequences for in vitro transcription. The vector is cut with an appropriate restriction enzyme such that either a sense or antisense transcript will be made. 13. The incubation time can be calculated according to the formula t = (Li–Lf)/ (k × Li × Lf), where t is time (in min), Li is the initial length of probe (in kb), Lf is the final length of the probe (in kb), and k is a rate constant of 0.11/kb/min.
Acknowledgments The authors thank Dr. Andrew Hamilton for providing a protocol for isolating small RNAs. Work on RNA-mediated silencing in our lab is supported by grants from the Austrian Fonds zur Fîrderung der wissenschaftlichen Forschung (grant no. P15611-B07) and the European Union (contract no. HPRN-CT-2002-00257). References 1. Finnegan, E. J. and Matzke, M. (2003) The small RNA world. J. Cell Sci. 116, 4689–4693. 2. Volpe, T., Kidner, C., Hall, I., Teng, G., Grewal, S., and Martienssen, R. (2002) Regulation of heterochromatin silencing and histone H3 lysine-9 methylation by RNAi. Science 297, 1833–1837. 3. Hall, I., Shankaranarayana, G., Noma, K., Ayoub, A., Cohen, S., and Grewal, S. (2002) Establishment and maintenance of a heterochromatic domain. Science 297, 2232–2237. 4. Zilberman, D., Cao, X., and Jacobsen, S. (2003) ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 299, 716–719. 5. Pal-Bhadra, M., Leibovitch, B., Gandhi, S., et al. (2004) Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 303, 669–672.
06_Matzke.qxd
82
4/16/05
12:05 PM
Page 82
Mette et al.
6. Wassenegger, M. (2000) RNA-directed DNA methylation. Plant Mol. Biol. 43, 203–220. 7. Aufsatz, W., Mette, M. F., van der Winden, J., Matzke, A., and Matzke, M. (2002) RNA-directed DNA methylation in Arabidopsis. Proc. Natl. Acad. Sci. USA 99, 16,499–16,506. 8. Mette, M. F., Aufsatz, W., van der Winden, J., Matzke, M., and Matzke, A. (2000) Transcriptional silencing and promoter methylation triggered by dsRNAs. EMBO J. 19, 5194–5201. 9. Aufsatz, W., Mette, M. F., van der Winden, J., Matzke, M., and Matzke, A. (2002) HDA6, a putative histone deacetylase needed to enhance CG methylation induced by dsRNAs. EMBO J. 21, 6832–6841. 10. Jones, L., Ratcliff, F., and Baulcombe, D. (2001) RNA-directed transcriptional silencing in plants can be inherited independently of the RNA trigger and requires Met1 for maintenance. Curr. Biol. 11, 747–757. 11. Sijen, T., Vijn, A., Rebocho, A., et al. (2001) Transcriptional and posttranscriptional gene silencing are mechanistically related. Curr. Biol. 11, 436–440. 12. Melquist, S. and Bender, J. (2003) Transcription from an upstream promoter controls methylation signaling from an inverted repeat of endogenous genes in Arabidopsis. Genes Dev. 17, 2036–2047. 13. Kanno, T., Mette, M. F., Kreil, D.P., Aufsatz, W., Matzke, M., and Matzke, A. J. M. (2004) Involvement of putative SNF2 chromatin remodeling protein DRD1 in RNA-directed DNA methylation. Curr. Biol. 14, 801–805. 14. Papp, I., Mette, M. F., Aufsatz, W., et al. (2003) Evidence for nuclear processing of plant microRNA and short interfering RNA precursors. Plant Physiol. 132, 1382–1390. 15. Billy, E., Brondani, V., Zhang, H., Muller, U., and Filipowicz, W. (2001) Specific interference with gene expression induced by long, dsRNAs in mouse embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 98, 14,428–14,433. 16. Hamilton, A. and Baulcombe, D. (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286, 950–952. 17. Donzé, O. and Picard, D. (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e46. 18. Depicker A., Stachel, S., Dhaese, P., Zambryski, P., and Goodman, H. (1982) Nopaline synthase: transcript mapping and DNA sequence. J. Mol. Appl. Genet. 1, 5561–5573.
07_Walchli.qxd
4/16/05
12:05 PM
Page 83
7 Strategies for the Design of Random siRNA Libraries and the Selection of anti-GFP siRNAs Mouldy Sioud and Sébastien Wälchli 1. Introduction Various methods have been devised to elucidate gene function in a highthroughput format. With the potential to silence any gene once the sequence is known, small, interfering RNAs (siRNAs) have been considered ideal for functional analysis and gene target validation (1–3). Furthermore, the technology has unprecedented target flexibility. By performing RNAi on a large scale using siRNA libraries, this reverse-genetic method can essentially be used as a forward-genetic screening tool. In this respect, genomewide siRNA screens in Caenorhabditis elegans using libraries of in vitro-transcribed long doublestranded RNAs (dsRNAs) have been useful in gene discovery and functional annotation in various processes, including embryonic development (4,5). To increase the speed of RNA interference (RNAi) screening in mammalian cells, several groups have designed methods for the high-throughput development of hairpin-producing plasmid libraries (6–8). These libraries were either constructed from double-stranded cDNAs, which were cleaved into multiple DNA fragments and then cloned into appropriate vectors (6,7) or by the creation of a large collection of retroviral vectors encoding a large number of distinct hairpin siRNAs (8). Among the application of siRNA libraries would be the search for new target genes critical for various cellular processes such a metastasis and drug resistance. Moreover, the same approach can be used for the selection of effective siRNAs for therapeutic applications. As with any genetic approach, however, the power of each RNAi screen will depend on the nature of the libraries and the appropriate choice of the functional readout. In view of the high efficacy of siRNA in vitro and in vivo, we From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
83
07_Walchli.qxd
4/16/05
12:05 PM
Page 84
84
Sioud and Wälchli
have reasoned that siRNA random libraries may also be useful for functional gene discovery. Previously, random ribozymes and antisense libraries have been used to identify novel functional genes (9,10). In this chapter, we outline two strategies for the construction of random siRNA libraries and their potential applications. 2. Materials 2.1. Buffer Solution 1. 10X TBE buffer: 890 mM Tris-borate, pH 8.3, 20 mM EDTA. 2. 10X deoxynucleotides stock mixture: 5 mM each dNTP. 3. 10X polymerase chain reaction (PCR) buffer: 500 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1.5 mM MgCl2. 4. 10X restriction enzyme buffers (supplied by the manufacturers).
2.2. Enzymes and Reagents 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.
T4 DNA ligase (1 U/µL). DNA polymerase. Tap DNA polymerase. dNTPs (10 mM each). Lipofectamin, USA 2000 (Invitrogene). Plasmid miniprep kit (Qiagen). Plasmid maxiprep kit. Luria–Bertani (LB)/ampicillin plates. Fetal calf serum (FCS). Growth medium (appropriate for cell type). Chloroform/isoamyl alcohol (24 : 1, v/v). 10% sodium dodecyl sulphate (SDS). 30% acrylamide/0.8% N,N′ methylene bis-acrylamide. Phenol.
2.3. Vectors 1. 2. 3. 4.
pcDNA3 (Invitrogen). pEGFP-N3 (Invitrogen). GeneBusterTM vector (Genordia, Sweden). pcMV-DsRed (Invitrogen).
2.4. Oligonucleatides 1. DNA oligonucleotides (Invitrogen). 2. T7 and T3 DNA primers carrying appropriate restriction sites.
2.5. Cells 1. HEK 293 cells. 2. Escherichia coli competent cells, DH5α (Invitrogen), LB medium.
07_Walchli.qxd
4/16/05
12:05 PM
Page 85
Design of Random siRNA Libraries
85
Fig. 1. Schematic diagram for the construction of the dual random siRNA library.
3. Methods 3.1. Construction of a Dual Random siRNA Library 1. The procedure of constructing the dual siRNA library is summarized in Fig. 1. The strategy employs a self-priming oligonucleotide that contains two recognition sequences GGTCTC for BsaI restriction enzyme. Also, it contains internal 18 degenerated bases, denoted as N, which represents A, T, C, or G. The designed oligonucleotide is self-annealing and priming (5′GAATATGGTCTCGAAAA(N)18CTTTAGAGACCATATGCCAAAAGGCATATGGTCTC 3′). In addition, we have used a non-self-priming oligonucleotide and a reverse primer (see Note 1).
07_Walchli.qxd
86
4/16/05
12:05 PM
Page 86
Sioud and Wälchli
2. The designed oligonucleotides are converted into dsDNA by T4 DNA polymerase and in the presence of 0.5 mM of each dNTP, and then the resulting dsDNA is digested, with BsaI leaving the random siRNA sequences flanked by four nucleotides AAAA/GAAA 5′ overhangs (see Fig.1). 3. The cleaved DNA is purified by 15% agarose gels and then ligated into GeneBuster vector™ (Genordia) that contains four TTTT/CTTT 3′overhangs as recommended by the manufacturer’s instructions. The principle of the vector is identical to that published by Zheng et al. (11). 4. Once the ligation reaction is completed, electroporate the mixture into E. coli DH5α, add 1 mL SOC medium, and incubate for 1 h at 37°C with agitation. 5. Plate 200 µL of cells on prewarmed LB agar plates containing 50 µg/mL ampicillin. 6. Incubate plates overnight at 37°C. 7. Collect cells from the LB agar plates by scraping and purify plasmids using Qiagen maxiprep kits, which provide high-quality plasmid DNA for transfection of eukaryotic cells. This plasmid preparation constitutes the random siRNA pool that should be stored at –20°C until use.
3.2. Subcloning of the siRNA Library into the pcDNA3 Vector Although the constructed library can be used for functional analysis in eukaryotic cells, it is preferable to subclone it into a eukaryotic expression vector. Several choices of expression vectors are available. We chose the pcDNA3 vector (Invitrogen). 1. To generate the siRNA cassettes, set up the following 100 µL PCR reaction: 81 µL water, 10 µL 10X Buffer, 2 µL dNTPs (5 mM each), 2 µl BglII-T7 primer (20 µM), 2 µL NotI-T3 primer (20 µM), 2 µL pooled plasmids (0.2 µg). 2. Add 2 U of Tap polymerase and carry out the PCR reaction using the following parameters: 1 min at 94°C, followed by 20 cycles consisting of 30 s at 52°C and 30 s at 72°C. A final elongation step at 72°C for 5 min is carried out, and the reaction mixture is cooled to 4°C. Perform three PCR reactions. 3. Check 5 µL of the PCR reaction on 1.2% agarose gel for the presence of the expected PCR product. The siRNA cassette should be around 600 bp in length. 4. Extract the reaction mixture with phenol, followed by extraction with chloroform/isoamyl alcohol (24 : 1), and collect the DNA by ethanol precipitation and centrifugation. 5. Digest about 4 µg of the amplified DNA with the two restriction enzymes whose recognition sequences were engineered into the T7 and T3 primers (e.g., BglII and NotI) and then purify the cleaved DNA by a 1.2% agarose gel. 6. Subsequent to purification, ligate the DNA into, for example, BglII and NotIcleaved pcDNA3 vector. 7. Electroporate the ligation mixture into E. coli DH5α and plate out cells on LB agar plates containing 50 µg/mL ampicillin. 8. Collect bacteria and prepare plasmids using Qiagen maxiprep kits. DNA plasmid at this stage is pure enough for transfecting eukaryotic cells (see Note 2).
07_Walchli.qxd
4/16/05
12:05 PM
Page 87
Design of Random siRNA Libraries
87
3.3. Selection of Anti-GFP siRNAs from Random siRNA Libraries The embryonic kidney HEK 293 T cells are maintained in RPMI 1640, supplemented with 10% FCS and antibiotics. 1. On the day before transfection, cells are trypsinized and 106 cells are plated in tissue culture dishes in 5 mL complete medium (RPMI supplemented with 10% FCS). 2. To select siRNAs against green fluorescent protein (GFP), cells are transfected with the siRNA library (10 µg) and pEGFP-N3 plasmid encoding GFP protein (1 µg). To visualize the transfected cell population by flow cytometry, the pcMV-DsRed (0.2 µg), encoding the Discosoma sp. red fluorescent protein, is included as a selection marker for transfection. 3. After 24 h transfection time, negative cells that express the red fluorescence but not the GFP are sorted by flow cytometry. This step is expected to enrich for truly transfected cells that have received GFP and active siRNA sequences. For an illustration, see Fig. 2. 4. Plasmid-expressing siRNAs are rescued from the sorted cells (GFP negative, DsRed positive) by alkaline lysis/SDS method, precipitated with ethanol, and then transformed into E. coli DHα5. 5. The following day, plasmids are prepared using Qiagen maxiprep kits and the selection step was repeated by transfecting HEK 293 T-cells as described above. 6. After the desired rounds of selection, single colonies appearing on LB ampicilin plates are picked up; plasmid prepared using Qiagen miniprep and siRNA sequences are determined.
3.4. Data Analysis In order to detect changes in the desired phenotype, several rounds of selection may be needed. To enrich for anti-GFP siRNAs and/or miRNAs (see Note 3), the selection protocol was repeated five times. After the last round of selection, the percentage of GFP negative cells and DsRed positive cells increased significantly. Indeed, flow cytometry analysis shows that GFP was more attenuated in cells transfected with the selected libraries (Fig. 2D, gate P2) than in cells transformed with the parental library (Fig. 2B, gate P2), indicating that our selection protocol does enrich for anti-GFP siRNAs (12). The present approach, which requires no prior sequence information, should provide an additional tool for functional gene analysis and the selection of effective siRNAs or miRNAs (see Note 4). An additional strategy for the expression of hairpin type siRNA library is outlined in Fig. 3. 1. In the first step, the self-priming oligonucleotide is extended with DNA polymerase to generate dsDNA. 2. After primer extention, purify the dsDNA with 15% polyacrylamide gel. 3. Dissolve the sample in PCR reaction mixture, add the reverse primer, and incubate the sample at 94°C for 5 min.
07_Walchli.qxd
88
4/16/05
12:05 PM
Page 88
Sioud and Wälchli
Fig. 2. Enrichment of anti-GFP siRNAs as detected by flow cytometry. To evaluate the effectiveness of the designed library, the green fluorescent protein is used as a working model. In this experimental protocol, HEK 293 T-cells are transfected with the random dual siRNA library in combination with pEGFP-N3 plasmid encoding GFP and pcMV- DsRed encoding the red protein. Cells were harvested 16 h after transfection and analyzed by flow cytometry. Cells that are identified as negative for GFP and positive for Ds-Red are sorted and plasmids rescued. Data are from the first round of selection (A,B) and the fourth round of selection (C,D). Fig. 3. (opposite page) Strategy for the design of hairpin-type random siRNA libraries. The expression of the siRNAs from the U6 promoter would generate siRNAs with extra sequences that correspond to the linker used used for priming. Experimental data indicate that this extra sequence has no effects on siRNA activity. On the contrary, it enhanced the activity of siRNAs (see Note 5).
07_Walchli.qxd
4/16/05
12:05 PM
Page 89
89
07_Walchli.qxd
4/16/05
90
12:05 PM
Page 90
Sioud and Wälchli
4. Place the sample at 4°C, add 2 U Tap polymerase, and then incubate the sample at 72°C for 10 min. The key here is that complementary sense and and antisense DNA sequences can be generated by this strategy. Digest the filled DNA with the appropriate restriction enzymes and then ligate into the appropriate expression vector.
4. Notes 1. For some unknown reasons, self-priming oligonucleotides are not efficiently cleaved by BsaI restriction enzyme. Therefore, we have also used a non-self-priming oligonucleotide and a reverse primer (5′ GAATAAGGTCTCGAAAG(N)18TTTAGAGACCATATGCC 3′; 5′ GGCATATGGTCTCTAAAA 3′). After annealing and primer extention, dsDNA is processed as in Subheading 3. 2. A quick evaluation of whether the pool of random siRNAs possesses silencing activity should be made by transfecting cells expressing a reporter gene such as GFP. Silencing activity is indicated by the knockdown of the reporter gene. However, the silencing effect will vary according to the frequency of each siRNA within the library. 3. By using random sequences, it might be possible to select siRNAs that function as microRNAs; that is, only the translation is arrested. Indeed, some of the selected anti-GFP molecules are partially homologous to GFP mRNA. However, an siRNA targeting the following site was selected (5′ GGCACAAGCUGGAGUACAA 3′). 4. Another application of the random siRNA libraries would be the selection of effective siRNA or microRNA against known target genes. Indeed, by fusing any target gene with a reporter gene such as GFP, siRNA targeting the fusion mRNA can be easily quantitated. After selection, sequence analysis of individual clones will indicate which part of the fusion transcript is targeted. 5. As illustrated in Fig. 3, the self-priming oligonuleotide with random sequences contains a self-priming linker, which will be part of the expressed siRNA sequences. To test whether the addition of such extra sequence would affect siRNA activity in human cells, a siRNA targeting the GFP with an additional sequence (5′-GCAAGCUGACCCUGAAGUUCUCCCGGG-3′) was expressed in HEK-293 cells under the U6 promoter. The expressed siRNA inhibited GFP expression. The inhibition was even more pronounced than the parental siRNA (5′-GCAAGCUGACCCUGAAGUUC-3′). Thus, the addition of extra sequences does not affect siRNA activity and therefore the construction of siRNA libraries with self-priming is feasible.
Acknowledgments This work was supported by the Norwegian Cancer Society. We thank Dr. Anne Dybwad for critical reading of the manuscript. References 1. Elbashir, S. M., Harborth, M. J., Ledecknel, W., Yalcin, A., Weber, K, and Tuchl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.
07_Walchli.qxd
4/16/05
12:05 PM
Page 91
Design of Random siRNA Libraries
91
2. Hannon, G. J. (2002) RNA interference. Nature 418, 244–251. 3. Sioud, M. (2004) Therapeutic siRNAs. Trends Pharmacol. Sci. 25, 22–28. 4. Kamath, R. S., Fraser, A. G., Dong, Y., et al. (2003) Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421, 231–237. 5. Kamath, R. S. and Ahringer, J. (2003) Genome-wide RNAi screening in Caenorhabditis elegans. Methods 30, 313–321. 6. T. S., Myers, J. W., and Blau, H. M. (2004) Restriction enzyme-generated siRNA (REGS) vectors and libraries. Nat. Genet. 36, 183–189. 7. Luo, B., Heard, A. D., and Lodish, H. F. (2004) Small interfering RNA production by enzymatic engineering of DNA (SPEED). Proc. Natl. Acad. Sci. USA 101, 5313–5314. 8. Berns, K., Hijmans, E. M., Mullenders, J., et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431–437. 9. De Backer, M. D., Nelissen, B., Logghe, M., et al. (2001) An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat. Biotechnol. 19, 235–241. 10. Kawasaki, H., Onuki, R., Suyama, E., and Taira, K. (2002) Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat. Biotechnol. 20, 376–380. 11. Zheng, L., Batalov, S., Zhou, D., Orth, A., Ding, S., and Schultz, P. G. (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA 101, 135–140. 12. Sioud, M. (2004) Therapeutic potential of small interfering RNAs. Drugs of the Future, 29, 741–750.
07_Walchli.qxd
4/16/05
12:05 PM
Page 92
08_Myers.qxd
4/16/05
12:58 PM
Page 93
8 Silencing Gene Expression with Dicer-Generated siRNA Pools Jason W. Myers and James E. Ferrell, Jr. 1. Introduction With the explosion of genomic information, there is an increasing need to analyze gene function in a high-throughput fashion. This makes reverse genetic approaches extremely attractive; however, in most mammalian and vertebrate systems it has been difficult and time-consuming to develop a cellular model deficient in one or more proteins. The discovery of RNA interference (RNAi) has made loss-of-function studies relatively quick and easy and amenable to high-throughput formats (1–3). Double-stranded RNAs (dsRNAs) 21 nucleotides in length, known as small interfering RNAs (siRNAs), are introduced into the cytosol, where they are unwound (4), allowing the antisense strand to interact in a sequence-specific manner with the complementary mRNA (5). Binding of the antisense strand to the target mRNA triggers cleavage of the mRNA (6). siRNA-mediated gene silencing is very specific, most likely because of the high specificity of nucleotide base-pairing. The design of effective siRNAs has been a major obstacle in siRNA-mediated gene silencing, as there is great variability among siRNAs in terms of their effectiveness. We reasoned that the tedious process of siRNA design could be eliminated if a simple method to prepare a large number of distinct siRNAs could be developed. We then realized that nature had already designed a method and it simply had to be recapitulated. Dicer, an RNase III family enzyme, cleaves dsRNA into a pool of siRNAs suitable for gene silencing. Therefore, we (7) and others (8–10) have produced a recombinant version of Dicer (r-Dicer) and used it to digest in vitro–transcribed dsRNAs into a complex pool of siRNAs (d-siRNAs) (7). Nearly every pool of d-siRNAs is capable of eliciting From: Methods in Molecular Biology, vol. 309: RNA Silencing: Methods and Protocols Edited by: G. G. Carmichael © Humana Press Inc., Totowa, NJ
93
08_Myers.qxd
94
4/16/05
12:58 PM
Page 94
Myers and Ferrell
specific gene silencing (11). This approach, in vitro dicing, eliminates the need to identify an individual effective siRNA and has proven to be very useful for transiently silencing many endogenous genes in several types of cultured cell (7,11–13). Unlike Caenorhabditis elegans, Drosophilia melanogaster, or other invertebrates, RNAi-mediated gene silencing in mammalian cells must be accomplished with an siRNA because dsRNAs greater than 30 basepairs are cytotoxic (14–18). There are many types of siRNA to choose from: chemically synthesized siRNAs (5), in vitro–transcribed siRNAs (19), short-hairpin RNAs (shRNAs) (20–23), or siRNAs (24,25) that are encoded from DNA in vivo. The shRNAs are equivalent to siRNAs once the loop is removed by the cellular Dicer. All of these siRNAs are, in general, used as a single siRNA targeting a single gene, but in some cases, three to five different siRNAs, all targeting the same gene, are pooled to increase the odds of attaining efficient gene silencing. In vitro dicing pushes this pooling concept further; a diced pool of siRNAs typically contains hundreds of different oligonucleotides, all targeting the same gene (Gong et al., unpublished data). Each technique has advantages and disadvantages, but in vitro dicing is simple, cost-effective, and scalable to high-throughput formats, more so than many of the individual siRNA approaches even when considering that d-siRNAs are not capable of providing stable gene suppression. The major benefit of in vitro dicing is that it eliminates the need to design and test siRNAs for efficacy and potency. This both simplifies and decreases the cost of gene silencing experiments. Nearly every pool of d-siRNAs elicits specific gene silencing (11), whereas typically only one out of three individual siRNAs is a potent gene silencer (26,27). Thus, to silence one gene, at least three individual siRNAs must be designed and tested, thereby increasing the cost and amount of work. This is especially a problem if a large collection of genes or even a genome is to be silenced, because the number of assays will be three times greater if siRNAs are used instead of d-siRNAs. Several groups have designed a clever scheme to generate libraries of shRNA (28–30) or siRNA (31) expression vectors from a cDNA library. This process reduces the cost but does not eliminate the need to find potent gene silencers and, therefore, may be best suited to forward genetic screens. In vitro dicing is suitable for high-throughput reverse genetic screens for several reasons. Although siRNA selection criteria have been improved (4,26,27), the potency of individual siRNAs can vary over three orders of magnitude, 0.1 nM to 100 nM, making high-throughput silencing very complicated. If the concentration is too low, many individual siRNAs will not be effective, and if it is too high, silencing will be accompanied by off-target and nonspecific affects. For example, in many screens, siRNAs are being used at 100 nM (nmoles of
08_Myers.qxd
4/16/05
In Vitro Dicing
12:58 PM
Page 95
95
siRNA per liter of culture volume), a concentration that will likely provoke offtarget and nonspecific silencing, but if the concentration is lowered, many of the targets will not be silenced. The lack of a standard concentration for attaining specific and efficient gene silencing will result in many false-positive and falsenegative results. However, nearly every pool of d-siRNAs is effective and specific between 1 and 30 nM and the potency of different pools of d-siRNAs targeting different genes varies by only twofold to threefold. Thus, for screening applications, d-siRNAs can be used at a standard concentration, thereby improving the quality of the resulting data. The specificity of siRNA-mediated gene silencing has been scrutinized (32–34) and it has been argued that a pool of siRNAs, like d-siRNAs or siRNAs generated by bacterial RNase III digestion, will further increase the possibility of off-target gene silencing. However, the opposite may be argued as well. A complex mixture of siRNAs will certainly contain more off-target matches than a single siRNA would, particularly if the pool consists of short siRNAs (12–15 nucleotides) like those produced by RNase III digestion. However, the concentration of any individual siRNA in a complex d-siRNA pool is quite low—perhaps approx 1/300th of the total siRNA concentration (Gong et al., unpublished data)—and so, unless many different members of the pool share the same off-target effects, the effects should be insignificant. In support of this view, the gene silencing achieved in C. elegans by the complex pools of d-siRNAs produced from large dsRNAs in vivo has proven to be quite specific in worms; time and time again the RNAi-induced phenotype reiterates the null phenotype (35). Indeed, analysis of the silencing of closely related gene pairs indicates that d-siRNAs are likely to be highly specific. The hypothesis is that if the gene with the highest degree of nucleotide identity to the target is not silenced when the target is silenced, then it is unlikely that more distantly related genes would be silenced. For example, only the target gene is silenced when we analyze closely related gene pairs like cyclin B1 and cyclin B2, cyclin-dependent kinase 1 (Cdk1) and cyclin-dependent kinase 2 (Cdk2) (Myers et al., unpublished data), and cdc25C and cdc25A (7), suggesting that off-target gene silencing is not a likely consequence of d-siRNA-mediated gene suppression. It will be of interest to test the specificity of d-siRNAs globally through expression profiling using DNA microarrays. This chapter describes the materials and methods necessary to produce r-Dicer and d-siRNAs for gene silencing experiments in any given system capable of siRNA-mediated gene silencing. The basic approach is as follows. The r-Dicer is expressed in insect cells using a common insect cell expression system. After partial purification, the r-Dicer is used to cleave long dsRNAs into a complex pool of d-siRNAs. The long dsRNAs are in vitro transcribed from PCR (polymerase chain reaction) products. Finally, the d-siRNAs are purified away from
08_Myers.qxd
4/16/05
12:58 PM
96
Page 96
Myers and Ferrell
all reaction components and introduced into the cells or organisms via common delivery tactics. The power of this approach is that it is very efficient: it requires only moderate hands-on time, it takes only 5–7 d to produce d-siRNAs and assay for gene silencing, and the odds of attaining high levels of specific gene silencing are very good. Finally, in vitro dicing was developed for highthroughput loss-of-function screening. Thus, the methods to produce d-siRNAs and attain gene silencing in a 96-well format are also presented. 2. Materials 2.1. Bacmid Preparation 1. RNeasy® Kit, including Qiashredder™ (Qiagen, Valencia, CA; cat. nos. 74104 and 79654, respectively); β-mercaptoethanol not included. 2. TE, pH 8.0: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA (ethylenediamine tetraacetic acid), pH 8.0; made with RNase-free reagents. 3. Agarose (Invitrogen, Carlsbad, CA, cat. no. 11510-019) or equivalent. 4. 50X TAE: 2 M Tris-acetate, 0.1 M EDTA. 5. 10X TBE: 0.89 M Tris base, 0.89 M boric acid, 0.02 M EDTA. 6. Ethidium bromide (Invitrogen, cat. no. 15585-001) or equivalent. 7. 2X RNA loading buffer: 95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 18 mM EDTA, and 0.025% sodium dodecyl sulfate (SDS); made with RNase-free reagents and stored at – 20°C. 8. RNase-free H2O (Invitrogen, cat. no. 10977-015); or treat nanopure H2O with 0.1% DEPC (item 9) for 6 h to overnight in a fume hood with continuous mixing and then autoclave for 30 min to inactivate DEPC. Incomplete activation can inhibit enzymes used in subsequent manipulations. Store at room temperature. 9. DEPC (diethyl pyrocarbonate) (Sigma-Aldrich, St. Louis, MO; cat. no. D5758); very toxic and should be handled in a fume hood; moisture causes hydrolysis to ethanol and carbon dioxide, thus stock solution should be stored under airtight conditions (e.g., wrap lid in parafilm and place in a desiccator) and at 4°C. 10. Superscript™ RTIII First-Strand Synthesis System for RT-PCR (Invitrogen, cat. no. 18080-051); includes 5X reaction buffer, 0.1 M DTT (dithiothreitol), 10 mM dNTPs, 50 µM oligo(dT)20, RNaseOUT™ (40 units/µL), Superscript™ RTIII (200 units/µL), and RNase-free H2O and E. coli RNase H (2 units/µL); stored at –20°C. 11. Nuclease-free 0.2-mL thin-wall PCR tube (E and K Scientific, Campbell CA; cat. no. 690002) or equivalent. 12. Platinum® Pfx polymerase (Invitrogen, cat. no. 11708-013); 10X Pfx Amplification Buffer and 50 mM MgSO4 are included; stored at –20°C. 13. Oligonucleotide primers, 10-nmol scale, desalted (Invitrogen). 14. 10X DNA loading buffer: 50% glycerol, 100 mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol; stored at room temperature. 15. 1-kb DNA ladder (Invitrogen, cat. no. 15615-016) or equivalent diluted with 10X DNA loading buffer (item 14); stored at –20°C (long term) or 4°C for several months. 16. QIAquick® PCR Purification Kit (Qiagen, cat. no. 28104).
08_Myers.qxd
4/16/05
In Vitro Dicing
12:58 PM
Page 97
97
17. NotI, XhoI, and BamHI restriction enzymes (New England Biolabs, Beverly, MA; R0189S, R0146S, and R0136S, respectively); 10X reaction buffers and BSA (bovine serum albumin) are included; stored at –20°C. 18. Bac-to-Bac® HT Vector Kit (Invitrogen, cat. no. 10584-027); many components and various storage conditions. 19. Nuclease-free 1.5-mL microcentrifuge tubes (E and K Scientific, cat. no. 280150) or equivalent. 20. QIAquick® Gel Extraction Kit (Qiagen, cat. no. 28704). 21. High DNA Mass Ladder (Invitrogen, cat. no. 10496-013) or equivalent diluted with 10X DNA loading buffer (item 14); stored at –20°C (long term) or 4°C for several months. 22. T4 DNA ligase (New England Biolabs, cat. no. M0202S); 10X buffer is included; stored at –20°C. 23. LB (Luria–Bertani) ampicillin plates: 10 g bacto-tryptone, 5 g bacto-yeast extract, 10g NaCl, and 15 g bacto-agar per liter containing 100 µg/mL ampicillin (item 24) (36); stored at 4°C and protected from light. 24. Ampicillin; dissolved in H2O at 50 mg/mL (36); should be filter-sterilized (0.22 µm) and aliquoted into 500 µL; stored at –20°C. 25. One Shot® TOP10 Chemically Competent Cells (Invitrogen, cat. no. C4040-50); stored at –80°C. 26. SOC (Invitrogen, cat. no. 15544-034) or 20 g bacto-tryptone, 5 g bacto-yeast extract, 0.5 g NaCl per liter plus 20 mM glucose (36); stored at room temperature. 27. 3- or 5-mm Glass beads (Fisher, Suwanee, GA; cat. no. 11-312A or 11-312C, respectively). 28. LB medium: 10 g bacto-tryptone, 5 g bacto-yeast extract, and 10g NaCl per liter (36); stored at room temperature. 29. 14-mL Polypropylene culture tubes (Becton Dickinson, Franklin Lakes, NJ; cat. no. 352059; distributed by Fisher Scientific, cat. no. 431144). 30. QIAprep® Miniprep Kit (Qiagen, cat. no. 27106). 31. Max Efficiency® chemically competent DH10Bac™ cells (Invitrogen, cat. no. 10361-012); stored at –80°C. 32. LB plates for bacmid growth: 10 g bacto-tryptone, 5 g bacto-yeast extract, 10g NaCl and 15 g bacto-agar per liter (36) containing 50 µg/mL kanamycin (item 33), 10 µg/mL tetracycline (item 34), 7 µg/mL gentamycin (item 35), 100 µg/mL bluo-gal (item 36), and 40 µg/mL isopropylthio-β-galactoside (IPTG) (item 37); stored at 4°C and protected from light. 33. Kanamycin; dissolved in H2O at 10 mg/mL (36); should be filter-sterilized (0.22 µm) and aliquoted into 500 µL; stored at –20°C. 34. Tetracycline; dissolved in ethanol at 5 mg/mL (36); store at –20°C protected from light; must be used in medium without magnesium ions; LB is fine. 35. Gentamycin (Sigma-Aldrich, cat. no. G1272); provided at 10 mg/mL in H2O; stored at 4°C. 36. Bluo-gal; dissolved in DMSO (dimethyl sulfoxide) at 20 mg/mL; should be dissolved in and stored in a glass or polypropylene tube; stored at –20°C and protected from light.
08_Myers.qxd
4/16/05
12:58 PM
Page 98
98
Myers and Ferrell
37. IPTG; dissolved in H2O at 200 mg/mL; should be filter-sterilized (0.22 µm) and aliquoted into 1 mL; stored at –20°C. 38. Solution I: 15 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase A; filtersterilized and stored at 4°C. 39. RNase A 100 mg/mL (Qiagen, cat. no. 19101); stored at room temperature. 40. Solution II: 0.2 N NaOH, 1% SDS; filter-sterilized and stored at room temperature. 41. 3 M Potassium acetate, pH 5.5; autoclaved and stored at 4°C. 42. Nuclease-free 2.0-mL microcentrifuge tube (E and K Scientific, cat. no. 280200) or equivalent. 43. Isopropanol. 44. 70% Ethanol; dilute 100% ethanol with H2O. 45. TE, pH 8.0 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0); should be sterile but does not need to be RNase free as in item 2. If same TE is used for RNA and DNA, be sure that TE remains RNase-free. 46. Platinum® Taq high-fidelity (Invitrogen, cat. no. 11304-011); 10X amplification buffer and 50 mM MgSO4 are included; stored at –20°C. 47. 30% (v/v) glycerol solution prepared by dilution in H2O.
2.2. Baculovirus Production 1. Sf-900 II SFM (Invitrogen, cat. no. 10902-096); stored at 4°C and protected from light. 2. Sf9 cells, serum-free adapted (Invitrogen, cat. no. 11496-015); stored in vapor phase of, or submerged in, liquid nitrogen. 3. 125-mL disposable Erlenmeyer flasks with vented caps (Corning; distributed by Fisher Scientific, cat. no. 431143) or equivalent. 4. Trypan blue (Invitrogen, cat. no. 15250-061) or equivalent. 5. Bright-Line® hemacytometer (Reichert, Buffalo, NY; distributed by Fisher Scientific, cat. no. 026715) or equivalent. 6. 250-mL disposable Erlenmeyer flasks with vented caps (Corning; distributed by Fisher Scientific, cat. no. 431144) or equivalent. 7. Tissue-culture-grade DMSO (Sigma-Aldrich, cat. no. D2650); stored at room temperature. 8. CryoTube® vials (Nunc; distributed by Fisher Scientific, cat. no. 377267) or equivalent. 9. Six-well tissue culture plates (Becton Dickinson; distributed by Fisher Scientific, cat. no. 353046) or equivalent. 10. Grace’s unsupplemented medium (Invitrogen, cat. no. 11595-030); stored at 4°C and protected from light. 11. 5-mL Polypropylene round-bottom tube (Becton Dickinson; distributed by Fisher Scientific, cat. no. 352063). 12. Cellfectin® (Invitrogen, Carlsbad, CA; 10362-010); stored at 4°C. 13. Fetal bovine serum (FBS) (Invitrogen, cat. no. 26140-079); stored in aliquots (5–30 mL) at –20°C 14. 10-cm Tissue culture dish (Becton Dickinson; distributed by Fisher Scientific, cat. no. 353003) or equivalent.
08_Myers.qxd
4/16/05
12:58 PM
Page 99
In Vitro Dicing
99
2.3. Expression and Purification of r-Dicer 1. T7 Tag® Antibody HRP conjugate (Novagen, Madison, WI; cat. no. 69048-3); stored at –20°C. 2. 24-Well tissue culture plates (Becton Dickinson; distributed by Fisher Scientific, cat. no. 353047) or equivalent. 3. D-PBS (Dulbecco’s phosphate-buffered saline) (Invitrogen, cat. no. 14040-182); stored at room temperature. 4. 6X SDS Laemmli sample buffer: 0.35 M Tris-HCl, pH 6.8, 36% glycerol, 10% SDS, 0.65 M DTT, 0.012% bromophenol blue; stored at –20°C; make 1X by dilution with H2O. 5. 40% acrylamide (Fisher Scientific, cat. no. BP14021); stored at 4°C; equivalent acceptable. 6. 2% bis-acrylamide (Fisher Scientific, cat. no. BP1404250); stored at 4°C; equivalent acceptable. 7. 40% 29 : 1 Acrylamide : bis-acrylamide (Fisher Scientific, cat. no. BP 14081); stored at 4°C; equivalent acceptable. 8. 4X Resolving gel buffer: 1.5 M Tris-HCl, 0.4% SDS (w/v), pH 8.8 (36). 9. 4X Stacking gel buffer: 0.5 M Tris-HCl, 0.4% SDS (w/v), pH 6.8 (36). 10. 10% APS (ammonium persulfate) (w/v); aliquoted into 10 mL; short-term storage at 4°C and long-term storage at –20°C. 11. TEMED (Invitrogen, cat. no. 14424-010); stored at 4°C; equivalent acceptable. 12. 10X SDS-PAGE running buffer: 0.25 M Tris-HCl, 1.92 M glycine, 1% SDS (w/v), pH 8.6. 13. Immobilon-P PVDF (polyvinylidene fluoride) membrane (Millipore; distributed by Fisher Scientific, cat. no. IPVH 00010) or equivalent. 14. 10X Transfer buffer: 0.2 M Tris-Hcl, 1.5 M glcyine, pH 8.2; used at 1X with 10% methanol. 15. Antibody diluent: D-PBS (item 3) containing 1% nonfat milk powder (item 16) and 0.01% TWEEN® 20 (item 17). 16. Nonfat milk powder (generic store brand). 17. TWEEN® 20 (Sigma-Aldrich, St. Louis, MO; P1379). 18. Immun-Star™ HRP Chemiluminescent Kit (Bio-Rad, Hercules, CA; cat. no. 1705040); contains one bottle each of Luminol/enhancer solution and peroxide buffer; stored at 4°C. 19. α-Extraction buffer pH 8.0: 50 mM phosphate buffer, 300 mM NaCl, 1% NP-40 (NP-40 alternative; Calbiochem, La Jolla, CA; cat. no. 492106); store at 4°C; 50 mM NaPO4 at pH 8.0 is made by mixing the appropriate ratios of 1 M monobasic and 1 M dibasic sodium phosphate with other components as described in ref. 36 (see Note 1). Solution containing protease inhibitors must be prepared fresh for lysis: Add protease inhibitors to 10 mL of α-extraction buffer, 50 µL of 200 mM PMSF (item 20), 1 µL each of 5.5 mg/mL leupeptin (item 21), 5.5 mg/mL pepstatin A (item 22), and 6.3 mg/mL aprotinin (item 23). 20. 200 mM PMSF (phenylmethyl sulfonylfluoride) dissolved in 95% ethanol (SigmaAldrich. cat. no. P-7626); store at 4°C; equivalent acceptable. PMSF is stable in
08_Myers.qxd
4/16/05
12:58 PM
Page 100
100
21. 22. 23. 24. 25.
26.
27.
28. 29. 30.
31.
32.
Myers and Ferrell aqueous solutions for only approx 30 min and should be added last; inhibition of proteases is irreversible. PMSF is very toxic and can penetrate skin once dissolved in ethanol. 5.5 mg/mL leupeptin dissolved in nanopure H2O (Sigma-Aldrich. cat. no. L2023); store at –20°C; equivalent acceptable. 5.5 mg/mL pepstatin A dissolved in DMSO (Sigma-Aldrich. cat. no. P-4265); store at –20°C; equivalent acceptable. 6.3 mg/mL aprotinin (Sigma-Aldrich, cat. no. A-6279); store at 4°C; equivalent acceptable. Talon™ resin (Clontech, Palo Alto, CA; cat. no. 8901-2); store at 4°C. β-Wash buffer pH 8.0: 50 mM phosphate buffer, 500 mM NaCl, 1% NP-40 (NP40 alternative; Calbiochem, cat. no. 492106); store at 4°C. 50 mM NaPO4 at pH 8.0 is made by mixing the appropriate ratios of 1 M monobasic and 1 M dibasic sodium phosphate with other components as described in ref. 36 (see Note 1). δ-Wash buffer pH 8.0: 50 mM phosphate buffer, 500 mM NaCl; store at 4°C. 50 mM NaPO4 at pH 8.0 is made by mixing the appropriate ratios of 1 M monobasic and 1 M dibasic sodium phosphate with other components as described in ref. 36 (see Note 1). γ-Elution buffer pH 8.0: 50 mM phosphate buffer, 500 mM NaCl, 150 mM imidazole; store at 4°C. 50 mM NaPO4 at pH 8.0 is made by mixing the appropriate ratios of 1 M monobasic and 1 M dibasic sodium phosphate with other components as described in ref. 36 (see Note 1). Slide-A-Lyzer® Dialysis Cassette: 3- to 15-mL capacity; 10,000 molecular weight cutoff (MWCO) (Pierce Biotechnology, Rockford, IL; cat. no. 66810). Dialysis buffer pH 8.0: 60 mM HEPES, pH 8.0, 500 mM NaCl, 0.1 M EDTA; make fresh and chill at 4°C prior to use. 50 mM MgCl2; prepare with RNase-free components or treat with DEPC and autoclave. Make sure DEPC is completely hydrolyzed so that r-Dicer is not inhibited; store at room temperature. Reaction dilution buffer: 60 mM HEPES, pH 8.0, 500 mM NaCl, 0.1 mM EDTA; prepare with RNase-free components or treat with DEPC and autoclave. Make sure DEPC is completely hydrolyzed so that r-Dicer is not inhibited; store at room temperature. 10X RNA loading buffer: 50% glycerol, 100 mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol. Make sure this buffer is prepared with RNase-free reagents; it cannot be autoclaved and, therefore, cannot be treated with DEPC; store at room temperature.
2.4. Production of In Vitro Transcription Templates Low DNA Mass Ladder (Invitrogen, cat. no. 10068-013) or equivalent diluted with 10X DNA loading buffer; stored at –20°C (long term) or 4°C for several months.
08_Myers.qxd
4/16/05
12:58 PM
Page 101
In Vitro Dicing
101
2.5. In Vitro Transcription and Dicing MEGAscript™ (Ambion, Autsin, TX; cat. no. 1334); includes all necessary components; stored at –20°C. 2.6. Purification of d-siRNAs 1. Micro-to-Midi™ Total RNA Purification System (Invitrogen, cat. no. 12183-018). 2. Lysis buffer: component of Micro-to-Midi Total RNA Purification System (item 1); β-mercaptoethanol must be added before use to 1% (v/v); prepare fresh. 3. β-Mercaptoethanol (Sigma-Aldrich, cat. no. M6250); store at 4°C. 4. RNase-free isopropanol; ACS grade. 5. RNase-free spin cartridge: component of Micro-to-Midi Total RNA Purification System (item 1). 6. 1X Wash buffer II: component of Micro-to-Midi Total RNA Purification System (item 1); make fresh by diluting the wash buffer II (5X) with 100% ethanol Do not dilute 5X Buffer with H2O. 7. 100% Ethanol; ACS grade.
2.7. Gene Suppression in Tissue Culture Cells 1. HeLa cells (American Tissue Type Collection, Manassas, VA; CCL-2); stored in vapor phase of, or submerged in, liquid nitrogen. 2. Complete growth medium: DMEM (item 3) containing 10% FBS and 1X penicillin–streptomycin–glutamine (item 4); stored at 4°C and protected from light (bottle can be wrapped in aluminum foil or, preferably, light should be blocked from entering the incubator); usable for 1 mo. 3. DMEM (Dulbecco’s modified Eagle’s medium) (Invitrogen, cat. no. 11995-65); stored at 4°C and protected from light. 4. Penicillin–streptomycin–glutamine (100X) (Invitrogen, cat. no. 10378-016); stored in 6-mL aliquots at –20°C and protected from light. 5. Trypsin–EDTA (1X) (Invitrogen, cat. no. 25300-054); stored at 4°C (short term) or at –20°C (long term). 6. Genesilencer™ (Gene Therapy Systems, San Diego, CA; cat. no. T500750); kit contains “siRNA diluent” and “Genesilencer™ siRNA transfection reagent”; store at 4°C. 7. ART (aerosol-resistant tips) (Molecular BioProducts; distributed by Fisher Scientific, cat. nos. Art 10 reach, 2140; Art 20P, 2149P; Art 200, 2069; Art 1000, 2279) or equivalent. 8. 2X Medium: DMEM (item 3) containing 20% FBS and 2X penicillin–streptomycin–glutamine (item 4); stored at 4°C and protected from light (bottle can be wrapped in aluminum foil or, preferably, light should be blocked from entering the incubator); stable for 1 mo. 9. OPTI-MEM® I (Invitrogen, cat. no. 31985-070); stored at 4°C. 10. Hoechst 33342 (Invitrogen, cat. no. H3570); stored at 4°C.
08_Myers.qxd
4/16/05
12:58 PM
Page 102
102
Myers and Ferrell
2.8. Assaying and Troubleshooting Gene Silencing 1. PARIS™ (Ambion, cat. no. 1921); kit contains many components stored at both 4°C and room temperature; note that different lysis buffers are used for fractionating nucleoplasm and cytoplasm. 2. M-PER® Mammalian protein extraction reagent (Pierce Biotechnology, cat. no. 78501); stored at room temperature. 3. Protease inhibitors used at a final concentration of 1 mM PMSF (Subheading 2.3., item 20), 30 µg/mL aprotinin (Subheading 2.3., item 23), 10 µg/mL each of leupeptin (Subheading 2.3., item 21), pepstatin A (Subheading 2.3., item 22), and chymostatin (item 4). 4. 5.5 mg/mL Chymostatin dissolved in DMSO (Subheading 2.2., item 7) (SigmaAldrich, cat. no. C7268); store at –20°C; equivalent acceptable. 5. Phosphatase inhibitors used at a final concentration of 50 mM β-glycerophosphate (item 6), 10 mM sodium fluoride (item 7), and 1 mM sodium orthovanadate (item 8). 6. 0.5 M β-glycerophosphate, dissolved in H2O (Sigma-Aldrich, cat. no. G6251); store at 4°C; equivalent acceptable. 7. 1 M Sodium fluoride, dissolved in H2O (Sigma-Aldrich, cat. no. S7920); store at 4°C; equivalent acceptable. 8. 100 mM Sodium orthovanadate dissolved in H2O (Sigma-Aldrich, cat. no. A6508); store at –20°C; equivalent acceptable; requires activation for maximal inhibition of phosphatases (37). 9. BCA Protein Assay Kit (Pierce Biotechnology, cat. no. 23225); kit contains two components; store at room temperature. 10. 96-Well plates (Costar; distributed by Fisher Scientific, cat. no. 3595). 11. Pre-Diluted Protein Assay Standards: Bovine Serum Albumin (BSA) Set (Pierce Biotechnology, cat. no. 23208); kit contains various concentrations of BSA; store at 4°C. 12. ZyMax™ HRP-conjugated secondary antibodies (1.5 mg/mL) (Zymed, San Francisco, CA; rabbit–anti-goat, cat. no. 81-1620; rabbit–anti-mouse, cat. no. 816720; goat–anti-rabbit, cat. no. 81-6120); store at 4°C. 13. Anti-Actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA; goat–anti-Actin, cat. no. SC-1616, recognizes human Actin; mouse–anti-Actin, cat. no. SC-8432, recognizes human Actin); store at 4°C. 14. Phospho-specific eIF2α antibody (Biosource International, Carmillo, CA; cat. no. 44-728G); store at –20°C. 15. Silencer™ siRNA Labeling Kit–Cy3 (Ambion, cat. no. 1632); store at –20°C. 16. Silencer™ siRNA Labeling Kit–FAM (Ambion, cat. no. 1634); store at –20°C.
2.9. High-Throughput Dicing 1. Multichannel pipets: Pipet-Lite™ with LTS™ (Rainin, Oakland, CA, cat. nos. L12-10, L12-20, L12-200, L12-300, and L12-1200); equivalents are acceptable, but these pipets are ideal for high-throughput applications.
08_Myers.qxd
4/16/05
In Vitro Dicing
12:58 PM
Page 103
103
2. Multichannel pipet tips (Rainin, cat. no. SS-L10, SS-L250, SS-L300, and RTL1200); required for use with LTS pipets; sterile tips and barrier tips are available and denoted with an “F” after the product number. 3. Multichannel reservoir basins (Labcor Products Inc., Concord, ON, Canada; distributed by Fisher Scientific, cat. no. 13681101.PK) or equivalent. 4. Platinum® PCR Supermix (Invitrogen, cat. nos. 11306-081 for 5000 reactions; also available in 96-well format, cat. nos. 11306-065 or 11306-073); only the primers and the template must be added to the supermix, thus saving time and preventing error. 5. Nuclease-free 96-well plates (Denville Scientific Inc., Metuchen, NJ; cat. no. C-18082). 6. Polarseal; foil adhesive tape for sealing 96-well plates (E and K Scientific, cat. no. T592100); works very well for sealing plates stored at –80°C; or equivalent. 7. MEGAscript™ can be purchased in bulk quantity (Ambion, inquire for catalog number); includes all necessary components. 8. Concert™ 96 RNA Purification Kit (Invitrogen, cat. no. 12173-011); each kit contains reagents sufficient to purify 192 d-siRNAs (see items 10–14). 9. 1-mL Deep well, 96-well plate (Axygen; distributed by VWR Scientific, West Chester, PA; cat. no. 10011-940); if 2-mL deep well required, order cat. no. 10011-942. 10. Lysis buffer: component of Concert™ 96 RNA Purification Kit (item 8); β-mercaptoethanol must be added before use to 1% (v/v); prepare fresh. 11. Filter binding plate: component of Concert 96 RNA Purification Kit (item 8). 12. 1X Wash buffer II: component of Concert 96 RNA Purification Kit (item 8); make fresh by diluting the wash buffer II (5X) with 100% ethanol Do not dilute 5X Buffer with H2O. 13. RNase-free H2O: component of Concert 96 RNA Purification Kit (item 8). 14. Nuclease-free 96-well collection plate: component of Concert 96 RNA Purification Kit (item 8). 15. Ultraviolet (UV)-plate, 96-well (Corning; distributed by Fisher Scientific, cat. no. 3635); low absorbance for UV and, therefore, appropriate for determining concentration of nucleic acid. 16. RediPlate™ 96 RiboGreen® RNA Quantitation Kit (Invitrogen, cat. no. R32700); other packaging available: cat. nos. R-11490 and R-11491. 17. 96-well tissue culture plates (Costar; distributed by Fisher Scientific, cat. nos. 3603 or 3904 depending on packaging); ideal for microscopy. 18. 96-well tissue culture plates (Costar; distributed by Fisher Scientific, cat. no. 3614); ultrathin well bottoms are ideal for high-resolution microscopy; sterile lids are ordered separately (Costar; distributed by Fisher Scientific, cat. no. 3931). 19. GeNunc™ 12-well modules (Nunc; distributed by PGC Scientifics, Frederick, MA; cat. no. 232034); nuclease-free; for support, frames are available, cat. no. (232042).
08_Myers.qxd
4/16/05
12:58 PM
104
Page 104
Myers and Ferrell
3. Methods The methods presented here describe how to (1) construct the pFastbacHTC-Dicer construct and Dicer bacmid, (2) produce high-titer baculoviral stocks for expression of the r-Dicer, (3) express and purify the r-Dicer, (4) design and produce templates for in vitro transcription, (5) set up in vitro transcription and dicing reactions, (6) purify d-siRNAs away from contaminating proteins and reaction components, (7) transfect d-siRNAs into cultured cells, (8) assay and troubleshoot gene silencing, and (9) perform high-throughput in vitro dicing. Many of the methods used here require general molecular biology skills. If the instructions provided here or by the manufacturer of the suggested kits are insufficient please refer to ref. 36. On the other hand, if you are highly skilled in molecular biology, you may want to disregard the detail in Subheading 3.1. The time to production of r-Dicer will be shortened if you begin culturing Sf9 cells (see Subheading 3.2., steps 1 and 2) while preparing the Dicer bacmid (see Subheading 3.1.). This will provide ample time to practice appropriate culturing techniques and ensure that Sf9 cells are healthy and growing properly. Finally, for more information regarding baculovirus biology, see published reference sources (38,39). 3.1. Bacmid Preparation This section describes (1) the pFastbac™-HTC vector and general methodology of the Bac-to-Bac® expression system, (2) the cloning of the Homo sapiens Dicer cDNA into pFastbac-HTC, (3) transposition of the pFastbac-HTC-Dicer into DH10Bac cells to produce the Dicer bacmid, and (4) selection of positive recombinants and purification of the Dicer bacmid. Many of the methods described in this section are derived from our interpretation of the protocol for the Bac-to-Bac expression system. If a more detailed explanation is desired or for additional troubleshooting information, please refer to the instructions provided by the manufacturer (Bac-to-Bac® Baculovirus Expression System Version D April 6, 2004, 10359) (http://www.invitrogen.com/content/sfs/manuals/bactobac_man.pdf). 3.1.1. pFastbac-HTC and the Bac-to-Bac Expression System Insect cells are a good expression system for large-scale production of enzymes like r-Dicer. Unlike bacteria (Escherichia coli) and yeast (Pichia pastoris), insect cells are capable of expressing very large proteins in soluble form as well as providing some degree of posttranslational modification. It is very simple to express recombinant enzymes in insect cells. A stock of high-titer baculovirus is produced and used to infect insect cells, forcing them to expresses the gene of interest. We have had good experience using the Bac-to-Bac® Expression System (Invitrogen). This system allows a recombinant baculovirus (40) to be selected without plaque purification, a technique that can be difficult
08_Myers.qxd
4/16/05
12:58 PM
Page 105
In Vitro Dicing
105
and time-consuming. The general approach is as follows. A cDNA encoding the gene of interest is cloned into a pFastbac vector, and a recombinant bacmid containing the gene is made in the DH10Bac cells and the bacmid is subsequently used to produce recombinant baculovirus as described in Subheading 3.2. In the pFastbac vector (41), the gene of interest is flanked by a polyhedrin promoter (38), a gentamycin-resistance gene, and the right and left recombination arms of the Tn7 transposon (42) (see Fig. 1). The DH10Bac cells contain a bacmid (bMON14272) (42) that is selected by kanamycin resistance. Once the pFastbac vector containing the gene of interest is transformed into the DH10Bac cells, the gene is transposed onto the bacmid, making a recombinant bacmid (40,42). The transposition occurs because the bacmid contains mini-attTn7 attachment sites appropriate for a transposase encoded by a tetracycline-resistant helper plasmid (pMON7124) (46). The insertion of the gene of interest disrupts a LacZα peptide. Thus, positive recombinants are selected as white colonies that are gentamycin, kanamycin, and tetracycline resistant. The recombinant bacmid is propagated in the DH10Bac cells, isolated, and used to make recombinant baculovirus. The relevant vector implemented here is pFastbac-HTC (see Fig. 1). The pFastbac HT vectors enable the user to add a 6X-His tag to the N-terminus of the gene of interest. The vectors are available in all three reading frames, HTA, HTB, and HTC. The reading frame is relative to the start codon located upstream of the 6X-His tag and is shifted at the BamHI site. 3.1.2. Cloning of Homo sapiens Dicer into pFastbac-HTC The Homo sapiens Dicer cDNA (NM_177438.1) (8–10,47–49) is amplified by PCR (polymerase chain reaction) from HeLa cDNA, digested with NotI and XhoI restriction enzymes, ligated into pFastbac-HTC, and transformed into TOP10 bacterial cells. 3.1.2.1. PREPARATION
OF
TOTAL RNA
FROM
HELA CELLS
1. Isolate total RNA from a 10-cm dish of HeLa cells growing in mid-log phase, approx 3 × 106 cells or approx 60% confluency, with the RNeasy® Mini Kit as directed by the manufacturer (see Note 2). 2. Determine concentration and purity by measuring absorbance at 260 and 280 nm after dilution of the RNA at 1 : 250 in TE, pH 8.0 (36). 1 OD260 = 40 µg/mL, so calculate the concentration of the RNA with the equation [RNA] = (A260)(40 µg/mL)(250) Calculate the purity or relative absence of protein contamination with the equation Purity = A260/A280
(should be ≥2)
The typical yield should be approx 100 µg and the elution volume is 100 µL, so the concentration should be approx 1 µg/µL.
08_Myers.qxd
106
4/16/05
12:58 PM
Page 106
Myers and Ferrell
Fig. 1. Schematic of the multiple-cloning site and functional elements present in the pFastbac-HTC vector (adapted from Invitrogen, Carlsbad, CA). The Dicer coding region is cloned into the pFastbac-HTC vector at the NotI and XhoI sites (in bold) in the correct reading frame with the 6X-His (histidine) amino-terminal tag and downstream of the TEV (tobacco etch virus) protease recognition site (54,55). The ampicillin-resistance gene and pUC ori (pUC origin) select for and allow amplification in bacteria. The right (Tn7R) and left (Tn7R) mini-Tn7 elements flank the Dicer gene to facilitate site-directed transposition into the bacmid (bMON14272) (42).
08_Myers.qxd
4/16/05
12:58 PM
Page 107
In Vitro Dicing
107
3. The integrity of the mRNA can be estimated from the integrity of the 28S and 18S rRNA (ribosomal RNA) species. The simplest method to determine the integrity of rRNA is by agarose gel electrophoresis (36). Traditionally, denaturing agarose gels, either glyoxal or formaldehyde, are used for electrophoresis of RNA. However, in this case, a good estimate of quality can be obtained by using a 1% native agarose gel so long as the rRNA is properly denatured prior to electrophoresis. The agarose gel should be buffered with either 1X TAE or 1X TBE. Ethidium bromide at a final concentration of 0.5 µg/mL should be added to the gel prior to casting. Be sure that the all solutions and electrophoresis equipment are RNase-free. 4. Mix 1 µg of RNA with an equal volume of 2X RNA loading buffer. If RNA is concentrated, 1 µg can be diluted with RNase-free H2O to 5 µL and then 5 µL of 2X RNA loading buffer should be added. Heat mixture at 95°C for 5 min and load directly onto the gel; there is no need to place on ice. Visualize the 28S and 18S rRNA bands with UV light and photograph. It can be assumed that the mRNA is intact if the 28S and 18S bands are sharp and free of smearing and the intensity of the 28S rRNA is 1.5- to 2-fold greater than the intensity of the 18S rRNA. Smearing below either band indicates degradation of the rRNA and presumably the mRNA (for more information on RNA integrity, see ref. 50). If only one intense band is seen, the rRNA was not properly denatured. Make sure that the RNA sample is heated thoroughly in the 2X RNA loading buffer.
3.1.2.2. PREPARATION
OF
HELA CDNA
1. Produce single-stranded cDNA from the total RNA (Subheading 3.1.2.1., Item 2) with the Superscript RTIII First-Strand Synthesis System for RT-PCR as described below from the manufacturer’s protocol. 2. Add the following components to a RNase-free PCR tube: 50 µM of 1 µL Oligo(dT)20, 5 µg Total RNA (up to 11 µL can be added), 1 µL of 10 mM dNTP mix (10 mM of each dNTP), and RNase-free H2O to 13 µL. 3. Heat mixture to 65°C for 5 min and chill on ice for 2 min. 4. Centrifuge briefly and add the following: 4 µL of 5X first-strand buffer, 1 µL of 0.1 M DTT, 40 units/µL of 1 µL RNaseOut, and 200 units/µL of 1 µL Superscript RT III. 5. Mix by gently pipetting up and down, centrifuge briefly, and incubate at 50°C for 60 min. 6. Inactivate the enzyme by heating to 70°C for 15 min. 7. Add 1 µL of E. coli RNase H (2 units/µL) and incubate at 37°C for 20 min. The cDNA does not need to be purified; it can be added directly to the PCR. Fig. 1. (Continued) The gentamycin-resistance gene provides a means for selection of the recombinant bacmid. The PH (polyhedrin) promoter (38) is upstream of the 6XHis element and Dicer coding region to provide high-level expression in insect cells. The SV40 (simian virus 40) poly adenylation signal (56) is downstream of the Dicer coding region and permits efficient transcription termination and poly adenylation of the Dicer mRNA.
08_Myers.qxd
4/16/05
12:58 PM
Page 108
108
Myers and Ferrell
3.1.2.3. PCR CONDITIONS
FOR
PRODUCING THE DICER INSERT
The T7 epitope tag (not to be confused with the T7 polymerase promoter) must be added to the N-terminus of the Dicer coding region. This is done with two rounds of PCR. First, the full-length Dicer insert is amplified so that the T7 epitope will be added to the N-terminus. Then, a second round of PCR, with a different sense strand primer, is used to add the NotI restriction site 5′ of the T7 epitope. To decrease the odds of introducing a deleterious mutation, the number of amplification cycles is kept to a minimum. 1. Platinum Pfx DNA polymerase is used to produce the Dicer insert, with the following primers : Sense 1 5′-ACTGGTGGACAGCCAATGGGTATGAAAAGCCCTGCTTTGCAAC-3′
Sense 2 5′-GAGAGTGCGGCCGCATGGCTAGCATGACTGGTGGACAGCCAA-TGG-3′
Antisense 5′-CCGCCGCTCGAGTCAGCTATTGGGAACCTGAGG-3′
The gene-specific sequence used to attain the Dicer cDNA is from the accession number NM_177438.1. The T7 epitope (ATGGCTAGCATGACTGGTGGACAGCAAATGGGT) is broken into pieces and shown in bold with the underline. The NotI (GCGGCCGC) and XhoI (CTCGAG) restriction sites, in bold, are added to flank the Dicer gene for subsequent subcloning into pFastbac-HTC (see Fig. 1). The bases at the 5′ end of the sense 2 and the antisense primers are just filler to ensure efficient digestion close to the end of the fragment. The Tm for the primers is calculated at 25 mM salt and 0.3 µM primer concentration. In the genespecific region of the sense 1 primer, which corresponds to the Dicer sequence, the Tm is 51.2°C, and for the entire primer, after the first round of amplification, the Tm is 63.3°C. For the sense 2 primer, the Tms are 52.3°C and 67.1°C, respectively. For the antisense primer, the Tms are 50.7°C and 63.6°C, respectively. 2. In a PCR tube, combine the following components and overlay with mineral oil if necessary: 5.0 µL of 10X Pfx amplification buffer, 1.5 µL of 10 mM dNTP mixture, 1.0 µL of 50 mM MgSO4, 1.5 µL of 10 µM sense 1 primer, 1.5 µL of 10 µM antisense primer, 2.0 µL cDNA, 1.0 µL Platinum Pfx DNA polymerase (2.5 units/µL), 36.5 µL DNase-free H2O. 3. Heat the reaction at 94°C for 2.5 min to denature the template and activate the enzyme. The Platinum technology provides an inactivating antibody against the polymerase and it must be denatured in order for the polymerase to work. Two annealing temperatures are used to increase the specificity: 55°C is used for the first three rounds of amplification, then the annealing temperature is changed to 60°C. The lower temperature allows the gene-specific region to prime the cDNA. However, after the first two rounds, the entire primer will match the template; thus, the annealing temperature is raised to improve specificity.
08_Myers.qxd
4/16/05
12:58 PM
Page 109
In Vitro Dicing
109
4. Follow the 2-min incubation with a three-step cycle; use three rounds of amplification: denature: 94°C for 15 s; anneal: 55°C for 30 s; extend: 68°C for 6 min (1 min per kilobase). Then switch the annealing temperature to 60°C and proceed with 12 more rounds of amplification: denature: 94°C for 15 s; anneal: 60°C for 30 s; extend: 68°C for 6 min (1 min per kilobase); maintain at 4°C after cycling. 5. You can run a portion of the PCR on an agarose gel; however, because only 15 rounds of amplification have been performed, it may be difficult to see a band. Thus, running a gel is really not necessary at this point. 6. Set up a second PCR to add th e NotI restriction site: 5.0 µL of 10X Pfx amplification buffer, 1.5 µL of 10 mM dNTP mixture, 1.0 µL of 50 mM MgSO4, 1.5 µL of 10 µM sense 2 primer, 1.5 µL of 10 µM antisense primer, 2.0 µL first PCR reaction, 1.0 µL Platinum Pfx DNA polymerase (2.5 units/µL), and 36.5 µL DNase-free H2O. 7. Heat the reaction at 94°C for 2.5 min to denature the template and activate the enzyme. Follow with a three-step cycle; use 20 rounds of amplification. As in step 4, two annealing temperatures will be used. 8. Follow the 2.5-min incubation with a three-step cycle; use three rounds of amplification: denature: 94°C for 15 s; anneal: 55°C for 30 s; extend: 68°C for 6 min (1 min per kilobase). Then switch the annealing temperature to 60°C and proceed with 17 more rounds of amplification: denature: 94°C for 15 s, anneal: 60°C for 30 s, extend: 68°C for 6 min (1 min per kilobase), maintain at 4°C after cycling. 9. Analyze PCR by running 5 µL on a 0.8% agarose containing ethidium bromide (see Subheading 3.1.2.1., step 3). Use the 10X DNA loading buffer. A good size marker is the 1-kb DNA ladder. The correct band is 5795 bp. For troubleshooting information, see Note 3. 10. If the correct band is present, or abundant enough to clone relative to contaminating bands, purify DNA away from the enzyme and reaction components using the QIAquick PCR purification kit as directed by the manufacturer. Elute in 30 µL EB (10 mM Tris-Hcl, pH 8.5; provided in the kit) so that the subsequent enzymatic steps can be performed in a smaller reaction volume. To verify recovery of the insert, run another 0.8% agarose gel (see step 9). The amount of DNA to load can be extrapolated from the previous gel.
3.1.2.4. DIGESTION AND GEL PURIFICATION AND THE DICER INSERT
OF THE PFASTBAC-HTC VECTOR
1. To digest the Dicer insert with NotI and XhoI, set up the following reaction and incubate at 37°C for 2 h (see Note 4): 0.5–1.0 µg of 25 µL DNA insert, 4 µL of 10X NEB buffer 3, 4 µL of 10X BSA, 2 µL NotI (10 units/µL), 1 µL XhoI (20 units/µL), 4 µL H2O. 2. To digest the pFastbac-HTC vector set up the following reaction and incubate at 37°C for 2 h (see Note 4): 2 µL of pFastbac-HTC 0.5 µg/µL, 4 µL of 10X NEB buffer 3, 4 µL of 10X BSA, 10 units/µL of 2 µL NotI, 20 units/µL of 1 µL XhoI, of 27 µL H2O. 3. After the 2-h incubation, add 5 µL of 10X DNA loading buffer to each reaction and load the 45 µL in a large well of a 0.8% agarose gel and allow sufficient time
08_Myers.qxd
4/16/05
12:58 PM
Page 110
110
Myers and Ferrell
for good resolution (e.g., run the bromophenol dye marker to the bottom of an 8cm gel). Run gel as described previously. 4. Visualize bands with UV light, photograph, and excise bands with a sharp scalpel or razor blade. Avoid a large excess of agarose by carefully trimming it away from the DNA. Place excised bands in a microcentrifuge tube. The linearized vector should migrate at 4858 bp and the digested insert at 5776 bp. It will be impossible to determine if the insert is digested or if the vector is digested with both enzymes. 5. Extract DNA with the QIAquick Gel Extraction Kit per manufacturer’s suggestions (see Note 5). Elute in 30 µL EB (10 mM Tris-HCl, pH 8.5; included in kit). 6. Run a 0.8% agarose gel to assess quality and quantity of the linearized vector and digested insert. The High DNA Mass Ladder is good for estimating the concentration of the digested vector and insert.
3.1.2.5. LIGATION
OF THE
DICER INSERT
INTO THE PFASTBAC-HTC VECTOR
The digested Dicer fragment is ligated into the digested pFastbac-HTC vector with T4 DNA ligase as described by the manufacturer (see Note 6). Mix the following components in a microcentrifuge tube, pipet up and down, centrifuge briefly, and incubate at room temperature for 20 min. After setting up the ligation reaction, thaw One Shot TOP10 Chemically Competent Cells on ice for the subsequent transformation (see Subheading 3.1.2.6.). Thaw one tube per ligation reaction—4 tubes in total if ligations are set up as described as follows: Vector-only control 50 ng of pFastbac-HTC digested with NotI and XhoI, 2 µL of 10X T4 DNA ligase buffer, 1 µL T4 DNA ligase (400 units/µL), H2O to final volume of 20 µL. Vector plus insert 50 ng of pFastbac-HTC digested with NotI and XhoI, 0.5-, 1-, and 3-fold molar excess of digested Dicer insert, 2 µL of 10X T4 DNA ligase buffer, 1 µL T4 DNA ligase (400 units/µL), H2O to final volume of 20 µL.
3.1.2.6. TRANSFORMATION INTO TOP 10 CELLS
OF THE
DICER-PFASTBAC-HTC CONSTRUCT
1. Other strains of bacteria or cells you made can be used instead of the commercially available competent cells. Other forms of transformation can also be used where appropriate. 2. Place LB plates containing 100 µg/mL ampicillin in an incubator at 37°C. This allows plates to warm to 37°C while performing the transformation and recovery. Prewarm two LB plates per transformation. 3. Mix one-half of the ligation into 50 µL of One Shot TOP10 Chemically Competent Cells. Do not pipet up and down. Save the remaining ligation at –20°C.
08_Myers.qxd
4/16/05
12:58 PM
Page 111
In Vitro Dicing
111
4. 5. 6. 7. 8.
Incubate on ice for 30 min. Heat shock the cells for 30 s at 42°C. Transfer tubes immediately to ice. Add 250 µL of SOC media and shake for 1 h at 37°C and 225 rpm. Evenly spread 60 µL (one-fifth) of the transformation on one prewarmed LB plate and the remaining 240 µL (four-fifths) on the second prewarmed LB plate. Glass beads or conventional plate spreaders could be used. Using 2 vol of the transformation will ensure that one of the plates will have well-isolated single colonies for selection (see Subheading 3.1.2.7.). 9. Return plates to the 37°C incubator and allow bacteria to grow for 16 h. 10. Count colonies and determine likelihood of subcloning success (see Note 7).
3.1.2.7. ISOLATE DNA
COLONIES AND SCREEN CLONES
FROM
FOR PFASTBAC-HTC-DICER
1. Select colonies and grow overnight in 3 mL LB containing 100 µg/mL ampicillin. Four to ten colonies should be a sufficient number to obtain a positive subclone (see Note 8). Place cultures in a shaking incubator at 37°C and 250 rpm and grow for approx 16 h. Disposable 14-mL culture tubes work well. Refer to QIAprep Miniprep Kit protocol for more information. 2. Isolate DNA with the QIAprep Miniprep Kit as directed by the manufacturer. 3. Digest each sample with either NotI or BamHI for 30 min to 2 h at 37°C. Mix as described below, gently pipet up and down, and centrifuge briefly. A master mix can be prepared if a large number of colonies were selected: For NotI: 100–200 ng of 1 µL miniprep DNA, 2 µL of 10X NEB buffer 3, 2 µL of 10X BSA, 1 µL NotI (10 units/µL), 14 µL H2O. For BanHI: 100–200 ng 1 µL miniprep DNA, 2 µL of 10X BamHI buffer, 2 µL of 10X BSA, 0.5 µL BamHI (20 units/µL), 14.5 µL H2O. 4. Add 2 µL of 10X DNA loading buffer to each digest and electrophorese on a 0.8% agarose gel as described previously. If the Dicer insert was ligated into the pFastbac-HTC vector, then the NotI digest will linearize the vector and the size should be 10,605 bp. However, if the Dicer insert is not present, the linearized vector will migrate at 4858 bp. Likewise for the BamHI digest; if the insert is present, two bands will be generated: one at 6020 bp and the other at 4585 bp. If it is just vector, the band will migrate at 4858 bp. The linearized pFastbac-HTC vector should be run as a control for size. Any other pattern of bands suggests a problem with vector and insert preparation, such as introduction of mutations into the insert. Cloning steps (Subheadings 3.1.2.3.–3.1.2.7.) should be repeated. The presence of the insert can also be confirmed by running undigested miniprep DNA and undigested pFastbac-HTC on a 0.8% agarose gel because the vector plus insert will migrate as a very large supercoiled band, much larger than the supercoiled vector. If undigested miniprep DNA is used, be sure to run undigested pFastbac-HTC vector as a control. 5. If the correct bands are seen after the digestion sequence, then subclone to ensure that it does not contain any deleterious mutations. Before proceeding, the Dicer
08_Myers.qxd
112
4/16/05
12:58 PM
Page 112
Myers and Ferrell cDNA should be sequenced rigorously because it is such a large gene and was amplified by PCR (see Note 9).
3.1.3. Transposition of the Dicer cDNA in DH10Bac Cells The transposition of the Dicer gene onto the bacmid (see Subheading 3.1.1.) takes place after a simple transformation of the pFastbac-HTC-Dicer construct into chemically competent DH10Bac cells. The transformation is performed as suggested by the manufacturer; see the Bac-to-Bac instruction manual for additional details and troubleshooting information. 1. Thaw one tube, 100 µL,Cof MAX Efficiency DH10Bac cells on ice, approx 20–30 min. Heat a water bath to 42°C. 2. Place DH10Bac cells into a prechilled 14-mL tube. The tube is important because of variation in heat transfer between different tubes (e.g., if the tubes are different in thickness or in composition). 3. Add 5 µL (200 pg/µL) of the sequence-verified pFastbac-HTC-Dicer construct to the cells and mix gently, but do not pipet up and down. 4. Incubate on ice for 30 min. 5. Heat shock the cells at 42°C for 45 s. 6. Transfer the tubes quickly back to ice for 2 min. 7. Add 900 µL of S.O.C. medium. 8. Place tube in a shaking incubator set at 37°C and 225 rpm. Allow cultures to incubate for 4 h. This incubation might seem long relative to normal recovery incubations used in routine transformations. However, this extended incubation is critical because the bacteria must deal with replication of a very large bacmid. 9. During the last hour of the incubation place four LB plates containing 50 µg/mL kanamycin, 10 µg/mL tetracycline, 7 µg/mL gentamycin, 100 µg/mL bluo-gal, and 40 µg/mL IPTG in a 37°C incubator. Be sure that the plates were prepared with Luria broth and not Lennox L broth because use of Lennox L results in fewer colonies and less intense color. 10. At the end of the 4-h recovery, plate 1, 10, 100, or approx 890 µL of the cells on the prewarmed LB plates. In order to efficiently spread the small volumes of cells, add 99 µL of SOC to the 1 µL of cells and 90 µL to the 10 µL. It is not necessary to add any medium to the 100 µL of cells, but in order to plate the 890 µL of cells, the volume must be reduced. Transfer the remainder of the cells (all 890 µL) to a microcentrifuge tube and spin for 2 min at 1000g. Aspirate the majority of the medium, leaving about 100 µL. Gently resuspend the cells by pipteting up and down and then transfer to one of the LB plates. Also, transfer the other 3 vol of cells, each in 100 µL, each to a different LB plate. Spread cells with glass beads or a conventional plate spreader. 11. Place plates in a 37°C incubator and check for colony growth at 24 h. As a general rule, it will take 48 h until colonies are the appropriate size for selection, but very small colonies might be visible at 24 h.
08_Myers.qxd
4/16/05
12:58 PM
Page 113
In Vitro Dicing
113
3.1.4. Selection of a Recombinant Bacmid Recombinant bacmids are first selected by blue/white screening of colonies. The bacmid DNA is then isolated with traditional alkaline lysis. General miniprep kits do not work well because the bacmid is so large. There are kits available for isolation of bacmid DNA but are not necessary. Finally, PCR screening is used to verify that the Dicer gene was transposed onto the bacmid. 3.1.4.1. SELECTION
OF
WHITE COLONIES AND PREPARATION
FOR
BACMID ISOLATION
1. To avoid false positives, select well-isolated, large, white colonies. Avoid colonies that appear gray or darker in the center because they might contain a mixture of bacteria that harbor both bacmids with and without the insert. Viewing the colonies under a dissecting microscope against a white background facilitates the selection process. 2. Four colonies should be restreaked on LB plates containing 50 µg/mL kanamycin, 10 µg/mL tetracycline, 7 µg/mL gentamycin, 100 µg/mL bluo-gal, and 40 µg/mL IPTG in a 37°C incubator. Colonies should be visible after overnight incubation at 37°C, in contrast to the previous 48-h incubation. This will confirm selection of bacmids containing the insert. 3. From the restreaked colonies, again select four colonies and grow in 3 mL of LB containing 50 µg/mL kanamycin, 10 µg/mL tetracycline, 7 µg/mL gentamycin. Grow liquid cultures overnight to stationary phase at 37°C and 250 rpm; because the bacmid is so large, bacterial growth is slower than normal. 4. A glycerol stock of the recombinant bacmid should be made. Take one LB platecontaining 50 µg/mL kanamycin, 10 µg/mL tetracycline, 7 µg/mL gentamycin, 100 µg/mL bluo-gal, and 40 µg/mL IPTG and divide into four quadrants using a Sharpie to label the bottom of the plate. Before isolating bacmid DNA, use a pipet tip or inoculation loop to streak a portion of each of the four cultures in one of the quadrants of the LB plate. Place the plates in the 37°C incubator overnight and store at 4°C once the colonies are visible. These colonies are essential for making a glycerol stock (see step 6 in Subheading 3.1.4.3.), which ensures that once a verified bacmid is found, transposition will not have to be repeated. Note that the bacmid cannot easily be transformed into bacteria, so a glycerol stock is very important.
3.1.4.2. ISOLATION
OF
BACMID DNA
Bacmid DNA can be isolated with a modified alkaline lysis protocol (developed by Invitrogen through communication with Peter deJong). The protocol that we use is described here. Additional information can be found in the Bac-to-Bac instruction manual. 1. Make sure solution I contains 100 µg/mL RNase A. RNase A can be added to the stock solution if all of the solution will be used within 6 mo. Alternatively, the
08_Myers.qxd
114
2. 3. 4. 5.
6.
7. 8.
9. 10.
11. 12. 13.
14.
15.
16.
4/16/05
12:58 PM
Page 114
Myers and Ferrell RNase A can be added fresh to a small amount of solution I prior to isolation of DNA. Transfer 1.5 mL of bacterial culture to a microcentrifuge tube and centrifuge at 14,000g for 1 min to pellet the cells. Remove the supernatant with an aspirator or pipet. Resuspend the pellet in 300 µL of solution I. Gently vortex or pipet up and down to resuspend. Add 300 µL of solution II and gently mix by inverting the tube five times. Incubate at room temperature for 5 min. The solution should become translucent and viscous. To precipitate cellular protein and genomic DNA add 300 µL of 3 M potassium acetate, pH 5.5, and gently mix by inverting the tube several times. Precipitate is white and thick. Place on ice for 5 min. Centrifuge for 10 min at 14,000g and room temperature. Avoid the precipitate and carefully transfer the supernatant to a 2-mL microcentrifuge tube containing 800 µL of isopropanol, mix gently, and incubate on ice for 10 min. This is a good stopping point if necessary because the precipitate can be stored overnight at –20°C. To pellet the bacmid DNA-precipitate, centrifuge for 15 min at 14,000g at room temperature. Carefully remove the supernatant without disturbing the pellet. Note that the pellet is often translucent and difficult to see. Holding the tube at the correct angle toward a light provides sufficient contrast to identify the location of the pellet. Keep track of the tube orientation during centrifug